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1.  CELLULAR COMMUNICATION  
	
Cellular	communication	is	a	fundamental	phenomenon	in	all-multicellular	organisms.	All	cells	
in	 a	 human	 body	must	 communicate	 with	 each	 other’s	 to	 govern	 biological	 functions,	 to	
ensure	 all	 processes	 from	 the	 development	 of	 an	 egg,	 to	 the	 survival,	 and	 to	 the	
reproduction.	 In	 multicellular	 organisms,	 cell	 survival	 is	 dependent	 on	 the	 reception	 of		
information	from	their	environment	[1].	
Cellular	 communication	 is	 a	 generic	 term	 that	 includes	 all	 types	 of	 inter	 and	 intra-cellular	
information	processing.	It	is	how	a	cell	sends	the	information	in	the	proper	route,	depending	
on	 the	 nature	 of	 the	 signal	 and	 of	 the	 target	 cells;	 and	 how	 a	 message	 is	 received	 and	
translated	 in	 the	 recipient	cell	with	 the	known	 three	steps	of	 cellular	 response:	 reception,	
transduction	and	response.		
McCreas	 described	 the	 cell-cell	 communication	 as	 “The	music	 that	 the	 nucleus	 hears”	 as	
cell’s	 response	 to	 the	 surrounding	 environment	 affects	 gene	 transcription	 programs.	 It	
means	 that	 cell-cell	 communication	 intervenes	 in	 morphogenesis,	 cell	 differentiation,	
homeostasis,	cell	growth	and	cell-cell	interactions	[2].	
	
1.1. Overview on different types of vesicles in cel lular communication 
	
Cellular	communication	is	based	on	sharing	information	that	could	be	achieved	via	different	
signaling	mechanisms	thus	it	could	be	generally	classified	into	direct	and	indirect;	or	by	the	
signal’s	path	into	intracrine,	autocrine,	juxtacrine,	paracrine,	synaptic	signaling,	endocrine	or	
microvesicles	as	described	in	the	table	below	(table	1).	
	
Signaling	mechanism	 Produced	signal	 Explanation	
Direct	 self-self	
communication		
Intracrine	 Signal	 is	produced	 in	 the	 target	 cell	 and	
affecting	itself	
Autocrine	 Signal	 is	produced	by	the	target	cell	and	
affecting	itself	via	a	receptor		
adjacent	
communication	
Juxtacrine	 Signal	 targets	 adjacent	 cells	 that	 are	
connected	by	cell-cell	junction		
Indirect		 local	
communication	
Paracrine	 Signal	 secreted	 interacts	 with	 nearby	
target	cells		
Synaptic	
signaling	
Neurotransmitter	secreted	 in	synapse	of	
close	cells	
long	 distance	
communication	
Endocrine	 Signal	 secreted	 into	 blood	 stream	
targeting	distant	target	cells		
microvesicles	 	 Signal	 secreted	 in	 extracellular	
microvesicles		
	
Table	1:	Illustration	of	different	types	of	cellular	communication	pathways.		
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However	in	here,	we	will	focus	on	vesicle-mediated	cellular	communication	with	a	special	
interest	into	exocytosis	and	exosomes.		
	
1.2. Focus on exocytosis vesicles and exosomes 
	
Both	 exocytotic	 vesicles	 and	 exosomes	 are	 considered	 as	 indirect	 cellular	 communication	
tools.	They	serve	 for	 the	delivery	of	a	certain	message	 for	a	nearby	or	distant	 target	cells.	
Indeed,	the	origin	of	genesis	is	different	but	they	both	share	some	common	characteristics.	
They	 are	 both	 vesicles	made	 of	 phospholipids,	 both	 crafted	within	 the	 cell	 and	 harboring	
selected	 components.	 While	 exocytosis	 is	 the	 direct	 secretion	 of	 soluble	 proteins	 in	 the	
extracellular	 milieu;	 exosomes	 are	 also	 considered	 as	 the	 result	 of	 the	 secretion	 of	
intraluminal	 vesicles	 into	 the	extracellular	milieu.	 They	both	 require	 a	 fusion	process	with	
the	 plasma	 membrane	 to	 secret	 their	 cargo	 or	 themselves,	 for	 exocytotic	 vesicles	 and	
exosomes,	 respectively.	 This	 fusion	 process	 implicates	 an	 interaction	 with	 the	 plasma	
membrane	 that	 is	 commonly	 mediated	 by	 Soluble	 N-ethylmaleimide-sensitive-Factor-
Attachment-proteins	 (SNARE	 proteins).	 Several	 ferlin	 proteins	 have	 been	 reported	 to	
mediate	different	membrane	and	vesicle	 fusion	processes	and	 interestingly,	 some	of	 them	
have	even	been	reported	to	interact	with	SNARE	proteins;	what	brings	to	this	protein	family	
a	particular	interest.		
	
2.  FERLIN FAMILY 
	
Ferlin	 is	a	proteins	family	with	a	main	 identifier	of	harboring	multiple	tandem	C2	domains.	
This	 protein	 group	 shows	 ancient	 origins	 in	 eukaryotic	 evolution	 and	 is	 detected	 in	 all	
eukaryotic	domains,	including	unicellular	organisms	[3].	This	suggests	an	origin	in	a	common	
ancestor	predating	eukaryotic	appearance.		
Up	to	date,	six	members	of	the	mammalian	ferlin	family	have	been	 identified	but	yet	they	
have	 not	 all	 been	 characterized.	 The	 nomenclature	 of	 “Ferlin”	 is	 in	 reference	 to	 their	
parental	 orthologue	 gene	 Fertilization	 factor	 1	 (Fer-1)	 in	 Caenorhabditis	 elegans	 [4].	 The	
protein	encoded	by	 this	gene	plays	an	 important	 role	 in	 spermatid	motility.	A	mutation	 in	
this	gene	provokes	 infertility	of	the	C.	elegans	 [5].	Ferlin	proteins	are	usually	named	based	
on	“Fer-1-L”	prefix	for	“Fer-1-Like”,	followed	by	a	number	representing	one	single	protein	of	
the	 family.	 The	 six	 known	 members	 of	 the	 ferlin	 family	 are	 fer1L1	 (known	 as	 Dysferlin),	
fer1L2	 (known	 as	 Otoferlin),	 fer1L3	 (known	 as	 Myoferlin)	 and	 the	 last	 uncharacterized	
members	are	fer1L4,	fer1L5	and	fer1L6.		
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2.1. Structure of Ferl ins 
	
All	 mammalian	 ferlin	 members	 are	 about	 200-240	 kDa	 proteins	 with	 alternative	 splicing	
reported	 for	 several	 paralogues.	 But	 in	 general	 terms,	 they	 all	 share	 some	 common	
characteristics;	 they	 are	 all	 type	 II	 transmembrane	 proteins	 with	 a	 single	 pass	
transmembrane	 region	 at	 the	 carboxy	 terminus	 (figure	 1).	 They	 all	 harbor	 a	 series	 of	
positively	 charged	 residues	 within	 the	 transmembrane	 domain	 that	 is	 thought	 to	 be	
important	 for	 their	 anchoring	 at	 the	 inner	 leaflet	 of	 the	 plasma	membrane.	 The	 cytosolic	
part	of	the	proteins	contains	multiple	C2	domains.	Some	members	harbor	specific	domains	
like	 SH3,	 FER-I,	 Fer-A,	 Fer-B,	 and	 DysF	 [5].	 Finally	 a	 putative	 extracellular	 domain	 was	
confirmed	in	one	study	conducted	by	Bernatchez	[6]	where	myoferlin-Hemagglutinin	tag	(at	
the	carboxy	terminus)	has	been	immunodetected	with	anti-Hemagglutinin	antibody	in	non-
permeabilized	COS7	cells	implying	that	this	domain	is	indeed	an	extracellular	one.			
	
	
Figure	1:	Ferlin	protein	family.	Schematic	structure	of	members	of	ferlin	proteins	showing	common	characteristics:	type	II	
transmembrane	proteins	harboring	a	tandem	repeated	C2	domains	in	their	cytoplasmic	region.	P.L.	McNeil	et	al.,	2005	[7]		
	
2.2 C2 domains 
	
Ferlin	proteins	family	is	a	unique	family	in	terms	of	their	possession	of	multiple	C2	domains.	
In	 fact,	 there	 are	 about	 a	 hundred	 known	 C2	 domain	 bearing	 proteins	 and	 they	 do	 not	
possess	 more	 than	 a	 couple	 of	 C2	 domains	 with	 an	 exception	 of	 “Multiple	 C2	 domain	
Transmembrane	 Proteins”	 bearing	 3	 C2	 domains,	 and	 “Extended	 Synaptotagmins”	 (also	
known	as	Tricalbins),	bearing	3	 to	5	C2	domains.	 In	general,	 all	members	of	 ferlin	have	at	
least	five	and	up	to	seven	C2	domains.	The	non-ferlin	C2	domain	bearing	proteins	are	known	
to	 be	 membrane-associated	 proteins	 implicated	 in	 protein-lipid,	 protein-Ca2+	 or	 protein-
protein	interactions	[5].		
The	 C2	 domains	 in	 ferlin	 proteins	 are	 named	 from	 the	 amino	 terminal	 to	 the	 carboxy	
terminal	 to	 be	 C2A,	 then	 C2B	 and	 so	 on.	 C2	 domains	 are	 defined	 to	 be	 a	 phospholipid	
binding	 domains	 involved	 in	 fusion	 processes	 in	 a	 Ca2+-dependent	 manner.	 Of	 note,	 C2	
domains	 of	 the	 well	 characterized	 protein	 Synaptotagmin	 have	 been	 shown	 to	 mediate	
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exocytotic	 vesicle	 fusion	 in	 a	 Ca2+-dependent	 manner.	 Back	 to	 ferlins,	 crystallographic	
studies	have	shown	that	the	C2	domains	are	independently	folding	domains	composed	of	8	
beta-strands	 forming	 a	 sandwich	 structure.	 A	 Ca2+-binding	 loop	 resides	 at	 one	 end	 of	 the	
beta-sandwich	 structure	 (figure	 2)	 and	 that	 the	 Ca2+-binding	 is	 mediated	 by	 a	 conserved	
aspartic	acid	residue	[8].			
	
	
Figure	2:	Crystallographic	structure	of	C2	domain.	Solution	structure	of	the	first	C2	domain	of	myoferlin.	Arrow	
representing		Aspartic	acid	residue.	Fahmy	et	al.,	2015	.[9]	
	
C2A	domain,	the	first	C2	domain	from	the	amino-terminal,	of	both	myoferlin	and	dysferlin	
binds	to	negatively	charged	phospholipid	mixture	similar	to	the	phospholipid	composition	of	
the	inner	 leaflet	of	the	plasma	membrane	[4].	Of	 interest,	 it	has	been	shown	that	only	the	
C2A	 domain	 is	 able	 to	 bind	 a	 mixture	 of	 50%	 phosphatidylserine	 and	 50%	
phosphatidylcholine	in	the	presence	of	1mM	of	Ca2+.	However	this	C2A	domain	failed	to	bind	
a	mixture	of	25%	phosphatidylserine	in	75%	phosphatidylcholine,	meaning	that	this	domain	
requires	a	certain	amount	of	negatively	charged	phospholipids	to	bind.	The	requirement	of	
negatively	 charged	 phospholipids	may	 be	 influenced	 by	 the	 number	 of	 positively	 charged	
residues	in	the	Ca2+-binding	loop	in	the	C2A	domain.	This	could	hypothesize	that	myoferlin	
and	 dysferlin	 interact	 with	 specific	 regions	 of	 the	 plasma	 membrane	 enriched	 with	 high	
concentration	of	negatively	charged	phospholipids	[4].	
Of	interest,	it	has	been	shown	that	neither	myoferlin	nor	dysferlin	can	bind	phospholipids	in	
resting	Ca2+	concentration,	which	is	about	0,1	µM;	however	they	require	1	µM	and	4,5	µM	of	
Ca2+	 concentration,	 respectively.	 It	 has	 been	 shown	 that	 cytosolic	 Ca2+	 concentration	 can	
reach	1	µM	or	even	more	after	various	 stimuli	 including	depolarization	and	 ligand	binding	
[10].	Meaning	that	myoferlin	and	dysferlin	are	implicated	in	specific	processes	inside	the	cell.	
More	interesting,	a	point	mutation	in	myoferlin	(I67D)	provokes	an	abolishment	of	the	Ca2+-
dependent	 phospholipid	 binding.	 Similar	 results	 have	 been	 shown	 with	 dysferlin,	 where	
point	mutation	at	 the	same	amino	acid	position,	 (V67D),	also	provokes	a	decrease	 in	Ca2+-
dependent	phospholipid	binding	properties.	It	means	that	the	introduction	of	neutral	amino	
acid	instead	of	an	acidic	residue	alters	Ca2+-dependent	phospholipid	binding	[4].		
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The	 same	 study	 has	 shown	 that	 unlike	 the	 C2A	 domain,	 the	 remaining	 C2	 domains	 of	
myoferlin	 were	 unable	 to	 bind	 this	 mixture	 of	 50%	 phosphatidylserine	 and	 50%	
phosphatidylcholine.	 But	 this	 does	 not	 imply	 that	 they	 do	 not	 bind	 to	 other	 mixtures	 of	
phospholipids.	In	fact,	their	role	is	still	unknown	but	like	all	the	other	C2	domains,	they	are	
probably	 implicated	 in	 protein-protein	 interactions.	 However,	 this	 has	 been	 criticized	 [11]	
and	will	be	detailed	later	on.	
In	 contrast,	 analysis	 of	 otoferlin	 C2	 domains	 showed,	 except	 the	 C2A,	 a	 Ca2+-dependent	
binding	 to	 liposomes	 composed	 of	 15%	 phosphatidylserine,	 55%	 phosphatidylcholine	 and	
30%	 phosphatidylethanolamine.	 Otoferlin	 C2A	 domain	 was	 demonstrated	 to	 have	 a	
significantly	shorter	top	loop	and	lacks	Ca2+-coordinating	aspartates.	Thus,	it	is	predicted	to	
be	unable	to	bind	with	Ca2+	[3]	and	considered	not	to	have	a	functional	C2A	domain.				
Of	 interest,	 the	 similarity	 between	 C2	 domains	 in	 paralogues	 is	 more	 important	 than	
between	C2	domains	within	the	same	protein,	e.g.	the	similarity	of	dysferlin-C2A	domain	is	
74%	with	myoferlin-C2A	while	its	similarity	with	other	C2	domains	of	dysferlin	is	up	to	15%	
[4][5].			
Otoferlin	lacks	Ca2+-sensitive	C2A	domain	implying	that	in	spite	of	the	overall	similarity	of	the	
protein	family,	each	member	has	its	specialized	function.	This	does	not	imply	that	they	can	
not	 interact	 together,	 co-help	 each	 other	 or	 even	 compensate	 each	 other’s	 functions,	 at	
least	partially.			
	
2.3. Non C2 domains 
	
Ferlins	can	be	segregated	 into	 two	major	categories	based	on	 their	possession	or	not	of	a	
DysF	 domain.	 	 “Type	 I	 ferlin	 group”	possesses	 a	DysF	 domain;	 this	 group	 includes	 Fer1L1,	
Fer1L3	and	Fer1L5;	while	“Type	II	ferlin	group”	does	not	have	a	DysF	domain	and	it	includes	
Fer1L2,	 Fer1L4	 and	 Fer1L6.	 However,	 the	 function	 of	 this	 DysF	 domain	 is	 still	mysterious.	
Another	common	feature	of	all	ferlins,	 is	that	they	all	possesses	Fer	domains	(FerI,	FerA	or	
FerB),	 which	 are	 specific	 motifs	 of	 60	 to	 70	 residues	 with	 a	 well	 conserved	 secondary	
structure,	 with	 a	 yet	 unknown	 functions.	 However,	 it	 seems	 that	 FerA	 appears	 to	 occur	
concomitantly	with	DysF	domains	(figure	3),	implying	probably	a	functional	relationship	[3].	
Ferlins	have	a	highly	conserved	C2B-Fer1-C2C	motif,	C2D	and	2	C-terminal	C2	domains	(C2E	
and	 C2F)	 adjacent	 to	 the	 transmembrane	 domain;	 while	 C2A	 and	 C2DE	 are	 variably	
expressed	in	different	ferlins.	This	means	that	Fer1	motif	may	be	essential	for	ferlin	protein	
function	as	it	is	a	well	conserved	domain	[3].	
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Figure	3:	Ferlin	protein	structure.	Figure	showing	the	similarities	and	the	differences	between	the	different	ferlin	members	
and	the	two	ferlin	groups	(I	and	II).	Angel	et	al.,	2012	[3].	
3.  FERLIN FUCTIONS 
	
Since	 all	 ferlins	 share	 common	 structural	 characteristics,	 especially	 tandem	 C2	 domains,	
their	structure-activity	relationship	proposes	a	role	that	is	dependent	on	their	phospholipids	
binding	capacity,	like	membrane	fusion	and	fission	processes.		
3.1. Dysferl in function 
	
Dysferlin	is	the	first	member	of	mammalian	ferlin	family	to	be	discovered	and	characterized.	
Its	 encoding	 gene	 was	 first	 identified	 to	 be	 responsible	 for	 two	 inherited	 recessive	
autosomal	diseases:	the	Limb	Girdle	Muscle	Dystrophy	type	2B	and	the	Miyoshi	Myopathy.	
Dysferlin	 is	 a	 230	 kDa	 protein	 containing	 six	 C2	 domains.	 It	 is	 highly	 expressed	 in	 adult	
skeletal	muscles	as	well	as	in	heart	where	its	main	immunoreactivity	is	at	the	cell	membrane	
[5].	 Dysferlin	 plays	 a	 major	 role	 in	 myofusion	 processes	 during	 myoinitiation	 and	
myoaugmentation.	Moreover,	it	is	implicated	in	muscle	repair,	where	in	its	absence,	muscle	
tears	are	not	adequately	repaired	and	myofibers	undergo	necrosis.	A	mutation	in	Dysferlin	
gene	 is	 characterized	 by	 defective	 membrane	 repair	 and	 interestingly	 accumulation	 of	
intracellular	vesicles	in	the	sub-sarcolemme	area	[12].		
	
3.2. Otoferl in  
	
Otoferlin	was	the	second	member	of	mammalian	ferlin	family	to	be	identified.	It	is	a	226	kDa	
protein	containing	five	or	six	C2	domains	depending	on	the	used	detection	algorithm.	It	also	
harbors	 a	 Ca2+-independent	 C2A	 domain,	 which	 is	 thought	 to	 be	 inactive.	 Otoferlin	 is	
expressed	in	the	auditory	Inner	Hair	Cell	ribbon	synapse;	precisely	at	the	surface	of	synaptic	
exocytosis	 vesicles.	 Otoferlin	 mediates	 exocytosis	 of	 synaptic	 vesicles	 by	 binding	 to	
exocytosis	component	syntaxin-1	and	Synaptosomal-associated	protein	of	25	kDa	(SNAP25)	
in	a	Ca2+-dependent	manner	[13].	Otoferlin	mutation	causes	an	autosomal	recessive	form	of	
non-syndromic	deafness;	and	in	consequence	otoferlin	null	mice	are	profoundly	deaf	[14].	
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3.3. Other ferl ins 
	
Caenorhabditis	elegans’	 ferlin	 (fer-1)	 is	 the	 first	 ferlin	 to	be	 identified;	 it	 is	detected	 in	 the	
sperm	acrosome	membrane.	Fer-1	mutant	worms	are	infertile	as	they	are	defective	in	fusion	
of	 spermatid	 vesicular	 organelles	with	 plasma	membrane	 during	 spermatogenesis	 [3][15].	
The	 fusion	 of	 these	 spermatid	 vesicular	 organelles	 adds	 extra	 membrane	 to	 the	 plasma	
membrane	at	 the	 fusion	 site;	which	 is	 required	 for	 the	extension	of	 the	pseudopodia	 that	
cause	 crawling	of	 the	 spermatids.	 Ten	different	mutations	have	been	 characterized	within	
Fer-1,	five	of	them	fall	within	the	C2	domains.	These	mutations	disrupt	Ca2+-sensitive	fusion	
potentials	 [5].	 Very	 interestingly,	 fer-1	 mutants	 exhibit	 vesicles	 accumulation	 on	 the	
cytoplasmic	face	of	the	plasma	membrane.		
	
Drosophila	ferlin	(Misfire)	is	found	in	the	testes	and	ovaries	of	the	adult	flies	where	it	plays	a	
role	 in	 fertilization.	 Male	 Drosophila	 mutants	 show	 defects	 in	 sperm	 plasma	 membrane	
break-down	post-fertilization,	 a	 process	 involving	 Ca2+-dependent	 exocytosis	 and	 essential	
for	release	of	the	sperm	DNA	[3][16].		
	
Fer1L4,	Fer1L5	and	Fer1L6	are	poorly	studied	and	their	functions	are	still	unknown.	They	all	
harbor	 five	 to	 six	 C2	 domains	 and	 databases	 suggest	 that	 they	 can	 undergo	 alternative	
splicing.	Except	for	Fer1L5,	which	shows	high	similarity	to	myoferlin;	 it	binds	to	EHD	family	
(EHD1	and	EHD2)	and	is	implicated	in	myoblast	fusion	[17].	
	
4.  DISCOVERY AND FUNCTION OF MYOFERLIN 
	
Fer1L3	was	discovered	in	2000	by	Davis	et	al.	[18]	and	Britton	et	al.	[19].	They	reported	the	
expression	of	 fer1L3	 in	both	heart	 and	 skeletal	muscles	 at	 both	mRNA	and	protein	 levels.	
They	named	fer1L3	as	“Myoferlin”	due	to	its	high	similarity	with	dysferlin	and	its	expression	
in	muscles.	 This	 study	 has	 reported	myoferlin	 to	 be	 expressed	 at	 the	 plasma	membrane,	
cytosol,	nucleus	and	nuclear	envelope	as	well.		
The	study	of	its	structure	revealed	that	it	is	a	235	kDa	protein	predicted	to	have	2061	amino	
acids.	It	contains	six	C2	domains:	C2A	at	the	amino	acids	1-82,	C2B	at	200-281,	C2C	at	359-
458,	C2D	at	1126-1231,	C2E	at	1538-1638	and	 finally	C2F	at	1790-1903.	Myoferlin	possess	
also	a	SH3	domain	at	amino	acids	676-689	lodging	between	the	C2C	and	C2D	domains;	and	
FerI,	FerA,	FerB	and	two	DysF	domains.		
It	 also	 has	 five	 potential	 tyrosine	 phosphorylation	 sites	 (629-953-1593-1611-1835)	 and	 3	
potential	 cAMP	 and	 cGMP-dependent	 protein	 kinase	 phosphorylation	 sites	 (35-183-575),	
which	 open	 the	 possibility	 of	 a	 potential	 role	 in	 cell	 signaling.	 It	 also	 bears	 a	 single	
transmembrane	 domain	 at	 2027-2042	 and	 finally	 an	 extracellular	 domain	 at	 2043-2061	
(figure	4).	
Myoferlin	 has	 8	 isoforms	with	 a	molecular	weight	 ranging	 from	17	 to	 235	 kDa.	 But	 up	 to	
date,	it	is	not	known	whether	the	different	isoforms	play	different	roles	in	the	cell	or	not.				
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Figure	4:	Schematic	structure	of	myoferlin.	Myoferlin	structure	showing	multiple	C2	domains,	SH3	domain,	FerI-A-B	
domains	and	two	DysFN.	Compiled	from	Davis	et	al,	2000;	Britton	et	al,	2000;	and	GenPept	at	NCBI.				
4.1. Myoferl in in non-cancer context 
	
Myoferlin	 role	has	been	described	 in	different	non-cancerous	contexts.	Myoferlin	 is	highly	
expressed	 in	myoblasts;	 especially	 those	myoblasts	 that	 have	 begun	 to	 differentiate,	 and	
plays	a	role	in	myofusion.	Myoferlin	also	plays	a	role	in	endocytosis	and	endocytic	recycling	
in	endothelial	cells.	
	
Myoferlin	in	muscles	
Different	studies	have	revealed	myoferlin	to	be	directly	implicated	in	myoblast	fusion	where	
it	 is	 highly	 expressed	 in	 elongated	myoblasts	 prior	 to	 fusion	 [20].	 It	 has	 been	 shown	 that	
myoferlin	is	expressed,	early	in	myofusion,	at	the	plasma	membrane	area	at	the	fusion	site	
but	then,	its	expression	is	declined	and	dysferlin	expression	increases	instead;	underlying	a	
specialized	fusion	of	each	protein	in	myoblasts	fusion	[4].	Of	interest,	 it	has	been	observed	
that	 transient	 vesicular	 structures	 appear	 at	 the	 site	 of	 membrane	 fusion.	 Doherty	 et	 al.	
proposed	that	these	structures	may	derive	from	the	endocytic	recycling	compartment	[21].		
Finally,	it	has	been	observed	that	myoferlin	is	overexpressed	in	muscle	cells	after	injury.	This	
overexpression	of	myoferlin	participates	 into	the	muscle	repair	as	 in	myoferlin	null	mice,	a	
delay	 in	membrane	 resealing	 is	 observed.	 The	mechanism	of	myoferlin	 response	 to	 injury	
has	 been	 suggested	by	Demonbreun	et	 al.	 to	 be	mediated	by	 the	 increase	 in	 intracellular	
Ca2+	 concentration	 that	 in	 turn,	 increases	 the	 activity	 of	 calcineurin	 and	 NFAT.	 NFAT	 is	 a	
transcription	factor	family	of	4	proteins,	of	which,	at	least	NFAT	1	and	3	bind	the	promotor	
of	 myoferlin	 increasing	 myoferlin	 expression.	 Myoferlin	 null	 mice	 phenotype	 was	
reproduced	 in	 NFAT	 null	 mice,	 implying	 an	 upper	 handed	 control	 of	 NFAT	 on	 myoferlin	
expression/role	[22].			
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Myoferlin	in	endothelial	cells	
While	myoferlin	was	 initially	 thought	 to	 be	 a	muscle	 specific	 protein,	 a	 study	 revealed	 its	
expression	 in	endothelial	cells.	 	 In	 this	context,	myoferlin	plays	an	 important	role	 in	VEGF-
receptor	signaling	upon	VEGF	induction.	VEGF-receptor	is	a	primary	tyrosine	kinase	receptor	
responsible	 for	 the	 majority	 of	 VEGF	 functions	 in	 endothelial	 cells.	 VEGF	 promotes	
proliferation,	 migration	 of	 endothelial	 cells	 via	 VEGF-receptor	 phosphorylation	 and	
downstream	 activation/phosphorylation	 of	 ERK,	 JUN	 and	 PLCγ.	 Myoferlin	 was	 proved	 to	
complex	 dynamin	 2	 and	 VEGF-receptor	 via	 its	 SH3	 domain	 that	 is	 known	 to	 interact	with	
proline	 rich	 proteins,	 like	 dynamin.	 This	 complex	 formation	 protects	 VEGF-receptor	 from	
casitas	 B-lineage	 lymphoma	 (CBL)	 dependent	 polyubiquitination	 and	 subsequent	
degradation.	 Myoferlin	 depletion	 provokes	 a	 decrease	 in	 VEGF-mediated	 proliferation,	
migration	of	endothelial	cells	and	VEGF-receptor	 recycling	 to	 the	surface.	 In	myoferlin	null	
mice,	it	was	observed	a	decreased	expression	of	VEGF-receptor	and	VEGF-mediated	vascular	
hyper-permeability.	 Interestingly	 in	 endothelial	 cells,	 myoferlin	 also	 regulates	 membrane	
resealing	after	physical	damage,	like	in	myoblasts	[6].		
Another	study	by	Yu	et	al.	confirmed	the	expression	of	myoferlin	in	endothelial	cells	showing	
its	implication	in	the	regulation	of	Tie	2-receptor	fate,	another	tyrosine	kinase	receptor.	Yu	
demonstrated	 that	 in	 a	 non-Tie	 2-challenged	 system,	myoferlin	 depletion	 decreased	 Tie	 2	
expression	without	alteration	of	its	mRNA	level,	neither	in	a	CBL-polyubiquitination	nor	in	a	
proteasome	dependent	manner	[23].		
	
Myoferlin	in	endocytic	recycling	and	vesicle	fusion	
Previous	data	would	make	one	think	that	myoferlin	governs	all	surface	proteins	trafficking;	
but	 it	has	been	shown	that	myoferlin	silencing	has	no	effect	on	 trafficking	of	non-tyrosine	
kinase	 receptors,	 like	G-coupled	 protein	 receptor	 and	 Bradykinin	 receptor	 (B2R).	 It	 seems	
that	myoferlin	plays	a	role	in	trafficking	of	only	some	specific	receptors	[23].		
Myoferlin	 contains	 the	 amino	 acid	 sequence	 “Asparagine-Proline-Phenylalanine”,	 a	 known	
binding	motif	of	EHD	proteins,	within	the	second	C2	domain	of	myoferlin	(C2B).	This	binding	
was	 shown	 to	 be	 Ca2+-independent	 as	 the	 C2B	 domain	 lacks	 a	 Ca2+-binding	 motif.	 EHD	
proteins	have	been	linked	to	endosomal	trafficking	including	cell	surface	recycling.		
Of	 interest,	 Davis	 et	 al.	 showed	 that	 myoferlin	 null	 mice	 myoblasts	 displayed	 a	 delay	 in	
transferrin-receptor	 recycling	 to	 the	 surface	 after	 transferrin	 uptake	 with	 no	 effect	 on	
transferrin	 uptake	 itself.	 This	 means	 that	 myoferlin	 does	 not	 seem	 to	 play	 a	 role	 in	 the	
endocytosis	 of	 receptor	 as	much	 as	 its	 subsequent	 fate	 determination,	 in	myoblasts	 [21].		
While	 Bernatchez	 et	 al.	 showed	 that	 myoferlin	 depletion	 in	 endothelial	 cells	 provoked	 a	
decrease	 in	 transferrin	 uptake	 itself	with	 no	 effect	 on	 surface	 receptor	 expression.	 In	 this	
study,	Bernatchez	highlighted	a	role	of	myoferlin	in	receptor-mediated	endocytosis	for	both	
Clathrin-Dependent	Endocytosis	and	Non-Clathrin-Dependent	Endocytosis.		
In	endothelial	 cells,	myoferlin	depletion	provokes	a	50%	decrease	 in	 the	 internalization	of	
both	 Transferrin	 and	 Cholera	 Toxin	 B,	 which	 are	 clathrin	 pits	 and	 caveolin/lipid	 raft	
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dependent	 endocytosis,	 respectively.	 Mechanistically,	 myoferlin	 and	 caveolin-1	 act	 on	
receptor	endocytosis	 in	a	 similar	 rather	 than	parallel	manner	 to	mediate	endocytosis.	 In	a	
cell	 free	system,	myoferlin	was	shown	to	directly	 interact	with	caveolin-1.	This	 shows	 that	
myoferlin	 is	 involved	 in	 both	 caveolin-mediated	 endocytosis	 and	 clathrin	 dependent	
endocytosis	[24].	
 
4.2.  Myoferl in in cancer context 
	
Since	the	role	of	myoferlin	has	been	starting	to	get	revealed	in	endothelial	and	muscle	cells,	
showing	an	important	implication	in	fusion,	fission	and	endocytosis;	there	was	an	increasing	
interest	 in	 understanding	 the	 probable	 role	 of	 myoferlin	 in	 cancer	 progression.	
Immunohistochemical	 evidences	 available	 from	 “Human	 Protein	 Atlas”	 database	 suggest	
that	 myoferlin	 is	 strongly	 expressed	 in	 several	 cancer	 types	 including	 pancreas,	 stomach,	
liver,	colorectal,	ovarian,	cervical,	endometrial,	thyroid,	breast	and	lung	cancers.	
Up	to	date,	myoferlin	has	been	studied	mainly	 in	four	cancer	types:	pancreas,	breast,	 lung	
and	oropharyngeal	cancers.	
	
Myoferlin	in	pancreas	cancer	
Myoferlin	 has	 been	 first	 identified	 to	 be	 overexpressed	 on	 the	 transcriptomic	 level	 in	
Pancreatic	Ductal	Adenocarcinoma	(PDAC)	[25–27].	Afterwards,	its	overexpression	has	been	
confirmed	 on	 the	 proteomic	 level	 thanks	 to	 the	 proteomic	 profiling	 of	 PDAC	 samples	
[28][29].	 Later	 on,	 another	 study	 not	 only	 confirmed	 the	 overexpression	 of	 myoferlin	 in	
PDAC,	but	also	revealed	that	myoferlin	expression	is	significantly	correlated	with	the	degree	
of	histological	differentiation	and	 that	 it	 is	 an	 independent	prognostic	marker	 for	 survival.	
Patients	having	high	myoferlin	expression	have	higher	tumor	grade	and	shorter	survival.	This	
seems	 to	 fit,	 as	 it	 is	 well-known	 in	 PDAC,	 that	 tumor	 grade	 is	 an	 important	 variable	 of	
survival	 where	 patients	 with	 high	 grade	 (poorly	 differentiated	 tumors)	 tends	 to	 have	 the	
worst	prognosis	[30].		
In	 their	 study,	Wang	 et	 al.	 showed	 that	 PDAC	 cell	 lines	 BxPC-3	 and	 CFPAC-1	 express	 high	
level	 of	myoferlin	 and	 that	myoferlin	 silencing	 decreased	 cell	 proliferation,	migration	 and	
colony	 forming	 ability.	 The	 decrease	 in	 cell	 proliferation	 seemed	 to	 be	 due	 to	 both	 an	
increase	 in	 apoptosis	 and	 a	 cell	 cycle	 arrest	 in	 S	 phase.	 Moreover,	 mouse	 model	 of	
subcutaneously	injected	myoferlin-knocked	down	cells;	showed	smaller	tumors	compared	to	
control	counterparts.		
	
Myoferlin	in	breast	cancer		
Myoferlin	 has	 also	 been	 shown	 to	 be	 overexpressed	 in	 breast	 cancer.	 Eisenberg	 and	
Friedman	proposed	a	potential	role	of	myoferlin	in	the	breast	cancer	cell	motility	[31].	Li	et	
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al.	showed	that	myoferlin	expression	in	breast	cancer	cell	lines	correlates	with	their	invasive	
potential.	Myoferlin	 is	highly	expressed	 in	highly	 invasive	cells	 (MDA-MB-231	and	BT	549);	
moderately	 expressed	 in	 less	 invasive	 cells	 (MCF7	 and	 T47D);	 weakly	 expressed	 in	 non-
invasive	MCF10A	cells.	Li	and	coworkers	also	showed	that	myoferlin	knockdown	in	MDA-MB-
231	increased	mesenchymal	to	epithelial	transition	(MET)	and	decreased	invasive	properties	
in	 matrigel	 and	 collagen-based	 assays.	 That	 was	 associated	 with	 a	 decrease	 in	 MMPs	
secretion	and/or	transcription	[32].	
The	 same	 group	 has	 further	 explained	 the	 effect	 of	 myoferlin	 knockdown	 on	 decreasing	
invasion	potential	to	be	related	to	the	acquisition	of	an	epithelial	phenotype.	This	phenotype	
change,	 due	 to	 myoferlin	 depletion,	 promotes	 maintenance	 of	 cell-to-cell	 junctions	 and	
migration	 as	 cohesive	 communal	 cell	 sheet	 or	 cluster,	 not	 affecting	 Euclidian	 traveled	
distance	but	indeed	affecting	accumulated	distance	and	velocity.	 In	other	words,	myoferlin	
depletion	 promotes	 slow	 but	 directional	 migration.	 Blackstone	 et	 al.	 proposed	 that	 this	
effect	is	mediated	via	an	increase	in	focal	adhesion	kinase	phosphorylation/maturation	[33].	
While	myoferlin	knockdown	did	not	have	an	effect	on	neither	cell	 cycle	nor	cell	growth	 in	
vitro;	myoferlin	knocked-down	in	MDA-MB-231	cells	gave	smaller	tumors	and	demonstrated	
less	tumor	burden	when	 injected	subcutaneously	 in	nude	mice.	The	tumors	displayed	high	
circularity	 and	 no	 invasion	 of	 the	 surrounding	 [33].	 Leung	 et	 al.	 also	 confirmed	 the	
expression	of	myoferlin	in	breast	cancer	cell	lines	showing	no	differential	expression	in	terms	
of	metastasis	potential	or	transformation.		
Interestingly,	our	laboratory	has	revealed	the	control	of	myoferlin	on	the	fate	determination	
of	EGF-receptor	and	its	consequent	effects	on	breast	cancer	cell	 lines.	Turtoi	et	al.	showed	
that	 myoferlin	 silencing	 enhanced	 and	 sustained	 EGF-receptor	 and	 down-stream	 AKT	
phosphorylation	 but	 not	 affecting	 internalization	 kinetics	 of	 EGF-receptor	 during	 EGF	
challenge	 in	MDA-MB-231	 cell	 line	 compared	 to	 counterpart	 control.	 They	 demonstrated	
that	 myoferlin	 silencing	 provoked	 a	 decrease	 in	 proteasome	 degradation	 of	
activated/internalized	receptor	proposing	that	sustained	signaling	is	linked	to	the	inability	of	
the	cells	to	properly	degrade	the	receptor	in	the	absence	of	myoferlin.		The	myoferlin	down	
regulation	 was	 also	 able	 to	 reduce	 EGF-induced	 cell	 migration	 in	 Boyden	 chamber.	 The	
authors	also	demonstrated	a	decrease	 in	epithelial	 to	mesenchymal	 transition	 (EMT)	after	
EGF	treatment	in	MDA-MB-468	cell	line.	Finally,	Turtoi	et	al.	showed	that	myoferlin	silencing	
in	MDA-MB-231	provoked	a	decrease	in	tumor	volume	in	Chorioallantoic	membrane	(CAM)	
assay,	this	decrease	in	tumor	volume	could	be	at	least	partially	explained	by	an	increase	in	
apoptosis	observed	after	an	EGF	challenging	in	vitro	[34].		
	
Myoferlin	in	lung	and	oropharyngeal	cancers		
Myoferlin	has	been	shown	to	play	a	key	role	in	lung	cancer	progression.	Myoferlin-depleted	
Lewis	 Lung	Carcinoma	 (LLC)	 cells	 gave	 50	%	 smaller	 tumors	 and	demonstrated	 less	 tumor	
burden	when	injected	into	nude	mice.	This	effect	was	further	confirmed	to	be	due	to	a	direct	
effect	 on	 LLC	 cell	 growth	 as	 there	 were	 neither	 increase	 in	 apoptosis	 nor	 a	 decrease	 in	
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micro-vessels	 density	 nor	 a	 decrease	 in	 VEGF-A	 serum	 levels,	 compared	 to	 counterpart	
control	[35].	
Recently,	 myoferlin	 has	 been	 reported	 to	 be	 expressed	 in	 non-small	 cell	 lung	 cancers	
patients	sections	and	correlates	with	VEGF-receptor	2	expression	and	poor	prognosis	 [36].	
Another	 study	 showed	 that	 myoferlin	 nuclear	 staining	 is	 associated	 with	 a	 poor	 overall	
survival,	 increased	 hazard	 death,	 tumor	 recurrence,	 perineural	 invasion,	 extracapsular	
spread,	 high	 T-stage	 and	 distant	 metastasis	 in	 oropharyngeal	 squamous	 cell	 carcinoma	
patients	[37].			
	
5.  EXOCYTOSIS  
	
Exocytosis	 is	the	trafficking	of	secretory	vesicles	to	the	plasma	membrane.	It	 is	the	base	of	
cellular	 communication	 in	multicellular	 organisms	 through	 the	 release	 of	 a	wide	 range	 of	
extracellular	 acting	 molecules	 like	 hormones,	 growth	 factors,	 plasma	 proteins,	 antibodies	
and	extracellular	matrix	components	to	exert	various	functions.	Exocytosis	could	be	whether	
constitutive,	 like	 the	 continuous	 secretion	 of	 extracellular	matrix	 components	 and	 plasma	
proteins;	or	regulated,	as	a	response	to	an	external	stimulus,	like	neurotransmitters	release	
at	the	synapses	(figure	5).	Cells	may	show	different	kinds	of	secretory	granules	composed	of	
different	 cargos	 that	 could	 be	 secreted	 by	 the	 same	 cell	 in	 a	 constitutive	 or	 regulated	
manner	to	ensure	different	physiological	functions	[38].			
	
                                   
 
Figure	5:	Illustration	of	exocytosis	types.	Constitutive	exocytosis	is	when	there	is	a	non-stop	secretion	of	extracellular	
components	while	regulated	exocytosis	is	triggered	upon	extracellular	stimuli. Alberts et al., 1998. 
 
Exocytosis	 vesicles	 formation	 starts	 at	 the	 trans-Golgi	 network	 (TGN)	 where	 the	 cargo	 of	
soluble	 proteins	 assembles	 at	 the	 inner	 surface	 of	 the	 TGN.	 It	 is	 thought	 that	 this	
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aggregation	 of	 proteins	 is	 the	main	 driver	 of	 the	 deformation	 of	 the	 TGN	membrane	 and	
budding	of	vesicles.	Nascent	granules	bud	at	the	surface	but	they	require	a	pinching	to	be	
released	as	immature	secretory	granules	(ISG)	into	the	cytoplasm.	At	that	point,	cholesterol	
seems	 to	 play	 an	 important	 role	 in	 mediating	 this	 fission	 process	 probably	 by	 directly	
facilitating	 negative	 membrane	 curvature	 at	 the	 bud-neck	 or	 indirectly	 by	 recruiting	 raft	
associated	proteins	 that	carry	out	 the	 fission	 [38].	 In	 ISG,	 the	 lipid	bilayer	of	 the	secretory	
vesicle	contains	phospholipids,	 like	phosphatidylserine,	and	proteins	required	for	secretory	
vesicles	acidification,	transport,	targeting	and	fusion.	While	the	dense	core	of	the	secretory	
vesicles	 contains	 the	 soluble	 protein	 cargo	 to	 be	 secreted,	 which	 indeed	 differs	 in	
composition	upon	cell	type	and	nature	of	the	messenger	[39]	[40].	However,	there	are	still	
unknowns	 in	 the	 exact	 composition	 of	 the	 vesicles	membrane	 components	 that	might	 be	
involved	in	vesicle	transport,	targeting	and	fusion.				
The	exact	composition	of	the	lipids	and	proteins	of	the	unilamellar	lipid	bilayer	membrane	of	
vesicles	 are	 not	 yet	 totally	 revealed.	 However,	 studies	 have	 identified	 some	 negatively	
charged	 phospholipids	 like	 phosphatidylserine	 and	 phosphatidylinositol;	 also	 other	
phospholipids	 like	 phosphatidylcholine,	 phosphatidylethanolamine,	 sphingomyelin.	 There	
are	evidences	suggesting	that	negatively	charged	phospholipids	on	the	outer	surface	of	the	
vesicles	membrane	and	cytoplasmic	leaflet	of	the	plasma	membrane	act	as	coupling	factors	
enhancing	 interaction	 between	 negatively	 charged	 phospholipids	 and	 positively	 charged	
motifs	 of	 SNARE	 proteins.	 It	 is	 believed	 that	 the	 anionic	 characteristic	 of	 the	 serine	 head	
group	 of	 phosphatidylserine	 promotes	 interaction	 between	 phosphatidylserine	 and	
positively	 charged	 SNARE	 proteins.	 SNARE	 proteins	 like	 the	 vesicular	 Synaptobrevin	
(VAMP2),	 the	 membranous	 Syntaxin1a	 (Syt1a)	 and	 membranous	 synaptosome-associated	
protein	 of	 25	 kDa	 (SNAP25),	mediate	 fusion	 events	with	 the	 plasma	membrane.	 All	 these	
proteins	 share	 a	 60-70	 long	 highly	 conserved	 juxtamembrane	 poly-basic	 amino	 acid	
sequence	 called	 SNARE	 motif	 that	 binds	 negatively	 charged	 phospholipids	 such	 as	
phosphatidylserine	 as	 mentioned	 [40].	 It	 was	 proven	 that	 a	 mutation	 of	 the	 Ca2+-
calmodulin/phospholipids	 binding	 motif	 of	 VAMP2,	 decreasing	 its	 net	 positive	 charge,	
decreases	 its	 interaction	 with	 negatively	 charged	 phospholipids	 and	 interferes	 with	 the	
normal	catecholamine	secretion	from	chromaffin	cells	[41].	As	well	Synaptotagmin	I	(SYT1),	a	
dual	C2	domains	bearing	protein	involved	in	membrane	fusion	events	and	exocytosis,	binds	
to	negatively	charged	phospholipids	in	a	Ca2+-dependent	manner,	thanks	to	its	C2	domains.	
Increasing	phosphatidylserine	levels	leads	to	an	increase	in	Ca2+-triggered	vesicles	fusion	by	
stabilizing	fusion	pores	in	PC12	cells	and	increase	Ca2+-dependent	SYT1	binding	in	liposomes	
[42].		
	
5.1. VEGF and angiogenesis in pancreatic cancer 
	
Pancreatic	cancer	is	considered	to	be	one	of	the	most	aggressive	cancers.	It	is	characterized	
by	 a	 very	 poor	 prognosis,	 with	 a	 five	 year	 survival	 rate	 ranging	 from	 0	 to	 18%	 and	most	
patients	suffer	from	metastasis	[43].	The	median	survival	 is	reported	to	range	between	2.5	
to	 8	 months	 [44].	 This	 is	 due	 to	 multiple	 factors	 including	 late	 diagnosis,	 resistance	 to	
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chemotherapy,	 high	 tendency	 of	 metastasis	 and	 a	 wide	 range	 of	 genetic	 and	 epigenetic	
alterations	[45].		While	surgical	resection	remains	the	only	curative	option;	only	20%	of	the	
patients	can	benefit	from	this	process	[46].	However,	the	five	year	survival	of	that	group	of	
resectable	patients	grow	only	to	20%	[47]	and	the	median	survival	raises	only	from	13	to	21	
months	[44].	Overall,	it	is	a	common	opinion	that	the	decline	in	mortality	observed	in	other	
cancer	diseases	has	so	far	not	taken	place	in	pancreatic	cancer	[48].		
Angiogenesis	 is	 required	 for	 invasive	 tumor	 growth	 and	 metastasis	 and	 it	 constitutes	 an	
important	 point	 in	 the	 control	 of	 cancer	 progression.	 For	 tumors	 to	 develop	 in	 size	 and	
metastasize,	they	must	make	an	"angiogenic	switch"	through	perturbing	the	local	balance	of	
pro-angiogenic	versus	anti-angiogenic	factors	[49].	Although	pancreatic	cancer	is	considered	
as	a	hypovascularized	tumor	due	to	its	characteristics	on	imaging,	yet	angiogenesis	is	critical	
for	the	development	and	growth	of	pancreatic	cancer	[43].	The	best-known	pro-angiogenic	
protein	is	the	vascular	endothelial	growth	factor-A	(VEGF-A).	VEGF-A	binds	to	VEGF-receptor	
2	on	endothelial	cell	and	promotes	the	migration	of	endothelial	cell	[50].			
In	general,	VEGF	is	an	attractive	therapeutic	target.	In	pancreatic	cancer	the	overexpression	
of	VEGF	and	VEGF-receptors	have	been	reported	[51].	Furthermore,	pancreatic	cancer	often	
exhibits	 enhanced	 foci	 of	 endothelial	 cell	 proliferation	 [49].	 Overexpression	 of	 VEGF	 in	
pancreatic	cancer	 is	demonstrated	to	be	significantly	associated	with	microvesicles	density	
(MVD)	and	that	advanced	stage	of	the	disease	is	significantly	more	frequent	with	high	MVD	
[52].	VEGF	 concentration	 correlates	with	poor	prognosis	 in	patients	 and	animal	models	 as	
well	 [51].	Actually,	 It	has	been	described	 that	VEGF	 transcription	 is	 increased	 in	PDAC	and	
that	patients	having	a	VEGF	plasma	concentration	lower	than	596	pg/ml	have	better	survival	
chances	 [53].	 Further	 studies	 showed	 that	 portal	 VEGF-A	 concentration	 is	 associated	with	
tumor	grade	and	size	but	not	with	survival	[54].	Hypoxia	is	associated	with	the	expression	of	
pro-angiogenic	 factors,	 including	 VEGF	 that	 plays	 a	 pivotal	 role	 in	 pancreatic	 cancer	 liver	
metastasis	 [55].	 Finally,	 it	 has	 been	 shown	 that	 patients	 having	 VEGF-receptor	 2	 negative	
tumors	gain	10	months	of	survival	compared	to	patients	how	are	positive	for	the	receptor	
[56].			
6.  EXOSOME BIOGENESIS 
	
Exosomes	 are	 small	 extracellular	 vesicles	 with	 a	 size	 ranging	 between	 50	 to	 150	 nm	 in	
diameter	[57].	They	correspond	to	the	intraluminal	vesicles	(ILV)	of	the	multivesicular	bodies	
(MVB),	which	are	secreted	upon	the	fusion	of	the	latter	with	the	plasma	membrane.	ILV	are	
formed	 by	 the	 reverse	 budding	 of	 the	 endosomal	 limiting	 membrane	 (figure	 6);	 when	
hundreds	 of	 ILV	 are	 formed,	 this	 structure	 is	 referred	 as	MVB.	 The	 latter	 structure	 could	
either	 fuse	 with	 lysosomes	 for	 the	 degradation	 of	 its	 content	 or	 fuse	 with	 the	 plasma	
membrane	releasing	ILV	as	exosomes	to	the	extracellular	milieu	[57][58].	During	the	reverse	
budding	 of	 the	 endosomal	 limiting	membrane,	 cargo	 proteins	 are	 segregated	 and	 packed	
within	 the	 lumen	 of	 the	 nascent	 vesicles.	 The	 mechanisms	 underlying	 the	 sorting	 of	 the	
proteins,	genetic	materials	and	 lipids	 into	the	 ILV,	the	docking	and	fusion	of	MVB	with	the	
plasma	membrane	are	largely	unknown	[59].			
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Figure	6:	Biogenesis	of	exosomes	from	the	endosomal	compartment.	Exosomes	are	produced	by	the	reverse	budding	of	
the	endosomal	limiting	membrane	of	the	late	endosomes.	MVB	can	fuse	with	lysosomes	for	the	degradation	of	their	
content	or	fuse	with	the	plasma	membrane	for	the	release	of	exosomes.	Kowal	et	al.,	2014	[60].	
	
Vesicles	with	hallmarks	of	exosomes	have	been	 isolated	from	diverse	body	fluids	 including	
blood	[61],	saliva	[62],	bile	[63],	breast	milk	[64],	semen	[65],	urine	[66],	cerebrospinal	fluid	
[67],	 ascites	 fluid	 [68]	 and	 amniotic	 fluid	 [69].	 As	well	 exosomes	 have	 been	 isolated	 from	
different	 cell	 culture	 supernatant	 of	 different	 cell	 types	 including	 erythrocytes	 [70],	 B-
lymphocytes	[71],	dendritic	cells	[72],	neurons	[73],	mast	cells	[74],	intestinal	cells	[75]	and	
more.		
Since	exosomes	formation	includes	two	inwards	budding	processes,	exosomes	maintain	the	
same	 topological	 orientation	 as	 the	 cell,	 with	 membrane	 proteins	 on	 the	 outer	 side	 and	
some	cytosolic	content	on	the	inner	side	[59].	The	content	of	exosomes	is	very	diversified	as	
exosomes	contain	proteins,	lipids	and	genetic	materials.	
Exosomes	 contain	 proteins	 that	 are	 usually	 present	 in	 the	 membrane	 regions	 prone	 to	
internalization,	 proteins	 of	 endosomal	 origin	 and	 cytosolic	 proteins.	 Generally,	 exosomal	
protein	content	is	 like	heat	shock	protein	(HSC70	and	HSC90),	cytoskeleton	proteins	(actin,	
tubulin,	meosin),	endosomal	 sorting	complex	 required	 for	 transport	 “ESCRT”	proteins	 (Alix	
and	Tsg101),	 tetraspanins	 (CD9,	CD63,	CD81,	CD82	and	CD151)	 and	proteins	 implicated	 in	
the	 transport	 (Rab2,	 Rab7	 and	 Rab11)	 [59][76][57].	 In	 consistency	 with	 their	 endosomal	
origin,	 no	proteins	 from	 the	nucleus,	mitochondria	or	 endoplasmic	 reticulum	are	 found	 in	
exosomes.	That	is	why	markers	of	mitochondria	(like	complex	IV)	or	endoplasmic	reticulum	
(like	GRP78)	are	often	used	as	negative	markers	for	exosomal	isolation	purity.	Finally,	some	
other	 protein	 content	 reflects	 the	 cellular	 origin	 of	 the	 exosomes,	 it	 means,	 harboring	 a	
specific	marker	of	the	cell	of	origin	(figure	7).	
Interestingly,	it	has	also	been	reported	that	exosomes	carry	mRNA	and	miRNA	[77][78].	This	
nucleic	acid	 content	of	 the	exosomes	was	demonstrated	 to	alter	 the	 transcriptome	of	 the	
recipient	cells	and	to	provoke	a	phenotype	change	[79].	Moreover,	it	has	been	reported	that	
	
	
18	
neuronal	 and	myoblast-derived	exosomes	 carry	mitochondrial	DNA,	which	 is	hypothesized	
to	integrate	into	recipient	cell’s	mitochondria,	but	yet	this	haven’t	been	proven	[57]	[77].	
	
	
Figure	7:	Exosomal	content	of	proteins,	lipids	and	nucleic	acids.	Charchar	et	al.,	2015	[80].	
	
Noteworthy,	 the	 total	 cellular	 content	 of	 mRNA	 was	 shown	 to	 be	 different	 from	 the	
exosomes,	 in	 other	words,	 some	mRNA	were	 never	 reported	 to	 be	 present	 in	 exosomes,	
implying	 probably	 a	 selection	mechanism.	 Some	 reports	 propose	 a	 Zip	 code	 at	 the	 3’UTR	
that	could	interact	with	some	sorting	proteins	[76].	On	the	other	hand,	the	miRNA	content	is	
not	reported	to	be	different	between	cells	and	exosomes	and	it	is	believed	that	miRNA	is	just	
packed	 into	 exosomes	 during	 the	 reverse	 budding	 of	 the	 endosomal	 limiting	 membrane.	
However,	 some	 reports	 suggest	 that	 miRNA	 could	 be	 selectively	 packed	 via	 a	 physical	
interaction	with	the	RISK	complex	proteins	[76].			
	
	
Figure	8:	Illustration	of	the	different	possible	exosomes	biogenesis	pathways.	Colombo	et	al.,	2014	[81].	
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In	general,	exosomes	biogenesis	 is	 far	 from	being	totally	understood.	This	could	be	due	to	
the	 presence	 of	 different	 biogenesis	 pathways	 within	 the	 same	 cell	 and	 certainly	 within	
different	cell	types	(figure	8).	Overall,	few	biogenesis	pathways	were	described,	among	then	
the	 ESCRT	 pathway.	 ESCRT	 proteins	 are	 a	 family	 of	 20	 proteins	 forming	 four	 soluble	
complexes,	and	they	have	been	reported	to	play	important	roles	in	exosomes	biogenesis.	It	
has	also	been	 reported	 that	 lipids	and	 tetraspanins	are	 implicated	 in	exosomes	biogenesis	
via	different	mechanisms.		
	
6.1. Exosomes in cel lular communication 
	
Pan	 and	 Johnston	 first	 described	 exosomes	 while	 studying	 the	 maturation	 of	 sheep	
reticulocytes	during	the	eighties	[82].	Exosomes	were	first	thought	to	be	a	way	for	the	cell	to	
eliminate	excess	or	unnecessary	materials	or	materials	 that	are	unable	 to	be	degraded	by	
the	 cell.	 However,	 a	 hypothesis	 was	 raised	 that	 exosomes	 could	 play	 a	 role	 in	 cellular	
communication.	 Since	 the	 discovery	 of	 genetic	material	 in	 exosomes,	 this	 hypothesis	was	
rendered	 stronger.	 Exosomes’	 cargos	 have	 been	 proven	 to	 alter	 the	 recipient	 cell’s	
transcriptome	and	lead	to	a	phenotype	change.		
In	 general,	 exosomes	 have	 been	 associated	 with	 the	 progression	 of	 some	 diseases	 like	
neurodegenerative,	 cardiovascular	 diseases	 and	 cancer;	 but	 also	management	 of	 some	 of	
these	 conditions.	 It	 has	 been	 shown	 that	 exosomes	 derived	 from	 an	 in	 vitro	 culture	 of	
human	embryonic	 stem	cells	 are	 able	 to	 reduce	 infarction	 size	when	 injected	 into	murine	
and	 swine	 models	 of	 ischemia.	 Another	 example	 of	 exosome	 communication	 between	
endothelial	 cells	and	smooth	muscles	was	shown	when	endothelial	 cell-derived	exosomes,	
rich	in	mir143/145,	were	able	to	reduce	atherosclerosis	lesion	formation	when	injected	into	
a	mouse	model	of	atherosclerosis	[79].		
Many	hypotheses	have	been	proposed	on	how	exosomes	act	on	target	cells.	Exosomes	can	
act	 directly	 on	 target	 cells	 via	 interaction	with	 surface	 proteins/receptors	 of	 the	 recipient	
cells.	Another	possibility	 is	 that	exosomes	 could	be	 cleaved	due	 to	 some	protease	activity	
releasing	 their	 content	 of	 soluble	 cargo	 that	 can	 interact	 with	 recipient	 cell	 surface	
receptors.	 Finally,	 exosomes	 can	 be	 totally	 internalized	 into	 recipient	 cells.	 The	 latter	
mechanisms	have	been	proved	by	the	transfer	of	labeled	exosomes	into	recipient	cells	and	
the	transfer	of	genetic	material	as	well	[77].		
	
6.2. Exosomes in cancer communication  
	
Since	many	cell	types	shed	exosomes,	one	could	expect	cancer	cells	to	adopt	this	very	same	
communication	pathway	with	their	environment.	 Interestingly,	 it	was	reported	that	cancer	
patients’	serum	contain	more	exosomes	than	normal	donors	and	that	increased	amount	of	
exosomes	correlates	with	advanced	disease	conditions.	Further	on,	 it	has	been	shown	that	
cancer	cell-derived	exosomes	have	higher	miRNA	content	compared	to	normal	cell-derived	
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exosomes.	 Moreover,	 miRNA	 content	 is	 also	 more	 abundant	 in	 exosomes	 derived	 from	
highly	metastatic	cancer	cells	compared	to	less	metastatic	ones.	This	enrichment	of	miRNA	
content	in	cancer	cell-derived	exosomes	was	not	a	reflection	of	an	overall	increase	in	cellular	
miRNA	 content	 when	 compared	 with	 normal	 cells	 but	 was	 a	 selective	 enrichment.	
Noteworthy,	 normal	 and	 cancer	 cell-derived	 exosomes	 also	 contain	 pre-miRNA	 but	 only	
cancer	 cell-derived	 exosomes	 harbors	 components	 essential	 for	maturation	 of	 pre-miRNA	
into	miRNA	like	DICER,	RLC,	AGO2	and	TBRP.	This	group	of	factors	were	shown	to	be	able	to	
conduct	the	maturation	of	pre-miRNA	in	exosomes	when	exosomes	were	incubated	in	a	cell	
free	system	[78].	This	 increase	 in	exosome	numbers	and	alteration	of	 their	content	 reflect	
the	importance	of	exosomes	in	cancer	cell	communication.		
Exosomes	in	tumor	context	have	been	proven	to	be	associated	to	many	events	during	cancer	
progression.	 Cancer-derived	 exosomes	 have	 been	 proven	 to	 be	 involved	 in	 angiogenesis	
where	glioblastoma-derived	exosomes’	mRNA	content	was	shown	to	be	translated	into	pro-
angiogenic	 proteins	 in	 the	 recipient	 cells	 [57].	 Immune	 cell	 exosomes	 are	 reported	 to	
contribute	in	the	battle	against	cancer.	It	has	been	reported	that	activated	T	cell	exosomes	
expressing	Fas	 ligand	are	able	 to	promote	apoptosis	of	 Jurkat	cells.	While	 for	B16	 (murine	
melanoma)	 and	 3LL	 (lung	 cancer)	 cells,	 FasL	 positive	 exosomes	 from	 activated	 T	 cells	
promote	 the	 invasiveness	 and	migration	 potentials;	 in	 other	 words,	 it	 promoted	 a	 tumor	
immune	escape	[83].					
It	 was	 very	 nicely	 shown	 by	Melo	 et	 al.	 that	 the	 breast	 cancer	 cell	MDA-MB-231	 derived	
exosomes	 are	 able	 to	 provoke	 a	 global	 change	 of	 mRNA	 profile	 of	 the	 recipient	 non-
tumorigenic	epithelial	MCF10A	cells.	 This	 cancer	 cells	derived	exosomes	were	also	able	 to	
increase	 viability,	 proliferation	 and	 colony	 forming	 ability	 of	MCF10A	 cells	 in	 vitro.	When	
MCF10A	cells	were	co-injected	with	the	cancer	cell-derived	exosomes	into	a	mouse	model,	
mice	did	develop	 tumors,	while	no	 tumors	were	detected	 in	 the	non-exosomes	condition.	
Moreover,	 cancer	 patients	 and	 normal	 donors’	 serum	 exosomes	 were	 isolated	 and	 co-
injected	 with	 MCF10A	 cells	 into	 mice;	 almost	 fifty	 percent	 of	 the	 mice	 co-injected	 with	
cancer	 patients’	 serum	 derived	 exosomes	 developed	 tumors	 (5/11	 mice)	 while	 no	 mice	
developed	tumors	when	co-injected	with	normal	donors’	derived	exosomes	[78].				
	
7.  MYOFERLIN A THERAPEUTIC TARGET IN VESICLE-MEDIATED CANCER CELL 
COMMUNICATION 
	
As	 previously	 mentioned,	 myoferlin	 has	 been	 identified	 to	 be	 overexpressed	 in	 different	
types	of	cancer	including	pancreas	and	breast	cancer.	Interestingly,	our	laboratory	identified	
myoferlin	as	an	accessible	marker	in	PDAC	in	the	aim	of	identifying	new	targets	for	diagnosis	
and	 therapeutic	applications.	This	 is	based	on	 the	hypothesis	 that	extracellular	matrix	and	
membrane	proteins	are	the	first	line	of	physical	interactions	of	cancer	with	the	surrounding	
microenvironment.	These	proteins	are	of	extreme	interest	in	therapeutic	applications	if	they	
are	proved	to	be	primordial	for	cancer	cell	viability.	
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Leung	et	al.	proposed	that	in	cancer	cells,	as	they	by-pass	cell-cycle	check	points	via	genetic	
instabilities	 or	 DNA	 mutations,	 they	 are	 able	 to	 proliferate	 in	 a	 continuous	 manner	
increasing	their	requirement	of	nutrients	uptake.	This	increase	in	nutrients	uptake	requires	
intense	plasma	membrane	fusion	and	fission	events.	This	uncontrolled	proliferation	may	also	
imply	an	intense	communication	with	the	surrounding	microenvironment	[35].	The	point	is,	
since	myoferlin	is	required	for	membrane	integrity	and	remodeling	to	ensure	homeostasis,	it	
could	be	an	interesting	therapeutic	target.	Moreover,	Bernatchez	et	al.	raised	the	hypothesis	
that	impaired	cell	growth	and	chemotaxis	in	endothelial	cells	lacking	myoferlin	may	be	due	
to	a	defect	in	the	endocytic	recycling	[24].		
A	number	of	precious	pieces	of	information	would	make	one	hypothesis	that	myoferlin	is	an	
important	 mediator	 for	 vesicle	 trafficking	 and	 cellular	 communication.	 Cellular	
communication	 is	 essentially	based	on	 sending	and	 receiving	 information	 from	one	cell	 to	
the	 other.	 A	 great	 deal	 of	 cellular	 communications	 is	 handled	 by	 vesicles;	 like	 exocytotic	
vesicles	or	exosomes,	which	are	both	vesicles	made	of	phospholipid.	
Starting	 by	 otoferlin,	 as	 previously	mentioned	 before,	 it	 has	 been	 proven	 that	 otoferlin	 is	
expressed	 in	 Inner	Hair	 Cells	where	 electron	microscopy	 showed	 that	 it	 is	 located	 on	 the	
exocytosis	 vesicles.	 Otoferlin	 has	 been	 proven	 to	 interact	 with	 essential	 components	 for	
exocytosis	like	Syntaxin-1	and	SNAP25	in	a	Ca2+-dependent	manner.	Moreover,	a	mutation	in	
otoferlin	leads	to	deafness;	implying	a	direct	role	in	exocytosis	of	neurotransmitters.		
Dysferlin,	 myoferlin	 and	 Fer-1	 have	 all	 been	 shown	 to	 be	 involved	 in	 membrane	 fusion	
processes	in	different	models,	whether	endothelial	cell	repair,	myoblast	fusion	or	C.	elegans	
sperm	motility.	 Interestingly,	all	 three	proteins	down	regulation	were	accompanied	by	 the	
observation	of	an	accumulation	of	different	 kind	of	 vesicles,	depending	on	 the	model	and	
the	protein,	at	the	inner	surface	of	the	plasma	membrane.	This	implies	a	key	role	in	vesicles	
fusion	with	the	plasma	membrane.	Moreover,	during	myoblast	differentiation,	myoferlin	 is	
observed	 to	 be	 present	 in	 vesicles	 [4].	 Myoferlin,	 Dysferlin	 and	 Fer-1’s	 structure-activity	
relationship	 implies	 a	 role	 in	protein-protein,	 protein-lipid	 interaction	 in	 a	Ca2+-dependent	
manner,	as	they	all	possess	multiple	tandem	C2	domains	as	shown	previously.	This	has	been	
confirmed	by	P.	Johnson	et	al.	where	they	showed	that	the	ferlin	proteins	not	only	passively	
stick	 to	 membranes	 but	 concretely	 are	 able	 to	 sculpt	 lipid	 bilayers	 which	 result	 in	 high	
curved	or	distorted	membrane	regions	that	could	facilitate	membrane	fusion	and	fission	or	
recruitment	of	 other	membrane	 trafficking	proteins	 [11].	Moreover,	 Posey	 and	 colleagues	
hypothesized	 that	 by	 analogy	with	 synaptotagmin,	 a	 key	 protein	 in	 exocytosis,	 one	 could	
expect	 that	 exocytosis	 events	 such	 as	 those	 related	 to	 vesicles	 fusion,	 and	 membrane	
organelles	fusion	are	regulated	by	ferlin	proteins	[5].			
Of	extreme	interest,	Redpath	et	al.	have	made	a	stunning	discovery	where	they	showed	that	
dysferlin	 has	 a	 special	 splicing	 variant	 mRNA,	 called	 40a,	 producing	 a	 protein	 that	 has	 a	
putative	calpain	cleavage	site.	This	enzymatic	cleavage	was	Ca2+-dependent	and	gave	rise	to	
an	about	70	KDa	protein	 in	vitro.	As	well	 in	vivo,	Dysferlin	70	kDa	protein	fragment,	called	
mini-dysferlin,	is	also	generated	and	has	been	proven	to	be	functionally	active	in	membrane	
repair	 after	 injury.	 Redpath’s	 observation	 was	 extended	 to	 both	 myoferlin	 and	 otoferlin,	
where	both	protein	generated	a	70	kDa	fragments	similar	to	mini-dysferlin	in	vitro.	But	what	
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was	extremely	interesting	is	that	calpain	cleavage	of	myoferlin,	unlike	dysferlin	and	otoferlin,	
does	not	necessary	require	Ca2+,	however	Ca2+	would	just	increase	the	cleavage	yield	[84].	
These	mini-proteins	 released	harbor	 the	very	 last	 two	C2	domains	at	 the	carboxy	 terminal	
(C2E	 and	 C2F)	 with	 the	 transmembrane	 region	 and	 the	 extracellular	 domain	 as	 well.		
Previous	phylogenetic	studies	revealed	that	the	two	most	carboxy	terminal	C2	domains	are	
the	most	evolutionally	conserved	within	the	ferlin	family	tree.	This	hypothesizes	a	preserved	
function	among	proteins	harboring	 them.	Also,	 these	mini-proteins	bearing	 these	C2E-C2F	
domains	 have	 a	 structure	 similarity	 with	 synaptotagmin	 family	 (figure	 9).	 Overall	 data	
strengthen	the	assumption	of	Doherty	and	coworkers,	and	proposed	a	role	of	myoferlin	 in	
constitutive	processes	like	vesicles	fusion	events.		
	
	
Figure	9:	C2	domain	bearing	proteins.	Calpain	enzymatic	cleavage	produces	mini-proteins	resembling	synaptotagmin.	
Modified	from	Pangrsic	et	al.,	2012	[13]	
	
Noteworthy	to	mention	that	a	mathematical	model	was	established	to	examine	the	role	of	
myoferlin	 in	 cancer	 cell	 invasion;	 as	 a	 tool	 to	 generate	 hypotheses	 which	 then	 can	 be	
experimentally	tested.	This	model	proposed	a	diversified	role	of	myoferlin	 in	breast	cancer	
invasion	 including	 a	 hypothesis	 that	myoferlin	 impacts	matrix	metalloprotease	 production	
and/or	secretion;	hypothesizing	a	probable	role	of	myoferlin	in	exocytosis	[31].	
Myoferlin	 has	 been	 reported	 to	 be	 located	 in	 different	 cellular	 compartments	 like	 plasma	
membrane,	cytoplasm,	nucleus	envelope	and	nucleoplasm	[85][5].	A	recent	study	confirmed	
the	 previous	 observation	 but	 also	 emphasized	 on	 the	 colocalization	 of	 myoferlin	 with	
secretory	pathway	markers	 in	general.	Myoferlin	strongly	colocalizes	with	early	endosomal	
Rab5-positive	 vesicles	 and	 most	 importantly	 with	 Rab7-positive	 large	 vesicles	 of	 late	
endosomes	 whether	 perinuclear	 or	 periplasmic.	 However,	 myoferlin	 showed	 occasional	
colocalization	with	Lamp-1-positive	vesicles	 [86].	This	may	 imply	 that	myoferlin	could	be	a	
player	in	endosomal	recycling	but,	to	a	less	extent,	involved	into	the	lysosomal	degradation;	
raising	 a	 hypothesis	 that	 it	 could	 be	 involved	 in	 multivesicular	 bodies	 biogenesis	 and	
exosome	biology.		
Mini-proteins	
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Moreover,	 while	 investigating	 the	 role	 of	 myoferlin	 in	 myoblast	 fusion,	 Doherty	 et	 al.	
showed	 the	 presence	 of	 transient	 vesicle-like	 structures	 at	 the	 site	 of	 membrane	 fusion.	
Their	 data	 proposed	 that	 these	 vesicles	 may	 be	 derived	 from	 the	 endocytic	 recycling	
component	 [21].	 The	 fact	 that	myoferlin	 interacts	with	 EHD	 protein	 family,	 known	 for	 its	
involvement	in	the	endosomal	trafficking	[12],	fortify	the	hypothesis	that	myoferlin	could	be	
present	in	endosomal	recycling	system	and	so	implicated	in	exosome	biogenesis	or	simply	be	
a	cargo	of	exosomes.			
It	was	so	worth	verifying	the	presence	of	myoferlin	in	exosomes.	Literature	review	showed	
the	identification	of	myoferlin	in	exosomes	isolated	from	trabecular	meshwork	cells	[87]	and	
urine	 [88].	Moreover,	 myoferlin	 has	 also	 been	 identified	 in	 cancer	 cell-derived	 exosomes	
from	ovarian	cancer	[89],	hepatocellular	carcinoma	[90],	squamous	carcinoma	[91],	prostate	
cancer	[92],	melanoma	[93],	colon	cancer	[94][95]	and	bladder	cancer	[96].	These	studies	did	
not	 directly	 investigate	 myoferlin	 expression	 or	 function	 in	 exosomes	 but	 myoferlin	 was	
present	among	a	list	of	proteins,	thanks	to	mass	spectrometry	proteomic	profiling	of	these	
exosomes.		
It	is	now	concrete	that	myoferlin	is	present	in	exosomes	but	unfortunately	no	study	has	tried	
neither	 to	 validate	 the	 presence	 of	myoferlin	 in	 exosomes	 by	 any	 other	mean	 than	mass	
spectrometry	nor	to	investigate	its	role	in	exosome	biogenesis	and/or	function.		
	
	
Parts	of	this	chapter	are	included	in	a	review	submitted	for	publication	in	Current	Medicinal	
Chemistry.	
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Breast	cancer	is	the	second	leading	cause	of	cancer	death	in	females	while	pancreatic	cancer	
is	 the	 fourth	 in	 the	 general	 population.	 Pancreatic	 cancer	 death	 rate	 is	 almost	 as	 its	
incidence	 rate,	 with	 a	 5	 years	 survival	 lower	 than	 5%.	 This	 implies	 that	 more	 exhaustive	
research	 on	 breast	 and	pancreatic	 cancers	 are	 required	 for	 a	 better	 understanding	 of	 the	
diseases.	The	comprehension	of	 the	molecular	pathways	and	mechanisms	that	control	 the	
cancer	progression	is	the	key	for	developing	new	therapeutic	tools	aiding	in	the	fight	against	
this	disease.	
This	 study	was	based	on	 the	previous	 reports	 indicating	an	overexpression	of	myoferlin	 in	
different	cancer	types	including	breast	and	pancreatic	cancers.	These	studies	suggested	that	
myoferlin	 might	 be	 implicated	 in	 tumor	 progression	 and	 metastasis	 dissemination,	
potentially	 and	 partially,	 by	 affecting	 different	 vesicular	 events.	 Myoferlin	 structure	 and	
reported	activity	suggest	a	potential	role	for	this	ferlin	in	cellular	communication	especially	
mediated	by	vesicles.		
In	 this	 work,	 our	 first	 objective	 was	 to	 study	 the	 role	 of	 myoferlin	 in	 pancreatic	 cancer	
progression.	We	aimed	 to	 investigate	whether	myoferlin	contributes	 to	 tumor	growth	and	
vascularization.	 Based	 on	 the	 reported	 role	 of	 myoferlin	 in	 different	 vesicle-mediated	
trafficking,	we	then	investigated	if	myoferlin	is	involved	in	exocytosis	of	the	main	angiogenic	
factor	 VEGF-A;	 and	 if	 myoferlin	 is	 associated	 with	 angiogenesis	 and	 survival	 of	 PDAC	
patients.		
The	second	objective	of	our	work	was	to	examine	if	myoferlin	was	present	in	pancreas	and	
breast	cancer	cell-derived	exosomes.	We	then	aimed	to	determine	myoferlin’s	putative	role	
in	both	the	formation	and	the	secretion	processes	of	exosomes	by	cancer	cells	and	finally	in	
the	delivery	of	their	cargo	to	the	recipient	cells,	such	as	endothelial	cells.	
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PART I :  STUDYING THE ROLE OF MYOFERLIN IN VEGF-A 
SECRETION AND VEGF-A MEDIATED ANGIOGENESIS IN 
PANCREAS CANCER MODEL 
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Myoferlin	plays	a	key	role	in	VEGFA	secretion	and	impacts	tumor-associated	angiogenesis	
in	human	pancreas	cancer.	
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1.  INTRODUCTION 
	
Despite	 intensive	 research,	 pancreatic	 ductal	 adenocarcinoma	 (PDAC)	 remains	 one	 of	 the	
most	deadly	forms	of	cancers.	Early-stage	of	the	disease	is	clinically	silent	and	the	diagnosis	
of	the	disease	is	mostly	made	at	an	advanced	stage.	The	late	diagnosis	contributes	to	one	of	
the	lowest	5-year	survival	rates	(<5%).	Today,	PDAC	are	treated	by	surgery	and/or	adjuvant	
therapy,	 increasing	only	 slightly	 the	median	 survival	 of	 the	patients.	 There	 is	 therefore	an	
urgent	need	to	develop	new	effective	therapies	for	PDAC	patients.		
Myoferlin	 is	 a	 member	 of	 the	 ferlin	 family	 of	 proteins	 and	 is	 an	 ortholog	 of	 the	 ferlin-3	
protein	of	C.	elegans.	Myoferlin	is	a	calcium-sensitive	phospholipid	binding	protein	harboring	
several	C2	domains	and	required	for	membrane	processes,	including	cell	fusion,	endocytosis,	
membrane	repair,	and	vesicle	transport,	in	both	normal	[3,6,21,24,85]	and	cancer	cells	[35].	
Our	laboratory	and	others	have	reported	the	overexpression	of	myoferlin	in	several	cancers	
including	 pancreatic	 adenocarcinoma	 at	 both	 gene	 [25,26,97]	 and	 protein	 levels	 [28–30].	
However,	 very	 few	 studies	 have	 yet	 explored	 the	 potential	 role	 of	 this	 protein	 in	 cancer	
progression	 and	 development.	 Recently,	 myoferlin	 was	 found	 to	 be	 important	 for	 breast	
cancer	invasion	[31,32,98].	Our	laboratory	showed	that	myoferlin,	is	a	key	regulator	of	EGFR	
activity	 in	human	breast	cancer	cells	 [34].	 Interestingly,	 it	was	reported,	 in	a	Kaplan-Meier	
survival	 curve,	 that	 patients	 with	 myoferlin-positive	 PDAC	 had	 a	 significant	 lower	 overall	
survival	than	those	with	a	myoferlin-negative	tumor	[30].	As	a	consequence,	myoferlin	could	
represent	 a	 potential	 therapeutic	 target	 for	 PDAC,	 however	 the	 understanding	 of	 the	
mechanism	 by	 which	 myoferlin	 contributes	 to	 tumor	 growth	 and	 progression	 remains	
unclear.	
Several	genetically	engineered-mouse	models	 (GEMM)	have	been	established	and	validate	
to	study	the	PDAC	and	to	address	translational	issues.	Unfortunately,	beside	the	fact	that	the	
GEMMs	 are	 not	 easily	 accessible	 and	 require	 dedicated	 facilities,	 their	 implementation	 in	
new	 therapy	 screening	 is	 time	 consuming.	 In	 consequence,	 there	 is	 an	 obvious	 need	 for	
simpler	 and	 faster	 PDAC	 models	 such	 as	 xenografts.	 We	 have	 recently	 optimized	 and	
validated	 a	 refined	 model	 based	 on	 the	 grafting	 of	 BxPC-3	 cells	 on	 the	 chorioallantoic	
membrane	(CAM)	[99].	We	used	this	model	 to	evaluate	the	 functional	 role	of	myoferlin	 in	
pancreatic	 tumor	 development.	 We	 observed	 a	 decrease	 in	 the	 tumor	 growth	 after	
myoferlin	silencing.	The	tumor	volume	reduction	was	accompanied	by	a	surprising	pale	color	
of	 the	 tumors,	 suggesting	 a	 decrease	 of	 the	 blood	 vessel	 density	 inside	 the	 tumor.	 We	
further	investigated	the	VEGFA	production/secretion	by	myoferlin-silenced	BxPC-3	cells	and	
showed	that	myoferlin	is	required	for	an	optimal	VEGFA	secretion	in	cell-conditioned	media.	
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2.  MATERIAL AND METHODS 
2.1 Cells  and chemicals 
	
Human	pancreatic	adenocarcinoma	cells	BxPC-3	(ATCC	CRL-1687)	were	a	generous	gift	from	
Prof.	 Bikfalvi	 (Inserm	 U1029,	 Bordeaux,	 France).	 PANC-1	 cells	 (ATCC	 CRL-1469)	 were	 a	
generous	gift	from	Prof.	Muller	and	Burtea	(NMR	Laboratory,	University	of	Mons,	Belgium).	
All	reagents	were	purchased	from	Sigma	(Bornem,	Belgium)	unless	mentioned	otherwise.	
2.2 Cell  culture 
	
BxPC-3	 cells	 were	 culture	 in	 Roswell	 Park	 Memorial	 Institute	 -	 RPMI1640	 medium	
supplemented	with	 2.5g/L	 glucose,	 1mM	sodium	pyruvate	 and	10%	heat	 inactivated	 Fetal	
Bovine	 Serum	 –	 (FBS).	 PANC-1	 cells	 were	 maintained	 in	 DMEM	 supplemented	 with	 FBS	
(10%).	Cells	were	cultured	in	a	37°C	humid	incubator	supplied	with	5%	CO2.	Cells	were	used	
between	passage	1	and	10	and	passed	one	to	five	by	trypsin	(200	mg/L)	detachment	when	
reaching	near	confluence.		
	
2.3 Small  interfering RNA transfection 
	
BxPC-3	 cells	 were	 transfected	 using	 Lipofectamine	 (Life	 Technologies,	 Carlsbad,	 NM)	 in	
DMEM	medium	supplied	with	2mM	Glutamine	and	10%	heat	inactivated	FBS	and	following	
the	 manufacturer’s	 recommendation.	 Cells	 were	 transfected	 with	 40nM	 siRNA	 against	
myoferlin	(Eurogentec,	Seraing,	Belgium	–	siRNA#1	CCCUGUCUGGAAUGAGAUUTT;	siRNA#2	
GAUUGAGGGCCGACAGUUATT)	or	GL3	 targeting	 luciferase	 (Eurogentec,	 Seraing,	Belgium	–	
CUUACGCUGAGUACUUCGATT)	 as	 irrelevant	 siRNA.	 Medium	 was	 changed	 6h	 after	
transfection.	Analyses	were	conducted	48h	after	medium	change.	
PANC-1	cells	were	transfected	with	40nM	siRNA	against	myoferlin	using	calcium	phosphate	
as	 described	 previously	 [100].	 Myoferlin	 siRNA	 sequences	 are	 the	 same	 as	 above.	 ON-
TARGETplus	 non-targeting	 pool	 (Thermo	 Fisher-Dharmacon,	 Whaltham,	 MA)	 was	 used	 as	
irrelevant	siRNA	control.	
	
2.4 Cell  growth 
	
Equal	 densities	 of	 cells	 were	 seeded	 in	 complete	 medium	 and	 were	 harvested	 at	 the	
indicated	 time-points.	 For	 rescue	 experiment,	 recombinant	 human	 VEGFA	 (R&D	 systems,	
Minneapolis,	 MN	 -	 10	 ng/ml)	 was	 added	 to	 1%	 FBS	 culture	 media	 every	 24h,	 cells	 were	
harvested	96h	after	the	seeding.	The	cell	numbers	were	indirectly	determined	using	Hoechst	
incorporation.	Results	were	expressed	as	DNA	content.	
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2.5 Annexin V/propidium iodide staining  
	
Proportion	of	apoptotic	cells	was	determined	by	annexin	V-FITC	and	non-vital	dye	propidium	
iodide	(PI)	staining	with	a	FITC-Annexin	V	apoptosis	detection	kit	I	(BD	Biosciences,	Franklin	
Lakes,	NJ)	according	to	the	manufacturer’s	instructions.	Flow	cytometry	was	performed	on	a	
FACSCalibur	 II™	 and	 samples	 were	 analyzed	 using	 CellQuest™	 software	 (BD	 Biosciences,	
Franklin	Lakes,	NJ).		
	
2.6 Western blotting 
	
Cells	were	 lysed	in	RIPA	buffer	(NaCl	150mM,	Na-deoxycholate	0.5%,	Triton	X-100	1%,	SDS	
0.2%,	Tris-HCl	pH	7.5	50mM)	in	the	presence	of	protease	and	phosphatase	inhibitors.	Ten	µg	
of	 heat	 denaturated	 proteins	 were	 separated	 by	 SDS-PAGE	 then	 electrotransfered	 onto	
nitrocellulose	membrane.	
Antibodies	 were	 purchased	 from	 Sigma	 (Bornem,	 Belgium):	 myoferlin	 antibody	 (rabbit	 -	
HPA014245),	 or	 Santa	 Cruz	 Biotechnology	 (Santa	 Cruz,	 CA):	 HSC70	 antibody	 (mouse	 -	
sc7298).	Antibodies	were	diluted	 in	 TBS-Tween	 (0.1%)	 containing	milk	 (5%)	 and	 incubated	
for	 2	 h	 at	 room	 temperature.	 Corresponding	 secondary	 antibodies	 were	 diluted	 in	 TBS-
Tween	(0.1%)	containing	milk	(5%)	and	incubated	for	1	hour	at	room	temperature.		
	
2.7 Quantitative real-t ime PCR 
	
Total	 RNA	 was	 extracted	 with	 trizol	 reagent	 (Life	 Technologies,	 Carlsbad,	 NM)	 using	
manufacturer’s	 instructions.	 RNA	 concentration	 was	 measure	 using	 Nanodrop	 ND-1000	
Spectrophotometer	 and	 RNA	 integrity	 was	 assessed	 using	 the	 Agilent	 2100	 Bioanalyser	
(Agilent	Technology,	Santa	Clara,	CA).	Reverse	transcription	was	realized	using	Transcriptor	
First	 Strand	 cDNA	 Synthesis	 kit	 (Roche,	 Basel,	 Switzerland).	 Human	 VEGFA	 was	 detected	
using	 FastStart	 Universal	 Probe	 Master	 (Rox)	 TaqMan	 reaction	 buffer	 (Roche,	 Basel,	
Switzerland),	 lab-designed	 probe	 (5’-CTTGCCTTGCTGCTCTACC-3’)	 and	 primers	 (forward	
primer:	 5’-AGTTCATGGATGTCTATCAGCGCAGCT-3’,	 backward	 primer:	 5’-
CTTGCCTTGCTGCTCTACC-3’).	 Gene	 expression	 was	 normalized	 with	 the	 endogenous	 18S	
rRNA	using	a	commercially	available	probe	based	assay	(Applied	Biosystems,	Carlsbad,	NM;	
4310893E).	
	
2.8 VEGFA ELISA Assay 
	
VEGFA	 protein	 level	 in	 the	 conditioned	 medium	 was	 quantified	 using	 Human	 VEGFA	
Quantikine	ELISA	Kit	(R&D	systems,	Minneapolis,	MN)	following	the	manufacturer’s	protocol.	
VEGFA	levels	were	normalized	to	the	number	of	cells.	
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2.9 Immunofluorescence 
	
After	 siRNA	 transfection	 procedure,	 3.5	 X	 104	 cells	 were	 plated	 on	 coverslip	 in	 24-well	
plates.	After	48	h	of	 siRNA-mediated	 silencing,	 cells	were	washed	with	DPBS,	 fixed	 in	PFA	
4%,	permeabilized	with	triton	X-100	0.5%	for	5	minutes,	blocked	with	Bovine	Albumin	Serum	
2%	 for	 30	minutes.	 Coverslips	were	 incubates	 overnight	 at	 4°C	with	 the	 primary	 antibody	
against	 VEGFA	 (Santa	 Cruz	 Biotechnology,	 mouse	 -	 sc73344)	 diluted	 in	 PBS-BSA	 solution.	
Afterwards,	coverslips	were	washed	3	times	in	PBS-BSA	solution	and	incubated	with	Alexa-
fluor	 488	 conjugated	 (Invitrogen,	 A11029)	 or	 Alexa-fluor	 633	 conjugated	 (Invitrogen,	
A21070)	secondary	antibody	for	1	h	at	room	temperature.	Followed	by	3	additional	washes	
and	 nuclei	 labeling	 with	 10	 ng/ml	 of	 Hoechst	 33258	 and	 sections	 were	 mounted	 with	
Mowiol.	 Colocalisation	 of	 myoferlin	 (Sigma,	 Bornem,	 Belgium,	 rabbit	 –	 HPA014245)	 and	
sec5/exoc2	 (ProteinTech,	 Chicago,	 IL,	 mouse	 –	 66011-1-Ig),	 a	 multiple	 protein	 complex	
essential	for	targeting	exocytic	vesicles,	was	evaluated	after	confocal	image	acquisition	using	
Pearson’s	correlation	coefficient,	Mander’s	coefficient	and	Li’s	approach	[101].	
Images	were	acquired	using	Leica	(Leica	Microsystems,	Wetzlar,	Germany)	TCS	SP5	Confocal	
microscope	 and	 analyzed	with	 ImageJ	 (Rasband,	W.S.,	 ImageJ,	 U.	 S.	 National	 Institutes	 of	
Health,	Bethesda,	Maryland,	USA,	http://imagej.nih.gov/ij/,	1997-2014).	
	
2.10 Ultrastructural  analysis  
	
Cells	were	fixed	for	1.5	h	at	4	°C	with	2.5%	glutaraldehyde	in	a	Sörensen	0.1	M	phosphate	
buffer	 (pH7.4)	 and	 post-fixed	 for	 30	min	with	 2%	 osmium	 tetroxide.	 After	 dehydration	 in	
graded	 ethanol,	 samples	 were	 embedded	 in	 Epon.	 Ultrathin	 sections	 obtained	 with	 a	
Reichert	 Ultracut	 S	 ultramicrotome	were	 contrasted	with	 uranyl	 acetate	 and	 lead	 citrate.	
Observations	 were	 made	 with	 a	 Jeol	 (Tokyo,	 Japan)	 JEM-1400	 transmission	 electron	
microscope	at	80	kV.	
	
2.11 Tumor growth on chick chorioal lantoic membrane (CAM) 
	
As	described	previously,	BxPC-3	 cells	were	grown	on	CAM	 for	7	days	 then	 tumor	volumes	
have	 been	 calculated	 as	 an	 ellipsoid.	 In	 order	 to	 visualize	 the	 tumor	 vasculature,	 tumors	
sections	have	been	subjected	to	FITC-conjugated	SNA	(Sambucus	nigra	agglutinin)	staining	as	
previously	described	[99].	Densitometric	profiling	and	quantification	were	performed	using	
ImageJ	 (Rasband,	 W.S.,	 ImageJ	 V1.48,	 U.	 S.	 National	 Institutes	 of	 Health,	 Bethesda,	
Maryland,	USA,	http://imagej.nih.gov/ij/,	1997-2014).	
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2.11 Immunochemistry and scoring 
	
A	 series	 of	 26	 pancreas	 adenocarcinoma	 and	 16	non-tumoral	 pancreatic	 tissues,	 including	
pancreatitis,	were	obtained	 from	University	Hospital,	University	 of	 Pisa	 (Italy),	 as	 formalin	
fixed,	 paraffin	 embedded	 tissue	 blocks.	 These	 cases	 were	 previously	 described	 in	 a	
biomarker	discovery	study	from	our	 laboratory	[28].	Sections	were	stained	with	antibodies	
against	 myoferlin	 (rabbit,	 Sigma)	 or	 PECAM-1/CD31	 (mouse,	 Dako)	 followed	 by	 a	 second	
step	using	the	according	peroxidase-conjugate.	
Sections	were	observed	and	scored	by	an	independent	pathologist	(M.A.)	who	was	blind	to	
the	purpose	of	 the	experiment.	CD31	 scoring	was	done	according	 to	 the	hotspot	method.	
This	 technique	 is	 widely	 used	 in	 diagnosis	 and	 showed	 a	 significant	 correlation	 between	
microvessel	density	and	PDAC	grade	[101].	The	three	most	intense	hotspots	were	identified	
and	 the	 average	microvessel	 number	 per	 high	 power	 field	 (HPF	 –	 400X,	MCX100,	Micros	
Austria,	St	Veit/Glan,	Austria)	was	calculated.	Myoferlin	scoring	was	done	by	an	evaluation	
of	the	intensity	(ranging	from	0	to	3)	and	of	the	extent	of	the	staining	(ranging	from	0	to	4).	
	
2.12 Myoferl in gene expression and survival  analysis 
	
Myoferlin	 gene	 expression	 in	 normal	 and	 PDAC	 tissue	 was	 analysed	 using	 the	 Pancreas	
Expression	Database	[102].	A	population	of	PDAC	patients	(GSE2150122	[103])	were	classify	
in	high-risk	and	low-risk	groups	on	the	basis	of	survival.	Data	were	censored	on	the	survival	
months	 without	 stratification.	 Survival	 curves	 were	 compared	 by	 a	 log-rank	 Cox	 test.	
Myoferlin	 expression	 was	 analyzed	 in	 each	 group	 using	 the	 SurvExpress	 [104]	 web-based	
tool.	
	
2.13 Ethics statement  
	
All	 animal	 (CAM)	 experiments	 were	 approved	 by	 the	 Animal	 Welfare	 Committee	 of	 the	
University	of	Liège	(approval	#1590).	All	human	sections	were	used	with	the	agreement	of	
the	 Human	 Ethic	 Committee	 of	 the	 University	 of	 Liège	 and	 from	 the	 University	 Hospital	
(approval	#B707201420895).	
	
2.14 Statist ics 
	
All	 results	were	 reported	 as	means	with	 standard	deviation	 (s.d.)	 or	 Standard	 Error	Mean	
(s.e.m.)	 as	 described	 in	 legends.	 Statistical	 analysis	was	 performed	using	 one-way	or	 two-
way	ANOVA	depending	on	the	number	of	grouping	factors.	Group	means	were	compared	by	
an	unpaired	Student’s	t-test	or	Bonferroni’s	post-test	according	to	the	group	number.		
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P<0.05	was	considered	as	statistically	significant.	All	experiments	were	performed	as	several	
independent	biological	replicates.	
	
3.  RESULTS 
	
3.1 Myoferl in is  essential  for BxPC-3 tumor growth on CAM 
	
The	functional	role	of	myoferlin	in	pancreatic	tumor	growth	on	CAM	was	evaluated.	Grafted	
BxPC-3	cells	grew	as	a	unique	spheric	nodule	in	the	connective	tissue	of	the	CAM	(Figure	1A).	
We	observed	a	significant	50%	decrease	of	the	tumor	final	volume	after	myoferlin	silencing	
by	siRNA#1	or	siRNA#2	(Figure	1B).	96h	after	silencing	the	myoferlin	expression	was	reduced	
by	 90%.	 The	 volume	 decrease	 was	 mainly	 due	 to	 a	 reduction	 of	 the	 tumor	 thickness.	
Intriguingly,	the	volume	reduction	was	accompanied	by	a	bleaching	of	the	tumors	compared	
to	controls	(Figure	1A),	suggesting	a	decrease	of	the	blood	vessel	density	inside	the	tumor.	
The	vessel	density	was	evaluated	after	a	FITC-conjugated	Sambucus	nigra	(SNA)	staining.	 It	
showed	a	drastic	reduction	of	stained	structures	in	the	tumor	core	of	the	myoferlin-silenced	
condition	compared	to	the	no	siRNA	condition	(Figure	1D-E).	The	lack	of	vessels	in	the	tumor	
suggests	an	impairment	of	the	tumor-associated	neoangiogenesis.	
	
3.2 Myoferl in-si lencing reduces pancreatic cel l  growth 
	
To	investigate	whether	the	tumor	size	reduction	observed	in	the	CAM	assay	was	only	due	to	
the	lack	of	vascularization	or	to	a	direct	effect	on	the	cell	growth,	we	examined	the	BxPC-3	
cell	time-dependent	growth	after	siRNA	myoferlin	silencing	(Figure	2A).	Our	results	showed	
an	80%	and	50%	cell	growth	reduction	(p<0.001)	respectively	with	siRNA#1	and	siRNA#2.	As	
VEGFA	is	known	to	stimulate	the	growth	of	pancreatic	cells	[105],	we	thaught	that	the	cell	
growth	reduction	could	have	been	the	result	of	the	alteration	of	a	VEGFA	autocrine	loop	by	
myoferlin-silencing.	To	test	this	hypothesis	we	tried	to	rescue	the	cell	proliferation	by	adding	
VEGFA	 in	 the	 culture	 media	 of	 myoferlin-silenced	 cells.	 VEGFA	 was	 unable	 to	 lessen	 the	
inhibition	of	proliferation	induced	by	the	myoferlin-silencing	(Figure	2D).	We	then	asked	the	
question	whether	 this	 reduction	was	 due	 to	 an	 induction	 of	 apoptosis	 and	 performed	 an	
annexin	V/propidium	 iodide	 staining	at	48,	72	and	96h	 (Figure	2B)	 following	 the	 silencing.	
None	of	the	individual	siRNA	was	able	to	significantly	induce	apoptosis.	Comparable	results	
were	 obtained	 using	 another	 human	 pancreatic	 cancer	 cell	 line,	 PANC-1.	 In	 these	 cells	
siRNA#1	 and	 siRNA#2	 reduced	 the	 cell	 growth	 respectively	 by	 70%	 and	 30%	 (Figure	 2C,	
p<0.001)	without	inducing	apoptosis	(Figure	2D).		
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Figure 1. Effects of myoferlin silencing on BxPC-3 tumor growth on CAM and blood vessel density. (A) Macroscopic 
aspect of tumors obtained from control and myoferlin-silenced BxPC-3 cells implanted on CAM on day 11 of embryonic 
development and let to grow for 7 days. Pictures were taken from the bottom side view of the tumors. Scale bar represents 5 
mm. (B) Tumoral volumes calculated using an ellipsoid formula at day 7 post-implantation. (C) Western blot detection of 
myoferlin in 10µg total proteins isolated from BxPC-3 cells implanted on CAM after siRNA transfection. HSC70 was used 
as a loading control. (D) Sections of tumors grown on CAM and collected at day 7 post-implantation. Sections were stained 
with FITC-conjugated SNA (green) visualizing blood vessels inside the tumors, and with DAPI (blue) visualizing nucleus. 
Scale bar represents 100 µm. Density profile of green channel (blood vessels) was represented under each section. (E) Blood 
vessel density (% of tumor area) in SNA stained sections. Results are expressed as mean ± s.e.m. ***P<0.001, **P<0.01, 
*P<0.05. n>8 in each condition. 
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Figure 2. Effect of myoferlin silencing on BxPC-3 and PANC-1 cell growth. (A & C) Time-dependent effects of 
myoferlin siRNA transfection on (A) BxPC-3 and (C) PANC-1 cell proliferation. (B & D) Time-dependent effects of 
myoferlin siRNA transfection on (B) BxPC-3 or (D) PANC-1 apoptotic cell ratio by annexin V/PI flow cytometry. 
Doxorubicin was used as an apoptosis inducer positive control. (E) Rescue of a 96h BxPC-3 cell growth with addition of 
recombinant VEGFA (10 ng/ml). Results are expressed as mean ± s.d. ***P<0.001. n=3 in each condition. 
3.3 Myoferl in is  essential  for VEGFA secretion by BxPC-3 cel ls  
	
Since	we	showed	that	myoferlin-silencing	reduced	blood	vessels	density	in	BxPC-3	grown	on	
CAM,	we	decided	to	focus	on	this	aspect	and	checked	whether	myoferlin-silencing	reduced	
VEGFA	 production.	 BxPC-3	 cells	were	 selected	 as	 a	model,	 as	 they	 are	 known	 to	 produce	
more	 VEGFA	 than	 PANC-1	 cells	 [106].	 Thus,	 we	 measured	 the	 VEGFA	 concentration	 in	
conditioned	medium	and	VEGFA	gene	expression	in	BxPC-3	cells	after	myoferlin-silencing.	
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Figure 3. Effects of myoferlin silencing on VEGF secretion. (A) VEGFA concentration determined by ELISA in the conditioned medium 
of BxPC-3 cells after 48 h of siRNA-mediated myoferlin silencing. VEGFA concentration was standardized to the cell number. (B) Relative 
VEGFA gene expression of BxPC-3 after 48 h of siRNA-mediated myoferlin silencing. (C) Immunocytochemistry of BxPC-3 sparse cells 48 
h after siRNA-mediated myoferlin silencing showing the effect of myoferlin silencing on VEGFA intracellular localization. VEGFA was 
stained with Alexa Fluor 488-conjugated antibody (green) and nucleuses were stained with Hoechst (blue). White arrows indicate VEGFA 
localization at plasma membrane. Scale bars represent 7,5µm. (D) Ultrastructural observation of BxPC-3 cells transfected during 48 h with 
siRNA against myoferlin. Scale bars represent 2µm. L = lysosomes, N = nucleus. Black arrows indicate accumulation of small vesicles close 
to the plasma membrane. Results are expressed as mean ± s.e.m. ***P<0.001. n=3 in each condition. 
VEGFA	concentration	in	the	conditioned	medium	was	determined	by	ELISA	48h	after	siRNA	
transfection	and	normalized	to	 the	cell	number.	Results	showed	a	40%	decrease	 in	VEGFA	
concentration	 in	 the	 conditioned	 medium	 of	 myoferlin-silenced	 condition	 (p<0.001)	
compared	 to	 both	 controls	 (Figure	 3A).	 To	 determine	whether	VEGFA	 reduction	occurs	 at	
transcriptional	 level,	 we	 analyzed	 VEGFA	 mRNA	 level	 by	 RT-qPCR	 48h	 after	 siRNA	
transfection.	 We	 found	 that	 myoferlin	 silencing	 did	 not	 significantly	 affect	 VEGFA	 gene	
expression	in	BxPC-3	cells	(Figure	3B).	
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Ferlins	 have	 been	 described	 as	 an	 active	 sculptor	 of	 lipid	 bilayers	 facilitating	 membrane	
fusion	 [11].	As	 such,	we	hypothesized	 that	 the	observed	VEGFA	concentration	decrease	 in	
conditioned	medium	after	myoferlin	silencing	might	be	the	result	of	exocytosis	impairment.	
To	 test	 this	 hypothesis,	 we	 examined	 by	 immunofluorescence	 the	 VEGFA	 localization	 in	
BxPC-3	 cells	 48h	 after	 myoferlin	 siRNA	 transfection.	 Results	 showed	 no	 or	 low	 VEGFA	
staining	in	control	conditions	suggesting	a	dynamic	exocytosis	of	the	protein.	In	contrast	to	
control	 cells,	 a	 clear	 accumulation	 of	 VEGFA	 at	 the	 vicinity	 of	 the	 plasma	membrane	was	
observed	 in	 myoferlin-silenced	 cells	 (Figure	 3C).	 Furthermore,	 ultrastructural	 analysis	
revealed	the	accumulation	of	small	vesicles,	surrounded	by	a	membrane,	in	the	cytosol	close	
to	the	plasma	membrane	(Figure	3D)	in	the	myoferlin-silenced	BxPC-3	but	not	in	the	control	
cells.	
Immunofluorescence	 experiments	 indicate	 that	 in	 BxPC-3	 cells,	Myoferlin	 colocalized	with	
sec5/exoc2,	a	component	of	a	complex	essential	for	targeting	exocytic	vesicles,	mainly	at	the	
periphery	of	the	cells	 (Figure	4A).	Pearson’s	coefficient	 is	the	simplest	way	to	measure	the	
dependency	of	pixels	in	dual-channel	images.	Despite	its	sensitivity	to	background	noise	and	
its	ambiguity	with	heterogeneous	localization	throughout	the	samples,	it	showed	a	75	±	6%	
(N=13)	correlation	(Figure	4D).	In	order	to	relieve	the	Pearson’s	limitations,	we	performed	a	
Mander’s	correlation	analysis.		
 
Figure 4. Colocalization of myoferlin and exocytic complex protein. (A) Representative image of BxPC-3 sparse cells 
stained for nuclei (blue channel), for sec5/exoc2 (green channel) and myoferlin (red channel). Merged image show partial 
colocalization of sec5/exoc2 and myoferlin. (B-C) Representative intensity correlation analysis (ICA) performed for 
complete colocalization in the (B) green channel (sec5/exoc2) and in the (C) red channel (myoferlin). (D) Mean value (± s.d.) 
of several several colocalization factors obtained from 13 different observation fields: Pearson’s coefficient (PC), Manders’ 
coefficient after background thresholding (M1 = green/red; M2 = red/green), Li’s intensity correlation quotient (ICQ). 
It	 showed	 that	 86	 ±	 11%	 (M1)	 of	 the	 green	 channel	 (sec5/exoc2)	 coincide	 with	 a	 red	
(myoferlin)	 signal	 and	 that	 64	 ±	 18%	 (M2)	 of	 the	 red	 channel	 (myoferlin)	 coincide	with	 a	
green	(sec5/exoc2)	signal.	The	Mander’s	coefficient	remains	very	sensitive	to	noise,	thus	we	
confirmed	 this	 result	 using	 the	 Li’s	 approach	 able	 to	 discriminate	 coincidental	 events	 in	 a	
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heterogeneous	situation.	In	the	case	of	colocalization	the	product	of	(Ai-a)*(Bi-b)	is	positive	
and	therefore	the	dot	cloud	of	the	intensity	correlation	analysis	(ICA,	Figure	4B-C)	is	mostly	
concentrated	on	the	right	side	of	the	x=0	line.	The	Intensity	Correlation	Quotient	(ICQ)	varies	
from	0.5	 (colocalization)	 to	 -0.5	 (exclusion)	when	an	artefactual	colocalization	give	a	value	
close	 to	 zero.	 In	 our	 experiment	 the	mean	 ICQ	 is	 0,45	 ±	 0,02,	 indicating	 a	 significant	 but	
partial	colocalization	between	myoferlin	and	sec5/exoc2.	
	
Figure 5. CD31 and myoferlin staining in PDAC sections. Immunoperoxydase staining of myoferlin (A-D) and CD31 (E-
H) in PDAC sections sorted according to their myoferlin staining extent. Areas surrounded by a black rectangle in A, B, E, F 
are shown at higher magnification in C, D, G, H 
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3.4 Myoferl in staining extent is  associated with blood vessel  density 
and with survival  in human PDAC 
	
Since	 myoferlin	 silencing	 provoked	 a	 decrease	 of	 VEGFA	 secretion	 in	 cell	 medium	 and	 a	
decreased	 blood	 vessels	 density	 in	 BxPC-3	 cells	 grown	 on	 CAM,	 we	 asked	 if	 a	 higher	
intratumoral	 vessel	 density	 characterizes	 patients	 bearing	 myoferlin-positive	 pancreatic	
tumor.	Twenty-six	PDAC	and	19	non-tumoral	pancreas	sections,	including	pancreatitis,	were	
immunostained	 for	 both	 myoferlin	 and	 CD31	 (Figure	 5).	 All	 endothelial	 cells	 showed	
consistent	moderate	CD31	 staining.	 The	vessel	density	 in	normal	pancreatic	 tissue	did	not	
exceed	2/HPF	except	 in	2	cases.	Cancer	cells	were	 the	main	structures	 immunoreactive	 to	
myoferlin.	Cases	were	grouped	according	to	low	(<50%)	or	high	(≥50%)	myoferlin	extent.		
	
Figure 6. Correlation between myoferlin and microvessel density or survival in PDAC patients. (A) Twenty-six PDAC 
sections and 16 non-tumoral pancreas sections were stained for myoferlin and CD31. Each marker was scored individually 
before the sorting of the sections according to their myoferlin staining extent (low or high). Microvessel densities 
(CD31/HPF) were compared between low and high myoferlin staining within each category (non-tumoral or PDAC). Results 
are expressed as individual data with the median (line). NS = not significant. (B) Boxplot of myoferlin gene expression in 
normal pancreas tissue, normal adjacent to tumor and PDAC tissue (from Pancreas Expression Database). (C) Kaplan-Meier 
curve of PDAC patients divided in two groups significantly different regarding survival (low-risk and high-risk groups). (D) 
Myoferlin gene expression according to the survival group. 
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In	 non-cancer	 cases	 there	was	 no	 significant	 differences	 in	 CD31	 between	 low-	 and	 high-
myoferlin	 groups.	 However,	 in	 cancer	 cases,	 a	 highly	 significant	 difference	was	 observed:	
high-myoferlin	 cases	 having	 higher	 CD31	 than	 low-myoferlin	 cases	 (Figure	 6A).	 Publicly	
available	 dataset	 allowed	 us	 to	 show	 the	 overexpression	 of	 myoferlin	 in	 PDAC	 tumor	 in	
comparison	to	normal	or	normal	adjacent	tissue	(Figure	6B)	and	to	classify	PDAC	patients	in	
two	 groups	 significantly	 different	 regarding	 survival	 (Figure	 6C).	 The	 high-risk	 group	 was	
characterized	by	 a	hazard-ratio	HR	=	1.86.	Myoferlin	 gene	was	 significantly	overexpressed	
(Figure	6D)	in	this	group.	
	
4.  DISCUSSION 
	
In	this	study,	we	demonstrate	that	myoferlin,	a	member	of	the	ferlin	family	highly	expressed	
in	 PDAC	 [28–30]	 and	 associated	 to	 a	 poor	 prognosis	 [30],	 plays	 a	 key	 role	 in	 PDAC	
progression,	at	least	in	part,	by	promoting	tumor	associated	angiogenesis.	
SiRNA-mediated	myoferlin	silencing	in	BxPC-3	cancer	cells	resulted	in	a	significant	reduction	
of	their	ability	to	grow	in	vitro	and	as	a	tumor	in	the	stroma	of	chorioallantoic	membrane,	a	
PDAC	model	we	recently	optimized	and	validated	[99].	We	selected	the	widely	used	BxPC-3	
cells	 for	their	ability	to	grow	on	CAM.	This	anti-tumor	growth	effect	was	associated	with	a	
massive	inhibition	of	capillaries	development	within	the	tumoral	stroma,	suggesting	a	loss	of	
pro-angiogenic	activities	of	the	cancer	cells.	Among	the	known	proangiogenic	factors,	VEGFA	
is	 regarded	 as	 one	 of	 the	 most	 important	 in	 malignant	 diseases	 since	 it	 is	 the	 most	
predominant	isoform	secreted	by	human	tumors	[43]	including	pancreatic	cancer	[105,107].	
Moreover,	the	involvement	of	VEGFA	in	our	results	is	supported	by	the	fact	that	VEGFA	had	
demonstrated	auto-	and	paracrine	pro-proliferative	effects	respectively	on	cancer	cells	and	
endothelial	 cells	 [106,108].	 In	addition,	 the	 role	of	VEGFA	 in	pancreatic	 tumor	progression	
has	 also	 been	 studied	 in	 animal	model.	 In	 these	 studies,	 inhibitors	 of	 the	 VEGFR	 tyrosine	
kinase	 or	 neutralizing	 antibodies	 against	 VEGFA	 or	 VEGFR2	 reduced	 the	 growth	 and	
angiogenesis	of	pancreatic	tumors	[109,110].		
As	 previously	 described,	 ferlin	 protein	 family	 is	 reported	 to	 be	 implicated	 in	 membrane	
fusion	processes	including	myoblast	fusion	(dysferlin)	[20]	and	synaptic	vesicle	exocytosis	at	
the	 auditory	 ribbon	 synapse	 of	 inner	 hair	 cells	 (otoferlin)	 [14].	 In	 consequence,	 we	
hypothesized	that	myoferlin	may	be	also	 implicated	 in	proangiogenic	 factors	exocytosis	by	
pancreatic	 cancer	 cells.	 In	 order	 to	 evaluate	 our	 hypothesis	 we	 analyzed	 VEGFA	
concentration	 in	 conditioned	medium	 of	myoferlin-silenced	 BxPC-3.	 A	 40%	 reduction	was	
observed	and	appeared	as	independent	of	a	transcriptional	effect.	VEGFA	immunodetection	
in	myoferlin-silenced	BxPC-3	cells	revealed	an	accumulation	of	this	protein	inside	the	cell	at	
the	vicinity	of	 the	plasma	membrane.	This	observation,	 together	with	 the	colocalization	of	
myoferlin	 with	 sec5/exoc2,	 is	 in	 agreement	 with	 our	 ultrastructural	 observation	 of	 small	
vesicles	 accumulated	 near	 the	 plasma	 membrane	 suggesting	 that	 exocytosis	 vesicles,	
containing	VEGFA,	were	 stalled	at	 the	plasma	membrane	 interface,	unable	 to	 fuse	with	 it.	
Several	observations	reported	 in	the	 literature	support	our	findings.	Myoferlin	 is	known	to	
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possess	several	C2	domains,	with	a	C2a	domain	able	to	bind	phosphatidylserine	in	presence	
of	Ca2+	[4],	making	it	able	to	interact	with	the	phospholipid	bilayer	after	Ca2+	intracellular	
concentration	increase,	a	common	feature	of	exocytosis.	Myoferlin	is	a	substrate	for	calpain	
whose	 enzymatic	 cleavage	 gives	 rise	 to	 a	 synaptotagmin-like	 module	 [84].	 Interestingly,	
synaptotagmin	 is	 a	 protein	 involved	 in	 Ca2+-triggered	 exocytosis	 [111],	 suggesting	 a	
potential	 role	 for	 the	 cleavage	 fragment	 of	myoferlin	 in	 exocytosis.	 Finally,	myoferlin	 has	
been	considered	as	a	regulator	of	protein	secretion	by	breast	cancer	cells	[31].	
Although	considered	as	an	hypovascular	tumor,	angiogenesis	 is	nonetheless	critical	 for	the	
development	and	growth	of	PDAC	[43].	In	patients	with	such	neoplasia,	VEGFA	expression	in	
the	tumor	and	high	serum	concentration	are	significantly	correlated	to	a	decreased	median	
survival	 time	 [53,112]	 and	 to	 metastasis	 progression,	 especially	 to	 the	 liver	 [107].	 The	
correlation	 between	 VEGFA	 expression	 and	 the	 survival	 remains	 significant	 even	 after	 a	
surgery	 putatively	 considered	 as	 curative	 [113].	 These	 results	 are	 consistent	 with	 the	
discovery	 that	 microvessel	 density	 and	 vascular	 proliferation	 index	 were	 significantly	
associated	 with	 larger	 tumor	 size	 and	 lymph	 node	 metastasis	 [114].	 A	 recent	 study	
demonstrated	 that	 focal	 VEGFA	 locus	 amplification	 is	 regularly	 detected	 in	 PDAC	 [115].	 A	
multi-institutional	phase	 II	 study	of	bevacizumab,	an	antibody	against	VEGFA,	gemcitabine	
and	 5-fluorouracil	 in	 advanced	 pancreatic	 cancer	 demonstrated	 a	 continued	 interest	 in	
VEGFA	as	a	valid	therapeutic	target	[116].	
Bevacizumab	and	axitinib,	a	VEGFR	tyrosine	kinase	inhibitor,	were	tested	in	a	phase	III	trial	in	
advanced	 pancreatic	 cancer.	 Unfortunately,	 they	 failed	 to	 show	 any	 survival	 benefit	 for	
bevacizumab	or	axitinib	in	combination	with	gemcitabine	[117,118].	However,	these	studies	
did	not	consider	separately	patients	with	a	high	basal	production	of	VEGFA	which	correlates	
with	 better	 progression-free	 and	 overall	 survival	 in	 bevacizumab-treated	 patients	 versus	
those	receiving	placebo	[119].	In	another	study,	the	pretreatment	plasma	VEGFA	levels	were	
described	 as	 ranging	 from	 0	 to	 462	 pg/ml	 [109],	 underlying	 the	 heterogeneity	 of	 this	
parameter	 in	 patients.	 According	 to	 the	 importance	 of	 a	 high	 VEGFA	 basal	 level	 in	 the	
response	to	targeted	therapy,	BxPC-3	cells,	known	for	their	high	production	of	VEGFA	[106],	
are	a	suitable	model	to	investigate	this	aspect.	
The	clinical	relevance	of	our	study	for	PDAC	patients	is	supported	by	the	observation	that	a	
higher	density	of	blood	vessels	characterized	PDAC	tumors	with	high	myoferlin	extent.	This	is	
of	particular	 interest	 as	 vascular	proliferation	 is	 associated	 in	PDAC	with	 a	poor	prognosis	
[114].	 Interestingly,	 publicly	 available	 dataset	 indicates	 that	 myoferlin	 gene	 expression	 is	
also	inversely	correlated	with	the	survival.	Recently,	the	same	association	was	described	at	
the	protein	level	[30].	
Beside	the	role	of	myoferlin	in	exocytosis,	this	protein	seems	to	control	tightly	the	function	
of	 several	 receptor	 tyrosine	 kinase	 (RTK)	 in	 cancer	 and	 normal	 cells,	 including	 endothelial	
cells.	 Our	 laboratory	 recently	 described	 myoferlin	 as	 a	 key	 regulator	 of	 EGFR	 activity	 in	
breast	 cancer	 [34].	 In	endothelial	 cells,	 it	was	 found	 to	 regulate	VEGFR2	biological	 activity	
through	 preventing	 its	 polyubiquitination	 and	 its	 subsequent	 degradation	 by	 the	
proteasome	 [6].	 In	 the	 same	 cell	 type	 the	 expression	 of	 angiopoietin-1	 receptor	 (TIE-2)	
seemed	to	be	myoferlin-dependent	[23].	In	normal	myoblasts,	myoferlin	was	demonstrated	
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as	an	essential	component	of	the	insulin-like	growth	factor	receptor	(IGF1R)	trafficking	and	
signaling	[12].	In	PDAC,	as	well	as	in	PDAC	cell	lines,	several	RTK	are	overexpressed	(VEGFR,	
EGFR,	FGFR,	PDGFR)	and	their	targeting	reduced	the	pancreatic	cell	growth	or	tumor	growth	
[120–122].	However,	in	our	conditions,	exogenous	VEGFA	was	unable	to	rescue	the	decrease	
of	proliferation	 induced	by	myoferlin-silencing,	 indicating	 that	 the	autocrine	 loop	 involving	
VEGFA	is	not	the	main	event	in	the	cell	proliferation	decrease.	
In	conclusion,	myoferlin	 is	 functionally	 important	 in	 the	context	of	PDAC.	 It	 is	essential	 for	
cell	and	tumor	growth	but	also	for	the	establishment	of	a	 functional	blood	vessel	network	
inside	the	tumor.	
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1.  INTRODUCTION 
	
Exosomes	 are	 small	 extracellular	 vesicles,	 ranging	 in	 size	 from	 50	 to	 150	 nm.	 They	 are	
derived	 from	 endosomal	 vesicles	 and	 secreted	 into	 the	 extracellular	medium	 upon	 fusion	
with	 the	 plasma	 membrane	 [123].	 Many	 cell	 types	 produce	 exosomes,	 and	 these	
extracellular	 vesicles	 can	 bear	 multiple	 functions	 involved	 in	 many	 biological	 processes,	
including	 cancer	 progression	 [124].	 Exosomes	 were	 shown	 to	 transform	 non-tumorigenic	
cells	[125–127],	modulate	cancer	cell	metabolism	[128],	angiogenesis	[129]	and	take	part	in	
conditioning	 the	 metastatic	 niche	 [130].	 Exosome	 accessibility	 in	 liquid	 biopsies	 (blood,	
urine,	 lymph)	and	their	correlation	with	patient	clinical	 features	 (metastatic	dissemination,	
tumor	relapse	or	response	to	therapy)	make	them	candidates	for	diagnostic,	prognostic	and	
therapy	 response	 indicators	 [131–133].	 Recent	 advances	 in	 the	 field	 demonstrated	 that	
exosomes	are	not	merely	 transport	 containers	 for	 intercellular	 trafficking.	They	are	 in	 fact	
fully	functional	entities	that	contain	all	the	machinery	required	for	de	novo	protein	synthesis	
and	processing	[78].	These	findings	are	the	evidence	for	the	existence	of	a	specific	proteome	
that	is	confined	to	the	exosomes.	The	understanding	of	key	factors	that	shape	the	proteome	
of	 exosomes	 is	 essential	 for	 identifying	 novel	 mechanisms	 that	 contribute	 to	 tumor	
progression	[134,135].		
Myoferlin	is	a	230kDa	membrane	protein	that	belongs	to	the	ferlin	family	of	proteins.	It	was	
first	 identified	 in	 muscle	 cells,	 where	 it	 contributes	 to	 cell/cell	 fusion	 and	 muscle	
regeneration	 [18,20].	 Further	 studies	 performed	 in	 endothelial	 cells	 demonstrated	 that	
myoferlin	 was	 important	 for	 membrane	 repair	 and	 endocytosis	 [24]	 as	 well	 as	 receptor-
mediated	 angiogenesis	 [6,12,23,34].	 In	 cancer,	 overexpression	 of	 the	 protein	 has	 been	
reported	in	breast,	lung,	and	pancreatic	tumors	[28,30,35,136],	where	it	has	been	associated	
with	 increased	 tumorigenic	 potential	 and	 angiogenesis	 [9,32,34,98].	 Mechanistically,	
myoferlin	has	been	shown	to	control	both	endocytosis	(EGFR,	VEGFR2,	IGFR	and	Tie-2)	and	
exocytosis	(VEGF)	of	several	growth	factors	and	their	receptors	[6,9,12,23,34,90].	Inspired	by	
myoferlins’	role	in	cell	membrane	biology,	we	hypothesized	that	myoferlin	could	be	essential	
to	exosomes	in	potentially	regulating	their	maturation,	secretion	or	internalization.	Indeed,	
our	 literature	research	strengthens	this	hypothesis	 in	showing	that	myoferlin	was	found	 in	
exosome	 proteomes	 from	 different	 cell	 lines.	 Using	 immunoblotting	 and	 electron	
microscopy,	we	confirm	that	myoferlin	 is	 indeed	present	 in	exosomes	derived	 from	breast	
and	 pancreas	 cancer	 cell	 lines.	 We	 show	 for	 the	 first	 time	 that	 myoferlin	 is	 determining	
factor	 for	 the	proteomic	diversity	of	 the	exosomes,	having	direct	 impact	on	their	 function.	
Collectively,	 our	 findings	 place	 myoferlin	 on	 the	 short	 list	 of	 key	 proteins	 important	 for	
cancer	exosome	biology.	
2.  MATERIALS AND METHODS 
2.1 Cell  culture and myoferl in-depleted cel l  l ines 
	
The	 cell	 lines	 used	 in	 this	 study	 (MDA-MB-231	 (HTB-26),	MDA-MB-468	 (HTB-132),	 BT-549	
(HTB-122),	Hs	578T	(HTB-126),	MCF7	(HTB-22),	ZR-75-1	(CRL-1500),	BT-474	(HTB-20),	SK-BR-
3	(HTB-30)	and	CFPAC-1	(CRL-1918))	were	obtained	from	American	Type	Culture	Collection	
(ATCC;	 Manassas,	 VA,	 USA).	 Human	 pancreatic	 adenocarcinoma	 cells	 BxPC-3	 (ATCC	 CRL-
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1687)	were	 a	 generous	 gift	 from	 Prof.	 Bikfalvi	 (Inserm	U1029,	 Bordeaux,	 France).	 PANC-1	
cells	(ATCC	CRL-1469)	were	a	generous	gift	from	Prof.	Muller	and	Burtea	(NMR	Laboratory,	
University	of	Mons,	Belgium).	All	cells	were	cultured	in	their	recommended	medium	at	37°C,	
5%	 CO2,	 and	 95%	 humidity.	 Isolation	 of	 human	 umbilical	 vein	 endothelial	 cells	 (HUVEC)	
(passages	 6–11)	 was	 described	 previously	 [137].	 HUVEC	were	 seeded	 onto	 gelatin-coated	
culture	flasks	and	cultured	in	EGM-2	medium	(Cat.	#:		CC3162/6;	Lonza,	Basel,	Switzerland)	
supplemented	with	5%	fetal	bovine	serum	(Cat.	#:	DE-802F;	Lonza).	
Stable	myoferlin	depletion	was	 achieved	using	 lentiviral	 shRNA	particles.	Myoferlin	 shRNA	
plasmid	(sequence	CCCUGUCUGGAAUGAGA	cloned	into	pLKO,	Sigma,	St.	Louis,	MO,	USA)	or	
control	shRNA	(Cat.	#:	SHC005;	Sigma,	St.	Louis,	MO,	USA)	were	cotransfected	with	pSPAX2	
(Addgene,	Cambridge,	MA,	USA)	and	a	VSV-G	encoding	plasmids	[138]	 in	 lenti-X	293T	cells	
(Clontech,	Mountain	view,	CA,	USA).	Titration	of	the	lentiviral	vectors	was	performed	using	
the	qPCR	Lentivirus	Titration	 (Titer)	Kit	 (Cat.	#:	LV900;	ABM,	Richmond,	BC,	Canada).	After	
transduction,	the	stably	transduced	clones	were	selected	following	Puromycin	treatment	(10	
μg/mL,	ant-pr-1,	Invivogen,	Toulouse,	FR).		
	
2.2 Exosome purif ication and characterization 
	
Cancer	cells	were	seeded	at	75%	confluence	and	allowed	to	grow	in	their	respective	culture	
medium	supplemented	with	exosome-depleted	serum.	After	48	hours,	supernatant	was	first	
centrifuged	for	20	minutes	at	2,000g	to	remove	floating	cells.	Cell-free	supernatant	was	next	
centrifuged	at	12,000g	for	45	minutes	and	filtered	(0.22	μm	filter)	to	remove	additional	cell	
debris.	The	collected	medium	was	then	ultracentrifuged	for	2	hours	at	100,000g	using	SW-28	
rotor	 and	 Optima	 LE80	 ultracentrifuge	 (Beckman	 Coulter,	 Brea,	 CA,	 USA).	 The	 exosome	
containing	pellet	was	washed	once	with	PBS,	centrifuged	again	for	2	hours	at	100,000g	and	
finally	suspended	either	 in	PBS	or	SDS-based	 lysis	buffer	 (50	mM	Tris-HCl,	1%	SDS,	pH	7.5,	
supplemented	 with	 protease	 and	 phosphatase	 inhibitors,	 (Cat.	 #:	 11873580001;	 Roche,	
Mannheim,	 Germany).	 The	 PBS	 fraction	 was	 used	 for	 functional	 assays	 and	 microscopy,	
whereas	the	SDS-lysate	for	Western	blot	and	proteomic	analysis.		
 
	
2.3 Electron microscopy and immunogold labell ing of isolated exosomes 
	
Labelling	 of	 cell-derived	 exosomes	 was	 performed	 as	 previously	 described[137].	 Briefly,	
exosomes	attached	on	 formvar-carbon	coated	grids	were	successively	washed,	 fixed	 in	2%	
formaldehyde	 and	 incubated	 with	 primary	 (2	 hours,	 RT,	 anti-MYOF	 (Cat.	 #:	 HPA014245;	
Sigma	Aldrich,	St.	Louis,	MO,	USA)	1/20	dilution	in	PBS-BSA	0.2%	supplemented	with	normal	
goat	 serum	 1/50)	 and	 secondary	 antibodies	 (1	 hour,	 RT,	 anti-rabbit	 coupled	 with	 gold	
particles	(Aurion,	Wageningen,	The	Netherlands)	diluted	1/40	 in	PBS-BSA	0.2%,	pH	8.2)	 for	
one	hour.	Samples	were	postfixed	for	10	minutes	in	2.5%	glutaraldehyde	and	counterstained	
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using	uranyl	acetate	and	lead	citrate.	Pictures	were	made	with	a	Jeol	JEM-1400	transmission	
electron	microscope	at	80	kV	(Jeol,	Peabody,	MA,	USA).		
	
2.4 Western blotting 
	
Cells	 or	 exosome	 pellets	 were	 first	 lysed	 in	 SDS-based	 buffer.	 Protein	 quantification	 was	
performed	 using	 the	 BCA	 quantification	 kit	 (Pierce,	 Thermo	 Scientific,	 Rockford,	 IL,	 USA).	
Desired	amount	of	proteins	were	mixed	with	Laemmli	buffer	 (60	mM	Tris-HCl	pH	6.8,	25%	
glycerol,	 2%	 SDS,	 14.4	 mM	 of	 2-mercaptoethanol	 and	 trace	 of	 bromophenol	 blue)	 and	
denatured	for	5	minutes	at	99°C.	Protein	samples	were	separated	by	SDS-PAGE	followed	by	
electro-transfer	 on	 PVDF	 membrane.	 The	 membranes	 were	 incubated	 with	 the	 selected	
primary	antibodies	 (outlined	below)	overnight	at	4°C	and	 then	probed	with	corresponding	
secondary	 antibody	 conjugated	 to	 horseradish	 peroxidase	 (anti-rabbit	 antibody	 (Cat.	 #:	
G21234;	 Life-Technologies,	 Gent,	 BE)	 and	 anti-mouse	 antibody	 (Cat.	 #:	 P0260;	 Dako,	
Glostrup,	 Denmark)	 for	 one	 hour	 at	 room	 temperature.	 The	 immunoblots	 were	 revealed	
using	 the	 chemiluminescent	 substrate	 (ECL	Western	 blotting	 substrate,	 Thermo	 Scientific,	
Rockford,	 IL,	 USA).	 Following	 antibodies	 were	 used:	myoferlin	 (Cat.	 #:	 HPA014245;	 Sigma	
Aldrich,	 St.	 Louis,	 MO,	 USA),	 caveolin-1	 (Cat.	 #:	 3238;	 Cell	 Signaling,	 Danvers,	 MA,	 USA),	
flotilin-1	 (Cat.	 #:	 3253;	 Cell	 Signaling),	 CD-9	 (Cat.	 #:	 2125-0909;	 AbD	 Serotec,	 Düsseldorf,	
Germany),	CD-63	(Cat.	#:	ab134045;	Abcam,	Cambridge,	United	Kingdom)	and	HSC70	(Cat.	#:	sc-
7298;	Santa	Cruz,	Dallas,	TX,	USA).		
	
2.5 Proteomic analysis of cancer cel l -derived exosomes 
	
Exosome	 purifications	 were	 performed	 in	 biological	 duplicates.	 Exosome	 pellets	 were	
directly	 lysed	 in	 the	 SDS-based	 lysis	 buffer	 supplemented	with	 protease	 and	 phosphatase	
inhibitors	 (for	details	 see	above).	Protein	extracts	were	 further	 reduced	with	dithiothreitol	
(100	 mM),	 alkylated	 with	 150	 mM	 of	 chloroacetamide	 and	 precipitated	 with	 20%	
trichloroacetic	 acid.	 Protein	 pellets	 were	 then	 washed	 with	 acetone,	 suspended	 in	
ammonium	 bicarbonate	 buffer	 (50	 mM	 NH4CO3,	 pH	 8.0)	 and	 digested	 with	 trypsin	
(sequencing	 grade,	 1/50:	 protease/	 protein;	 Promega,	Madison,	WI,	 USA).	 Finally,	 5	 μg	 of	
peptides	were	desalted	using	C18	ZipTip	(Millipore,	Billerica,	MA)	and	2.5	μg	were	injected	
on	 an	 Acquity	 M-Class	 UPLC	 ((Waters,	 Milford,	 MA,	 USA)	 connected	 to	 a	 QExactive	 Plus	
(Thermo	Scientific,	Bremen,	Germany),	in	nano	electrospray	positive	ion	mode.	The	samples	
were	loaded	on	a	Symmetry	C18	5μm	column	(180	μm	x	20	mm,	20	μL/min,	pH	10,	Waters),	
followed	by	a	 stepwise	elution	on	 the	analytical	 column	HSS	T3	C18	1.8	μm	 (75	μm	x	250	
mm,	pH	3,	Waters).	The	samples	were	loaded	on	the	trap	column	in	100%	solvent	A	(water	
0.1%	 formic	 acid)	during	3	minutes	 and	 subsequently	 separated	on	 the	analytical	 column;	
flow	rate	600	nL/min,	solvent	A	(0.1%	formic	acid	in	water)	and	solvent	B	(0.1%	formic	acid	
in	acetonitrile),	linear	gradient	0	min,	98%	A;	5	min,	93%	A;	135	min,	70%	A;	150	min,	60%	A.	
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The	 total	 run	 time	 was	 180	 min.	 The	 MS	 acquisition	 was	 conducted	 in	 data-dependent	
mode.	The	parameters	for	MS	acquisition	were:	MS	range	from	400	to	1750	m/z,	Resolution	
of	70,000,	AGC	target	of	1e6	or	maximum	injection	time	of	50	ms.	The	parameters	for	MS2	
spectrum	acquisition	are:	 isolation	Window	of	2.0	m/z,	collision	energy	of	25,	resolution	of	
17500,	AGC	target	of	1e5	or	maximum	injection	time	of	50	ms.	Protein	 identifications	and	
quantifications	 were	 conducted	 using	 MaxQuant	 vXX	 using	 UniProt®	 human	 database.	
Peptide	modiﬁcation	carbamidomethylation	was	set	as	fixed	and	oxydation	(M)	as	variable.	
	
2.6 Immunofluorescence 
	
Exosomes	 isolated	 from	 cancer	 cells	 were	 labelled	with	 PKH67	 dye	 (Cat.	 #:	 P7333;	 Sigma	
Aldrich,	 Saint-Louis,	 USA)	 according	 to	 the	 manufacturer’s	 instructions.	 Fluorescently-
labelled	 exosomes	 were	 then	 incubated	 with	 endothelial	 cells	 (HUVEC,	 seeded	 at	 30,000	
cells	in	24-well	plate)	for	different	time	points.	Following	the	treatment,	the	cells	were	fixed	
for	 15	 minutes	 in	 4%	 PAF,	 washed	 two	 times	 with	 PBS	 and	 mounted	 on	 slides	 for	
visualization	under	 a	 confocal	microscope.	 Images	were	acquired	using	 SP5	A0BS	 confocal	
microscope	(Leica,	Wetzlar,	Germany)	at	a	magnification	of	63X.	
2.7	miRNA	overexpression	and	exosome-mediated	transfer	to	endothelial	cells	
Murine	specific	miRNA	miR298	(Cat.	#:	PM12525;	Thermo	Scientific,	Rockford,	IL,	USA)	was	
transfected	 at	 a	 concentration	of	 25	nM	 in	 cancer	 cells	 using	 Lipofectamine	2000	 reagent	
(Cat.	#:	11668-019;	Invitrogen,	Carlsbad,	California,	USA).	MiR298-overexpressing	exosomes	
were	then	isolated	and	incubated	with	HUVEC	(seeded	at	30,000	cells	in	24-well	plate)	for	2	
hours.	 Following	 exosome	 treatment,	 total	 RNA	 was	 extracted	 from	 the	 endothelial	 cells	
using	the	DNA,	RNA,	and	protein	purification	kit	-	Nucleospin	(Cat.	#:	740955.250;	Macherey-
Nagel,	Duren,	Germany).	Reverse	transcription	was	performed	using	the	RevertAid	H	Minus	
First	Strand	cDNA	Synthesis	Kit	(Cat.	#:	K1631;	Thermo	Scientific).	Detection	of	the	miR298	
miRNA	was	 then	 performed	 using	Quantitative	 PCR,	with	 specific	 primers	miR298	 (Cat.	 #:	
002598;	Applied	Biosystems,	 Foster	City,	 California,	USA)	 and	miR-RNU44	 (Cat.	 #:	 001094;	
Applied	Biosystems,	Foster	City,	California,	USA).	RNU44	was	used	as	an	internal	control.	
	
2.8 Prol iferation of exosome-treated endothelial  cel ls 
	
HUVEC	were	plated	at	2	×	103	cells/well	 in	96-well	plates	and	cultured	overnight	in	EGM-2	
(100	μl/well).	Cells	were	incubated	with	1.5	µg	exosomes	per	well	for	72h	in	EBM-2	(Cat.	#:	
CC3156;	Lonza)	with	0.5%	DBS.	Bromodeoxyuridine	 (BrdU)	was	added	and	the	culture	was	
incubated	 for	8h.	BrdU	 incorporation	was	measured	with	 the	Cell	Proliferation	ELISA	BrdU	
(chemiluminescence)	kit	(Roche)	according	to	the	manufacturer’s	protocol.	
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2.9 Migration of exosome-treated endothelial  cel ls 
	
HUVEC	were	plated	at	5	×	104	cells/well	 in	48-well	plates	and	cultured	overnight	in	EGM-2	
(300	μl/well).	Cells	were	incubated	with	5	µg	exosomes	per	well	for	24h.	To	examine	wound	
healing,	the	conﬂuent	monolayers	were	mechanically	scratched	using	a	pipette	tip	to	create	
the	wound.	Cells	were	washed	with	PBS	and	EBM-2	(Cat.	#:CC3156;	Lonza)	0.5%	DBS	(Cat.	#:	
10371029;	 Gibco-Thermo	 Fisher,)	 was	 added	 to	 allow	 for	 wound	 healing.	 The	 distance	
between	 the	 two	 sides	 of	 the	wound	was	measured	with	 a	 graduated	 ocular	 lens	 and	 an	
epifluorescence	microscope	(CKX41;	Olympus,	Tokyo,	Japan).	The	distance	between	the	two	
sides	of	 the	wound	after	6h	of	migration	was	 subtracted	 from	 the	distance	at	 time	0	and	
represented	on	a	graph.	
	
3.  RESULTS 
	
	
3.1 Myoferl in is  expressed in exosomes derived from breast and 
pancreatic cancer cel l  l ines  
 
In	order	to	 investigate	the	possibility	 that	myoferlin	 is	a	constitutive	part	of	exosomes,	we	
sought	 to	 explore	 existing	 proteomic	 data	 from	 purified	 exosomes.	 To	 do	 so	 we	 have	
interrogated	 the	“Exocarta”	database	 (www.exocarta.org)	 for	 the	presence	of	myoferlin	 in	
extracellular	 vesicles.	 Interestingly,	we	 found	 that	myoferlin	 had	 been	 reported	 in	 several	
proteomic	 analyses	 of	 purified	 exosomes	 from	 different	 cellular	 origins	 (Table	 1,	 adapted	
from	exocarta).	To	validate	these	in	silico	data,	we	purified	exosomes	from	the	supernatant	
of	 breast	 and	 pancreatic	 cancer	 cell	 lines,	 and	 have	 evaluated	myoferlin	 expression	 using	
Western	blot.	 Isolated	exosomes	were	 characterized	by	a	 size	 ranging	 from	40	 to	400	nm	
with	an	average	size	of	155-160	nm.	Most	of	the	particles	were	surrounded	by	lipid	bilayer	
as	 showen	 by	 electron	 microscopy	 (supplemental	 figure	 1).	 On	 Figure	 1A,	 the	 results	
confirmed	 the	 presence	 of	 myoferlin	 in	 exosomes	 purified	 from	 all	 the	 cancer	 cell	 lines	
tested.	 We	 also	 confirmed	 the	 myoferlin	 presence	 in	 exosomes	 by	 electron	 microscopy;	
using	 an	 anti-myoferlin	 immunogold	 labelling	 of	 purified	 exosomes	 from	 MDA-MB-231	
breast	cancer	cells	(Figure	1B).	
	
3.2 Myoferl in si lencing affects the size and the protein content of 
tumor-derived exosomes 
	
In	order	 to	 further	elucidate	 the	 function	of	myoferlin	 in	exosomes,	we	have	assessed	 the	
exosome	production	and	 their	 size	 in	myoferlin-depleted	MDA-MB-231	and	BxPC-3	cancer	
cells	(Figure	2).		
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Table	1:	Exocarta	recapitulated	table.	Myoferlin	presence	in	different	tumour-derived	exosomes	
	
	
Figure	1:	Myoferlin	is	expressed	in	exosomes	from	breast	and	pancreas	cell	 lines.	(A)	Western	blot	analysis	of	myoferlin	
expression	in	exosome	isolations	from	multiple	breast	and	pancreas	cancer	cell	lines.	CD9	and	FLOT1	were	used	as	positive	
controls	 for	 exosomes	 whereas	 the	 GRP78	 and	 COX1	 were	 employed	 as	 negative	 controls.	 (B)	 Immunogold	 electron	
microscopy	of	exosome	preparations	from	MDA-MB-231	cells	stained	for	myoferlin.	
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Figure	 2:	 Loss	 of	myoferlin	 decreases	 exosome	 size	 but	 not	 quantity.	 (A)	 Validation	of	myoferlin	 depletion	 in	 exosome	
preparation	 from	 breast	 (MDA-MB-231)	 and	 pancreas	 (BXPC3)	 cancer	 cells.	 (B)	Measurement	 of	 exosome	 quantity.	 (C)	
Measurement	of	exosome	size.	
	
We	found	no	major	difference	in	the	quantity	of	exosomes	produced	by	myoferlin-depleted	
cells	 in	 comparison	 to	 the	 control	 condition	 (Figure	 2B;	measured	 as	 the	 relative	 protein	
quantity	extracted	from	purified	exosomes	normalized	to	cell	number).	However,	using	dual	
light	scattering,	we	observed	that	exosomes	derived	from	myoferlin-depleted	cells	showed	
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consistently	 a	 significantly	 smaller	 particle	 size	 (Figure	 2C).	 This	 suggested	 that	 exosomal	
content,	rather	than	exosome	production,	could	be	affected	by	the	absence	of	the	protein.			
To	 test	 this	 hypothesis,	 we	 sought	 to	 understand	 if	 the	 proteome	 content	 of	 myoferlin-
depleted	 exosomes	 would	 be	 different	 from	 those	 who	 kept	 myoferlin.	 Therefore	 we	
performed	a	proteomic	 analysis	 of	 exosomes	 isolated	 from	MDA-MB-231	and	BxPC-3	 that	
were	 silenced	 for	myoferlin,	 and	 compared	 them	 to	 control	 exosomes.	We	 identified	 307	
and	498	proteins,	in	MDA-MB-231	and	BxPC-3	respectively,	which	were	expressed	in	at	least	
50%	 of	 the	 replicates	 (Table	 S1).	 Expectedly,	 over	 75%	 of	 the	 identified	 proteins	 were	
predicted	to	have	an	exosomal	subcellular	localization	(Figure	3A).	Although	the	identity	of	
the	modulated	proteins	was	different	between	breast	and	pancreatic	exosomes	(only	34	%	
of	proteins	overlap,	Table	S2),	we	observed	that	the	regulatory	pathways	down-regulated	in	
absence	 of	 myoferlin	 were	 highly	 similar	 (Figure	 3B).	 Indeed,	 in	 both	 cell	 types,	 these	
pathways	 were	 related	 to	 endocytosis	 and	 other	 vesicle-mediated	 processes.	 From	 these	
data,	 we	 generated	 a	 list	 of	 32	 proteins	 that	 were	 consistently	 decreased	 in	 myoferlin-
depleted	 exosomes,	 independent	 of	 the	 cell	 type	 analyzed	 (Figure	 3C-D	 and	 Table	 S3).	
Among	 these	 selected	 proteins	 we	 notably	 found	 proteins	 that	 are	 essential	 for	 proper	
intracellular	vesicle	 transport	 (CAV1,	FLOT1,	FLOT2,	SXN6)	and	key	 regulators	of	 the	endo-
lysosomal	 trafficking	 (VAMP7,	 RAB7A),	 both	 processes	 requiring	 high	 number	 of	
vesicle/membrane	 fusion	 events.	 Interestingly,	we	 also	 observed	 a	 consistent	 decrease	 in	
CD63	protein	expression,	which	 is	an	 important	marker	of	extracellular	vesicles	and	of	 the	
major	 components	 regulating	 heme	 homeostasis	 (TFRC,	 FTH1).	 Decreased	 expression	 of	
several	 of	 these	 proteins	 was	 further	 validated	 using	 Western	 blot	 on	 purified	 exosome	
extracts	(Figure	3E).		
	
3.3 Myoferl in si lencing alters exosome fusion and cargo delivery in 
target cel ls  
	
In	addition	to	endocytosis,	tumor-derived	exosomes	can	reach	target	cells	 (e.g.	 fibroblasts,	
endothelial	 cells…)	 by	 fusing	 with	 their	 plasma	 membrane,	 resulting	 in	 the	 delivery	 of	
molecular	cargo	 [123].	We	therefore	aimed	to	 test	whether	 lack	of	myoferlin	could	 impair	
exosome	 fusion	with	 endothelial	 cells.	 For	 this	 purpose,	we	 treated	 endothelial	 cells	with	
PKH67-labelled	 exosomes,	 isolated	 from	 control	 and	 myoferlin-depleted	 cancer	 cells.	 We	
then	used	 immunofluorescence	 to	 follow	exosome	uptake	 in	HUVEC	after	 their	 incubation	
with	 the	 labelled	 exosomes.	 Following	 incubation,	 endothelial	 cells	 treated	 with	 control	
exosomes	 displayed	 a	 strong	 fluorescent	 signal	 (Figure	 4A).	 The	 absence	 of	 colocalization	
with	 CD31,	 a	 membrane	 protein	 specific	 of	 endothelial	 cells,	 confirmed	 that	 the	 vesicles	
have	entered	the	target	cells	(Supplemental	figure	2).		
In	contrast	to	this,	we	could	not	detect	any	fluorescence	in	HUVEC	incubated	with	exosomes	
lacking	myoferlin.	We	confirmed	this	effect	of	myoferlin	silencing	by	following	the	transfer	of	
a	specific	miRNA	between	the	exosomes	isolated	from	cancer	cells	and	the	endothelial	cells.	
To	 do	 so,	 we	 have	 overexpressed	 a	murine	miRNA	 (miR-298)	 in	 the	 cancer	 cells	 (in	 both	
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control	and	myoferlin	depleted	condition),	purified	the	exosomes	from	these	cells	and	then	
incubated	 them	with	 HUVEC.	 As	 shown	 in	 Figure	 4A,	 the	 expression	 of	 the	miR-298	 was	
hardly	 detected	 in	HUVEC	 treated	with	 exosomes	 lacking	myoferlin,	 in	 comparison	 to	 the	
control	condition.		
	
Figure	3:	Myoferlin	depletion	from	cancer	exosomes	induces	major	change	in	their	proteome	content.	
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Figure	4:	Myoferlin-deficient	exosomes	are	functionally	impaired	to	transfer	biological	message	to	neighboring	cells.	
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3.4 Myoferl in si lencing impairs exosome-mediated reprogramming of 
endothelial  cel ls  in vitro 
	
Having	established	that	myoferlin	deficiency	decreases	exosome	entry	and	cargo	release,	we	
next	asked	the	question	if	this	could	have	biological	consequences	for	target	cells.	In	order	
to	 evaluate	 this	 we	 have	 examined	 endothelial	 cell	 proliferation	 and	 migration	 following	
their	 incubation	 with	 control	 and	 myoferlin	 depleted	 exosomes	 from	 MDA-MB-231	 and	
BxPC-3	 cells.	 In	 comparison	 with	 naïve	 HUVEC,	 endothelial	 cells	 incubated	 with	 control	
exosomes	displayed	 increased	rates	of	proliferation	and	migration	(Figure	4C-D).	However,	
when	 the	 HUVEC	 were	 incubated	 with	 myoferlin-depleted	 exosomes,	 these	 effects	 were	
significantly	 attenuated,	 restoring	 the	proliferation	and	migration	 rates	 similar	 to	 those	of	
non-treated	cells	(Figure	4C-D).		
	
4.  DISCUSSION 
	
Cancer	 cell/stroma	 communication	 represents	 a	 key	mechanism	 required	 for	 both	 tumor	
growth	and	metastatic	dissemination.	A	paucity	of	studies	demonstrates	that	exosomes	are	
mediators	that	facilitate	inter-cellular	exchange	of	biomolecules,	assuming	an	important	role	
in	 cell-to-cell	 communication	 [81].	 In	 the	 current	 study	 we	 focused	 on	 myoferlin,	 a	
membrane	associated	protein,	which	has	recently	been	demonstrated	to	be	pro-oncogenic	
in	several	types	of	cancer	[9,31,32,34,35,98].	In	the	breast	cancer,	in	vivo	tumor	xenografts	
lacking	myoferlin	 have	 been	 described	 as	 smaller,	 less	 invasive	 and	 less	 vascularized	 than	
their	 control	 counterparts	 [98].	 Antitumor	 effects	 observed	 following	myoferlin	 depletion	
have	been	attributed	to	 impaired	membrane	repair/turnover	 [35],	 the	 inability	to	properly	
internalize	 growth	 factor	 receptors	 [34],	 impaired	 cancer	 cell	 motility	 [31,34,98]	 and	 the	
inability	to	sustain	tumor-associated	angiogenesis	[9,23].	However,	our	study	brings	forward	
an	 additional	 important	 role	 for	 myoferlin	 in	 tumor	 progression,	 namely	 the	 ability	 to	
modulate	tumor/stroma	crosstalk.	Indeed,	although	the	presence	of	exosomal	myoferlin	had	
been	 reported	 in	 several	 proteomic	 analyses	of	 tumor-derived	exosomes	 (see	Table	1),	 to	
our	knowledge,	 the	definitive	proof	of	 its	presence	 in	exosomes	has	not	been	provided	 to	
date.	 Starting	 from	 our	 original	 proteomic	 observation	 and	 strengthened	 by	 the	 previous	
studies,	 we	 demonstrated	 by	Western	 blotting	 and	 electron	microscopy	 that	myoferlin	 is	
indeed	 a	 major	 component	 of	 cancer	 cells-derived	 exosomes.	 In	 the	 present	 study	 we	
confirm	that	myoferlin	is	present	in	exosomes	derived	from	all	major	breast	and	pancreatic	
cancer	cell	lines	from	different	molecular	and	genetic	backgrounds.		Following	this,	we	next	
sought	 to	 examine	 if	 myoferlin	 depletion	 has	 any	 functional	 consequences	 for	 cancer-
derived	 exosomes.	 We	 have	 thus	 characterized	 the	 size	 and	 the	 quantity	 of	 exosomes	
secreted	by	myoferlin	depleted	cells.	The	analysis	showed	that	myoferlin	depletion	does	not	
affect	exosome	quantity	but	it	does	affect	their	size.	This	suggests	that	myoferlin	influences	
exosome	 cargo	 rather	 than	 the	 production	 by	 cancer	 cells.	 These	 findings	 have	 further	
motivated	us	to	examine	the	protein	content	of	myoferlin-depleted	exosomes	and	compare	
this	to	the	control	counterparts.	The	proteomic	analysis	of	isolated	exosomes	revealed	that	
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myoferlin	silencing	leads	to	a	significant	alteration	of	the	protein	content.	Notable	was	the	
decreased	 expression	 of	 several	 vesicular	 markers	 that	 are	 known	 to	 be	 expressed	 in	
exosomes	 (caveolin-1,	 flotilin-1	 and	 2,	 syntaxin	 6).	 The	 analysis	 also	 demonstrated	 the	
modulation	 of	 several	 members	 of	 the	RAB	 family	 of	 RAS-related	 GTP-binding	 proteins,	
which	 are	 important	 regulators	 of	 vesicular	 transport.	 Of	 these,	 RAB7A	 was	 commonly	
downregulated	 in	 myoferlin-depleted	 condition.	 RAB7A	 is	 a	 known	 marker	 of	 endo-
lysosomal	transition	whose	upregulation	has	been	associated	with	tumorigenesis	in	multiple	
organs	[139–141].	Recently,	Redpath	et	al.	showed	that	myoferlin	strongly	localized	in	RAB7-
positive	 late	 endosomes	 [86].	 The	 decrease	 of	 RAB7A	 expression	 observed	 in	 absence	 of	
myoferlin	could	therefore	reflect	another	mechanism	that	could	explain	the	observed	anti-
tumor	 effect.	 A	 further	 important	 observation	 resulting	 from	 the	 current	 proteomic	 study	
was	 the	 marked	 decrease	 of	 CD63	 following	 myoferlin	 silencing.	 CD63	 is	 a	 widely	 used	
exosomal	marker	and	its	expression	correlates	with	increased	aggressiveness	and	metastatic	
potential	of	breast	tumors	[142,143].	Our	data	have	also	pointed	that	ferritin	and	transferrin	
levels	were	 reduced	 in	myoferlin-depleted	exosomes,	 suggesting	 that	myoferlin	 could	also	
be	 important	factor	regulating	 iron	metabolism.	 Iron	metabolism	is	 frequently	deregulated	
in	cancer	[144]	and	high	levels	of	serum	ferritin	have	been	shown	to	correlate	with	adenoma	
formation	in	colon	[145],	clinical	outcome	of	pancreatic	cancer	patients		[146]	and	response	
to	 chemotherapy	 in	 breast	 cancer	 [147,148].	 Exosomes	 are	 thought	 to	 support	 tumor	
growth	by	reprogramming	cells	 from	the	tumor	microenvironment,	such	as	fibroblasts	and	
endothelial	cells	[126,149].	Myoferlin	was	previously	described	as	a	key	factor	in	the	process	
of	 cell-cell	 fusion	 [20],	 suggesting	 that	 similar	 mechanism	 may	 here	 also	 be	 underway.	
Indeed,	the	entry	of	exosomes	into	target	cells	involves,	among	other	mechanisms,	a	direct	
fusion	with	the	plasma	membrane	[123].	The	present	study	demonstrates	for	the	first	time	
that	silencing	myoferlin	delays	exosome	uptake	by	endothelial	cells.	This,	in	addition	to	their	
altered	 protein	 content,	 led	 to	 diminished	 ability	 of	 myoferlin-depleted	 exosomes	 to	
stimulate	endothelial	cell	migration	and	proliferation.	Although	the	consequences	for	tumor	
progression	 are	 evident,	 additional	 studies	 need	 to	 be	 conducted	 in	 order	 to	 understand	
how	 myoferlin	 contributes	 to	 the	 exosome	 uptake	 in	 the	 target	 cells.	 Hints	 towards	
answering	 this	 question	 may	 be	 provided	 by	 the	 recent	 study	 of	 Melo	 et	 al.	 [78]	 who	
elegantly	demonstrated	that	an	exosomal	maturation	process	outside	the	cell	is	required	to	
achieve	 proper	 release	 of	 their	 proteic	 and	 nucleotidic	 content	 in	 the	 target	 cells	 and	
subsequently	 initiate	 tumorigenesis.	 The	 fact	 that	 myoferlin	 is	 able	 to	 determine	 protein	
cargo	of	cancer-derived	exosome	could	explain	why	this	protein	is	overexpressed	in	cancer,	
and	 further	 underlines	 its	 importance	 in	 the	 regulation	 of	 both	 intra-	 and	 extracellular	
vesicle	trafficking	of	cancer	cells.	
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5.  SUPPLEMENTAL DATA  
	
Supplemental	Figure	1:		Morphological	characterization	of	exosomes	isolated	from	BxPC-3	cells.	A.	Dynamic	Light	
Scattering	of	isolated	exosomes.	B.	Electron	microscopy	of	isolated	exosomes.			
	
Supplemental	Figure	2:		Uptake	of	exosomes	derived	from	MDA-MB-231	and	BxPC-3	cell	lines	by	the	HUVEC	cells.	
Immunofluorescence	(red	channel:	CD31,	green	channel:	PKH67-exosomes,	bleu	channel:	nucleus)	showing	the	uptake	and	
localization	of	exosomes	derived	from	MDA-MB-231	and	BxPC-3	within	HUVEC	cells.	Colocalization	of	CD31	and	PKH67-
exosomes	was	assessed	by	2D	intensity	histogram.			
	
	
65	
 
 
 
 
 
 
 
 
General Discussion and Conclusion  
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
66	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
67	
Although	 the	 interest	 in	 cancer	 research	 rose	 exponentially	 during	 the	 last	 century	 but	
cancer	 is	 not	 a	 new	 disease.	 Autopsies	 of	 ancient	 Egyptian	 mummies	 have	 shown	 the	
presence	 of	 bone	 tumors	 [150]	 even	 also	 in	 some	 ancient	 prehistoric	 fossils	 [151].	
Nowadays,	 according	 to	 the	World	 Health	Organization	 (WHO),	 cancers	 figure	 among	 the	
leading	 causes	 of	morbidity	 and	mortality	worldwide,	with	 approximately	 14	millions	 new	
cases	and	8.2	millions	cancer	related	deaths	in	2012.		
Understanding	 the	mechanisms	 that	 control	 cancer	 progression	 is	 the	 key	 for	 developing	
new	therapeutic	tools	helping	 in	the	fight	against	this	disease.	Most	of	the	research	teams	
focus	on	the	cancer	cells	themselves;	while	 in	fact;	cancer	acts	 like	an	organ-like	structure.	
This	means	 that	 cancer	 communicates	with	 host	 systems	 including	 stromal	 cells,	 immune	
cells	 and	 blood	 vessels	 [152].	 This	 cancer	 communication	 with	 its	 environment	 is	 now	
recognized	as	a	key	factor	in	cancer	progression	as	it	plays	a	role	in	local	resistance,	immune-
escape	and	metastasis	dissemination	[153].		
Myoferlin	has	been	reported	to	be	over	expressed	in	pancreatic	and	breast	cancers	and	to	
be	associated	with	bad	prognosis	[30].	In	this	study,	we	confirm	myoferlin	expression	at	the	
cellular	 level	 in	 all	 tested	 breast	 and	 pancreatic	 cancer	 cell	 lines	 and	 we	 confirm	 its	
association	with	bad	prognosis	in	PDAC	cancer.	We	report	here	for	the	first	time,	myoferlin	
expression	 at	 the	 exosomal	 level	 in	 all	 tested	 breast	 and	 pancreatic	 cancer	 cell	 lines.	We	
further	show	the	implication	of	myoferlin	in	exocytosis	and	in	exosome	biology.	We	describe	
the	 role	 of	 myoferlin	 in	 the	 biogenesis	 and	 the	 fusion	 of	 exosomes	 and/or	 exocytosis	
vesicles.		
There	 is	 actually	 an	 immense	 body	 of	 literature	 studying	 different	 factors	 implicated	 in	
different	 kinds	of	 vesicle	biogenesis,	 targeting	and	 fusion.	Most	of	 these	 factors	are	being	
studied	 in	 normal	 physiological	 conditions,	 however,	 since	myoferlin	 is	 being	 further	 and	
further	 proposed	 to	 be	 a	 potential	 biomarker	 of	 cancer,	 it	 is	 of	 extreme	 interest	 to	
investigate	 its	 role	 in	 cancer	 communication.	 Targeting	 specifically	 cancer	 communication	
would	be	an	extremely	useful	tool	to	manage	cancer,	bypassing	limitations	and	side	effects	
of	actual	cancer	management	molecules.		
We	have	first	oriented	our	study	to	the	pancreas	cancer	as	our	laboratory	and	others	have	
reported	 that	 PDAC	 overexpresses	 myoferlin.	 Concretely,	 we	 have	 decided	 to	 use	 two	
pancreatic	 cancer	cell	 lines,	which	are	BxPC-3	and	Panc-1	cell	 lines.	Both	cell	 lines	express	
myoferlin	 but	 only	 BxPC-3	 cells	 express	 high	 levels	 of	 VEGF-A,	 which	 makes	 it	 a	 suitable	
model	to	study	angiogenesis.	Moreover,	our	 laboratory	had	previously	shown	that	this	cell	
line	is	able	to	grow	on	CAM	model,	actually	growing	inside	the	CAM	connective	tissue	giving	
rise	 to	 functionally	 vascularized	 tumors;	 these	 tumors	 grow	 as	 unique	 spherical	 nodules	
mimicking	 to	a	great	extent	 the	human	PDAC	 [99].	Overall,	BxPC-3	 tumors	grown	on	CAM	
could	 be	 a	 very	 interesting,	 easy,	 economically	 and	 ethically	 suitable	 model	 to	 study	
pancreatic	cancer	growth	and	angiogenesis.	Panc-1	cell	line	expresses	almost	the	same	level	
of	myoferlin	as	BxPC-3	cell	line,	however,	it	does	not	neither	grow	on	CAM	nor	produce	high	
levels	of	VEGF-A	but	yet,	it	is	widely	used	in	the	literature,	so	it	is	a	valid	cell	line	to	perform	
functional	studies.		
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The	work	of	Turtoi	et	al,	demonstrated	that	myoferlin	 is	essential	 for	breast	cancer	 tumor	
growth	 on	 CAM.	 Myoferlin	 depletion	 in	 MDA-MB-231	 cell	 line	 provoked	 a	 significant	
decrease	in	tumor	volume	[34].	Our	results	come	in	consistency	with	the	findings	of	Turtoi,	
where	we	 showed	 that	myoferlin	 depletion	 in	 BxPC-3	 tumors	 grown	on	CAM	gave	 rise	 to	
significantly	 smaller	 tumors	 when	 compared	 to	 normal	 counterparts	 (Publication	 1).	
Moreover,	 our	 observations	were	 extended	 to	 the	 tumor	 appearances,	where	we	noticed	
that	myoferlin-depleted	tumors	were	whitish	and	pale	compared	to	control	ones,	implying	a	
probable	alteration	in	the	vascularization	of	the	tumors.	
Myoferlin	depletion	has	been	reported	to	provoke	a	decrease	in	cell	proliferation	in	different	
cell	types	including	endothelial	cells	[23].	We	have	demonstrated	that	myoferlin	depletion	in	
BxPC-3	 cells	 in	 vitro	 provoked	 a	 significant	 decrease	 in	 the	 cell	 growth.	 We	 have	 also	
confirmed	the	same	effect	on	Panc-1	cells;	suggesting	a	VEGF-A-independent	effect	as	Panc-
1	 cell	 line	 produces	 almost	 no	 VEGF-A.	 These	 results	 are	 in	 consistency	with	Wang	 et	 al,	
findings	 [30]	as	they	have	demonstrated	a	significant	cell	growth	 inhibition	after	myoferlin	
silencing	on	both	BxPC-3	and	CFPac-1	cell	lines.		
Wang	demonstrated	that	myoferlin	depletion	provokes	a	slight	(5%)	but	significant	increase	
in	apoptosis	and	an	arrest	of	 the	cell	 cycle	 in	 the	S	phase	 in	both	BxPC-3	and	CFPac-1	cell	
lines.	 	Our	 results	 are	 not	 in	 consistency	with	Wang	 as	we	 show	 that	myoferlin	 depletion	
does	not	 significantly	 increase	apoptosis,	but	are	 in	 consistency	with	Leung	et	al.	 findings,	
where	they	showed	that	myoferlin	depletion	in	Lewis	Lung	carcinoma	cells	(LLC)	provoked	a	
decrease	in	cell	proliferation	without	an	increase	in	apoptosis	[35].	This	difference	between	
our	results	and	the	results	of	Wang	et	al.	could	be	due	to	the	different	technique	used,	as	
they	have	used	a	methodology	that	may	recognize	necrotic	cells	as	well.		
Overall	 results	explain,	 at	 least	 in	part,	 the	decrease	 in	myoferlin-depleted	 tumor	 sizes	on	
CAM	 but	 does	 not	 explain	 why	 myoferlin-depleted	 BxPC-3	 tumors	 have	 whitish	 pale	
appearances.	 Our	 immunostaining	 analysis	 of	 the	 tumors	 showed	 a	 decrease	 in	 the	
vascularization	 of	myoferlin-depleted	 tumors.	While	Wang	 et	 al.	 and	 Turtoi	 et	 al.	 did	 not	
investigate	MVD	in	their	respective	work,	Leung	et	al.	showed	that	myoferlin-depleted	LLC	
cells	 injected	 in	 mice	 lungs	 had	 no	 effect	 neither	 on	 MVD	 nor	 on	 serum	 VEGF-A	 levels	
[30,34,35].		
We	 are	 reporting	 for	 the	 first	 time,	 according	 to	 our	 knowledge,	 that	myoferlin	 depletion	
significantly	 decreased	VEGF-A	 secretion	 into	 the	 conditioned	medium.	 The	 implication	 of	
myoferlin	in	soluble	factor	secretion	has	previously	been	proposed	by	Eisenberg	et	at,	in	the	
context	of	breast	cancer	[31].		
Our	 immunofluorescence	 data	 showed	 the	 accumulation	 of	 VEGF-A	 at	 the	 vicinity	 of	 the	
plasma	membrane	concomitantly	with	the	accumulation	of	vesicle-like	structure	seen	by	the	
electron	 microscopy	 in	 the	 myoferlin-depleted	 condition.	 This	 hypothesizes	 that	 VEGF-A	
containing	 exocytosis	 vesicles	 are	 approaching	 the	 plasma	membrane	 to	 fuse	 and	 secrete	
their	cargo	of	VEGF-A	to	make	the	call	for	angiogenesis.	However,	this	does	not	occur	in	the	
absence	 of	 myoferlin.	 Therefore,	 we	 hypothesize	 a	 role	 of	 myoferlin	 in	 vesicle-mediated	
fusion	 events.	 Actually	 this	 is	 in	 consistency	 with	 previous	 observations	 made	 for	 other	
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members	of	the	ferlin	family	(dysferlin	and	Fer-1)	and	even	for	myoferlin	itself;	where	their	
depletion	 in	 different	 cellular	 models	 provoked	 also	 an	 accumulation	 of	 vesicle-like	
structures	in	the	plasma	membrane	area.		
The	major	contribution	of	this	work	is	to	show	that	myoferlin	plays	a	role	in	the	trafficking	of	
VEGF-A	containing	vesicles	by	pancreatic	cancer	cells.	This	is	probably	due	to	the	possession	
of	myoferlin	of	six	C2	domains	that	sculpt,	in	an	additive	manner,	the	vesicular	lipid	bilayer	
resulting	 in	 high	 curved	 or	 distorted	 membrane	 regions	 that	 could	 facilitate	 membrane	
fusion	and	fission	or	recruitment	of	other	membrane	trafficking	proteins,	as	shown	by	Marty	
[11].		
Mechanistically,	Xie	et	al,	have	shown	that	Exoc2/Sec5	is	expressed	at	the	surface	of	insulin	
secretory	granules	of	the	beta-cell	of	the	pancreas	and	that	it	plays	a	key	role	in	mediating	
docking	 of	 these	 vesicles	 to	 the	 plasma	 membrane	 [154].	 Our	 data	 show	 a	 partial	
colocalization	of	myoferlin	with	Exoc2/Sec5,	very	interestingly,	at	the	vicinity	of	the	plasma	
membrane	fortifying	our	hypothesis	of	myoferlin’s	implication	in	exocytosis	machinery.		
However,	we	do	not	know	where	myoferlin	is	located	in	the	exocytosis	process.	Myoferlin	is	
a	 type	 II	 transmembrane	protein	reported	to	be	present	at	 the	 inner	 leaflet	of	 the	plasma	
membrane.	In	the	current	work,	we	report	myoferlin	to	be	expressed	on	the	external	surface	
of	exosomes	(Publication	2).	So	myoferlin	could	also	be	present	on	the	external	surface	of	
exocytotic	vesicles	to	mediate	their	fusion	with	the	plasma	membrane,	like	SNARE	proteins	
[155,156].	
Plasma	membrane-anchored	myoferlin	could	interact	with	negatively	charged	phospholipids	
present	on	the	outer	surface	of	exocytotic	vesicles,	which	may	explain	why	insulin	secretory	
granules	 increase	 their	 composition	 of	 negatively	 charged	 phospholipids,	 as	mentioned	 in	
the	introduction.	Another	figure	is	that	myoferlin	could	be	recruited	on	the	outer	surface	of	
the	exocytotic	vesicles,	like	v-SNARE	proteins,	to	bring	extra-fluidity	to	the	exocytotic	vesicle	
membranes	 and	 facilitate	 their	 docking	 and	 fusion.	 Rein	 et	 al.	 proposed	 that	 v-SNARE	
proteins	 could	 be	 directly	 recruited	 at	 the	 external	 surface	 of	 exocytotic	 vesicles	 [157].	
Which	in	all	cases,	is	in	consistency	with	the	reported	role	of	myoferlin	in	mediating	fusion	
events	at	the	membrane	site	[5,20,22].		
Redpath	et	al,	demonstrated	the	constitutive	production	of	mini-myoferlin	that	has	a	great	
structure	 similarity	 with	 synaptotagmins	 [84].	 While	 synaptotagmin	 is	 expressed	 on	 the	
outer	 surface	 of	 exocytotic	 vesicles	 [158,159]	 mediating	 their	 fusion	 in	 a	 Ca2+-dependent	
manner;	it	is	very	speculative	that	myoferlin	could	act	exactly	like	synaptotagmin	(Figure	10).	
To	further	fortify	our	hypothesis,	we	showed	that	myoferlin	expression	in	PDAC	sections	 is	
positively	associated	with	 the	MVD,	while	 it	 is	known	that	VEGF-A	 is	associated	with	MVD	
[160].	This	means	that	myoferlin	could	play	a	role	 in	VEGF-A	exocytotic	machinery	and	so,	
VEGF-A	mediated	angiogenesis	in	PDAC	patients	as	it	does	for	BxPC-3	tumors	grown	on	CAM	
model.			
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Figure	10.	Hypothetic	model	of	myoferlin	involvement	in	exocytosis.	Exocytosis	vesicles	fusion	at	the	plasma	membrane	
and	the	interaction	between	C2	domains	bearing	proteins	(Synaptotagmin	or	myoferlin)	with	SNARE	proteins.	Fahmy	et	al.,	
2015	[9].	
	
It	 is	 of	 particular	 interest	 to	 further	 investigate	 the	 localization	 of	 myoferlin	 during	
exocytosis.	 In	 other	 words,	 knowing	 if	 myoferlin	 is	 present	 on	 the	 surface	 of	 exocytotic	
vesicles	or	on	the	inner	leaflet	of	the	plasma	membrane	interacting	with	the	other	element’s	
phospholipids	 or,	 may	 be,	 proteins.	 As	 well,	 it	 would	 also	 bring	 a	 great	 importance	 to	
investigate	if	BxPC-3	cells,	and	PDAC	in	general,	do	express	mini-myoferlin	or	not.	In	general	
terms,	 this	 will	 help	 to	 understand	 if	 myoferlin	 is	 implicated	 in	 other	 soluble	 factors	
secretion	 or	 if	 it	 plays	 solely	 a	 specific	 role	 in	 VEGF-A	 secretion.	 If	myoferlin	 is	 a	 general	
player	in	exocytosis,	this	implies	that	myoferlin	plays	a	pivotal	role	in	cancer	communication	
and	cross	talk	with	its	microenvironment.	In	that	case,	a	deeper	exhaustive	research	would	
provide	more	information	about	myoferlin	in	cancer	communication.		
However,	 we	 show	 in	 the	 present	 study	 that	 myoferlin	 does	 not	 solely	 play	 a	 role	 in	
exocytosis	vesicle	trafficking;	our	work	demonstrated	also	the	role	of	myoferlin	in	exosomes	
mediated	communication.		
As	mentioned	earlier,	we	have	demonstrated	by	immunoblotting	the	presence	of	myoferlin	
in	exosomes	derived	from	breast	and	pancreatic	cancer	cell	lines	of	different	molecular	and	
genetic	 backgrounds	 (Publication	 2).	 Actually,	 myoferlin	 presence	 in	 exosomes	 has	 been	
previously	mentioned,	indirectly,	in	the	literature.	A	query	on	exocarta	(www.exocarta.org),	
which	 is	 a	 database	 of	 proteomic	 studies	 of	 exosomes,	 shows	 that	 myoferlin	 has	 been	
identified	 in	 a	 multitude	 of	 cancer	 cell-derived	 exosomes.	 These	 studies	 did	 not	 target	
studying	myoferlin	in	exosomes,	however	myoferlin	was	one	protein	among	a	list	of	proteins	
identified	 thanks	 to	 proteomic	 profiling	 of	 exosomes.	 None	 of	 these	 studies	 have	 further	
investigated	myoferlin	role	 in	exosomes	or	event	confirmed	its	 identity	by	other	technique	
than	proteomic	profiling.	
We	 further	 confirmed	 the	 presence	 of	myoferlin	 in	 exosomes	 derived	 from	MDA-MB-231	
cell	line	by	immunogold	on	entire	adsorbed	exosomes.	Our	data	show,	for	the	first	time,	the	
abundant	presence	of	myoferlin	on	the	external	surface	of	exosomes.	The	antibody	used	for	
immunogold	 is	 oriented	 against	 an	 epitope	 within	 the	 C2	 domains	 region	 meaning	 that	
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myoferlin	 has	 its	 C2	 domains	 region	 oriented	 outside	 of	 the	 exosomes.	 This	 myoferlin	
orientation	is	unexpected	as	exosomes	undergo	two	reverse	budding	events,	one	from	the	
cell	 surface	 to	 form	 primary	 endosome	 and	 the	 second	 at	 the	 late	 endosomal	 limiting	
membrane	to	form	the	ILV	[124];	so	exosomes	normally	maintain	the	same	topology	of	the	
cell.	 For	 example,	 tetraspanins	 are	 transmembrane	 surface	 receptors	 [161];	 they	preserve	
their	external-surface	orientation	in	exosomes	[162],	but	in	exosomes	myoferlin	orientation	
was	reversed.	This	reversed	orientation	of	myoferlin	could	be	interpreted	in	different	ways.	
Myoferlin	 could	 have	 been	 recruited	 on	 the	 external	 surface	 of	 exosomes,	 or	 could	 have	
undergone	a	 flipping	event	 to	 revert	 its	orientation	or	 finally,	myoferlin	could	have	simply	
passively	stuck	on	the	exosome	surface.		
In	 all	 cases,	 this	 external-surface	 localization	 of	myoferlin	 hypothesizes	 a	 role	 in	 exosome	
fusion	 with	 the	 target	 cells	 or	 even	 selection	 of	 the	 target	 cells.	 Some	 external-surface	
proteins,	 like	 tetraspanins	 and	 ICAM-I,	 are	 proven	 to	mediate	 selection	of	 the	 target	 cells	
[163],	however,	we	have	no	data	regarding	myoferlin	implication	in	that	process.	Regarding	
fusion	 of	 exosomes,	 again	 some	 external-surface	 proteins,	 like	 tetraspanins	 and	 integrins,	
are	implicated	in	exosomal	fusion	via	the	establishment	of	a	network	with	target	cell	surface	
molecules	 and	 phospholipids	 [164][165].	 Noteworthy,	 CD9	 has	 been	 further	 reported	 to	
mediate	other	fusion	processes,	e.g.,	it	is	implicated	in	skeletal	muscle	fusion	events	[166].	
Since	 myoferlin	 mediates	 different	 fusion	 processes,	 it	 is	 probable	 that	 it	 could	 mediate	
exosomal	 fusion	 with	 the	 target	 cells.	 In	 the	 present	 work,	 we	 showed	 that	 exosomes	
derived	from	myoferlin-depleted	cancer	cells	are	less	able	to	fuse	or	to	be	up	taken	by	the	
target	HUVEC	cells.	We	also	showed	a	decrease	in	the	exosomal	shuttling	of	a	murine	miRNA	
from	donor	cells	to	recipient	HUVEC	cells	after	myoferlin	silencing	in	cancer	cells.	
On	 the	other	hand,	myoferlin	has	been	 reported	 to	 colocalize	with	Rab7+	 large	vesicles	of	
late	endosomes	near	nucleus	and	plasma	membrane.	It	occasionally	colocalizes	with	Lamp-1	
positive	 vesicles	 [86]	 meaning	 that	 it	 is	 most	 likely	 present	 in	 the	 endosomal	 trafficking	
compartment	 and	 least	 likely	 implicated	 in	 the	 lysosomal	 degradation	 pathway.	 We	
hypothesized	that	myoferlin	could	then	play	a	role	 in	MVB	biogenesis.	Our	results	showed	
that	myoferlin	depletion	did	not	alter	exosomes	quantity	but	it	did,	indeed,	alter	their	size.	It	
was	then	worthy	investigating	exosomal	content.		
We	demonstrated	in	this	study	that	myoferlin	depletion	from	BxPC-3	and	MDA-MB-231	cells	
provoked	a	significant	modulation	of	their	corresponding	exosomal	cargo,	implying	a	role	of	
myoferlin	 in	 cargo	 selection.	 Among	 several	 modulated	 factors,	 we	 reported	 the	 down	
regulation	 of	 several	 vesicular	markers	 like	 caveolin-1,	 flotillin-1,	 flotillin-2	 and	 syntaxin-6;	
also	 a	 down	 regulation	 of	 tetraspanins	 markers	 like	 CD63.	 This	 observation	 could	 be	 of	
extreme	 interest,	 as	 for	 instance,	 flotillin-1,	 flotillin-2	 and	CD63	have	 all	 been	 reported	 to	
play	a	role	in	exosome	biogenesis	and	cargo	selection	[167][168].		
Moreover,	we	showed	also	the	down	regulation	of	Rab7a	in	the	exosomes.	Although	its	role	
in	 cancer	 progression	 is	 controversial,	 Rab7a	 has	 been	 reported	 to	 have	 some	 pro-tumor	
effects	[139,169],[140].	On	the	same	path,	CD63	has	been	reported	to	act	as	pro-metastatic	
[143].	Overall,	our	results	propose	that	myoferlin	is	a	key	player	in	the	exosome	biogenesis	
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whether	 directly	 or	 even	 indirectly	 by	 down	 regulating	 other	 proteins	 implicated	 in	MVB	
biogenesis.	 Strikingly,	 it	 seems	 that	 myoferlin	 mediates	 the	 packaging	 of	 a	 selected	 pro-
cancerous	 cargo,	 which	 adds	 to	 the	 already	 proved	 explanation	 of	 the	 anti-tumor	 effect	
observed	in	the	myoferlin-depleted	tumors	in	various	studies.	
It	 has	 been	 previously	 reported	 that	 cancer-derived	 exosomes	 are	 able	 to	 induce	
proliferation	and	migration	of	HUVEC	cells	[170–172].	So	to	investigate	the	role	of	myoferlin	
in	exosome-mediated	tumorigenicity,	we	have	decided	to	investigate	a	phenotypic	change	in	
the	HUVEC	cells	after	incubation	with	exosomes	that	are	originated	from	myoferlin-depleted	
cells	 or	 not.	 In	 consistency	with	 the	 literature,	we	 showed	 that	 BxPC-3	 and	MDA-MB-231	
derived	 exosomes	 increase	 the	 proliferation	 and	 the	 migration	 of	 HUVEC	 cells.	 But	
interestingly,	 we	 showed	 that	 myoferlin	 depletion	 from	 these	 exosomes	 provoked	 a	
decrease	or	abolishment	of	these	effects.	It	means,	myoferlin-depleted	exosomes	provoked	
less	or	no	effect	on	endothelial	cell	proliferation	and	migration.	
There	are	two	possible	explanations	for	why	myoferlin-depleted	exosomes	mediated	less	or	
no	phenotypic	changes	in	endothelial	cells.	First	explanation	is	that	the	absence	of	myoferlin	
from	the	surface	of	exosomes	provoked	a	decrease	in	their	uptake	by	the	HUVEC	cells	and	so	
less	transfer	of	their	cargo,	as	we	reported	in	here.	Another	explanation	is	that,	as	we	had	
also	shown,	myoferlin	plays	a	role	 in	exosome	biogenesis	especially	 in	cargo	selection.	 It	 is	
very	 possible	 that	 exosomal	 content	 in	 the	 absence	 of	 myoferlin	 lacks	 pro-angiogenic	
factors.	Further	investigations	will	be	needed	to	confirm	this	hypothesis.		
Exosomes	 are	 of	 extreme	 importance	 in	 cancer	 communication.	 Communication	with	 the	
tumor	microenvironment	is	vital	for	tumor	progression	and	metastasis.	Cancer	cells	secrete	
exosomes	to	reprogram	their	niche	and	establish	favorable	conditions	for	tumor	growth	and	
invasion	 of	 healthy	 tissues.	 Cancer-derived	 exosomes	 are	 reported	 to	 be	 implicated	 in	
metastasis	dissemination	of	primary	tumors	[129,],	immune-escape	of	the	cancer	cells	[83],	
and	 also	 angiogenesis	 to	 guaranty	 tumor	 oxygenation,	 nutrients	 arrival	 and	 the	 transition	
from	hyperplasia	to	neoplasia	[174,175].	
Generally	speaking,	PDAC	is	considered	as	a	hypovascularized	tumor,	however	high	VEGF-A	
correlates	with	decreased	median	survival	time	[112]	and	with	decreased	survival	even	after	
surgical	 removal	 of	 the	 tumor	 [113].	 VEGF-A	 also	 correlates	with	 liver	metastasis	 [107]	 in	
PDAC	patients.	As	well	for	breast	cancer,	VEGF-A	is	associated	with	MVD	[176],	poor	survival	
and	relapse	[177].	This	implies	that	targeting	angiogenesis	is	an	important	tool	for	the	fight	
against	cancer.	However,	treatment	failure	of	anti-angiogenic	therapies	is	a	fact;	and	this	is	
so	 far	 explained	 by	 the	 multiplicity	 of	 the	 pro-angiogenic	 factors	 and	 the	 redundancy	 of	
angiogenic	signaling	pathways	within	the	tumor	[45].	Interestingly,	we	reported	myoferlin,	in	
here,	 as	 a	 novel	 player	 in	 vesicle-mediated	 communication.	 We	 have	 demonstrated	 the	
implication	of	myoferlin	in	exosome-mediated	communication	in	different	cancer	cell	types.	
We	 have	 also	 showed	 that	 myoferlin	 plays	 an	 important	 role	 in	 VEGF-A	 exocytosis	 in	
pancreatic	cancer.	This	means	that	myoferlin	could	be	a	very	 interesting	target	 in	the	anti-
angiogenic	 therapy	 especially	 if	 proven	 that	 myoferlin	 is	 a	 general	 player	 in	 cellular	
communication,	i.e.,	not	solely	playing	a	role	in	specific	soluble	factors	secretion	but	also	in	
different	exocytosis	events,	and	in	different	types	of	tumors.	
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Generally,	 myoferlin-depleted	 breast	 cancer	 in	 mice	 models	 have	 been	 described	 to	 be	
smaller	and	less	invasive	[98];	while	for	pancreas	cancer,	myoferlin-depleted	tumors	in	mice	
model	are	also	smaller	[30].	This	is	thought	to	be	due	to	an	impairment	in	membrane	repair	
[24,85],	 internalization	 of	 growth	 factor	 receptors	 [5,21,178]	 and	motility	 [32,33,98].	 Our	
current	 work	 brings	 a	 new	 aspect	 of	 the	 story,	 is	 the	 ability	 of	 myoferlin	 to	 mediate	
extracellular	communication	with	the	tumor	microenvironment	via	exosomes	and	exocytosis	
vesicles.	
A	 more	 thorough	 research	 is	 moreover	 required	 to	 investigate	 myoferlin	 implication	 in	
selective	 pro-cancerous	 cargo	 selection	 and	 target	 cell	 selection.	 Myoferlin	 has	 many	
domains	 with	 yet	 unknown	 functions.	 An	 investigation	 targeting	 myoferlin	 implication	 in	
mRNA	 and	 miRNA	 cargo	 selection	 could	 provide	 new	 insight	 for	 further	 myoferlin	
implication	in	cancer	communication.	As	previously	mentioned,	tetraspanins	for	instance	are	
reported	to	mediate	target	cell	selection.	So	due	to	function	resemblance	with	myoferlin	in	
terms	of	cargo	selection	and	fusion,	it	would	also	be	interesting	to	check	if	myoferlin	could	
play	a	role	in	that	process	too.		
	 	 	
	 	 	
	 	 ----------------------------------------	
	
As	 a	 conclusion	 of	 this	 study,	 we	 confirm	 myoferlin	 to	 be	 an	 important	 factor	 in	 PDAC	
progression.	 Myoferlin	 plays	 a	 role	 in	 tumor	 cell	 growth	 as	 well	 as	 VEGF-A	 mediated	
angiogenesis.	Mechanistically,	myoferlin	plays	a	role	in	VEGF-A	secretion	without	altering	its	
transcription.	Myoferlin	seems	to	mediate	VEGF-A	secretory	granules	docking	and	fusion	with	
the	plasma	membrane	in	order	to	secrete	their	cargo	and	to	make	the	call	for	angiogenesis.	
In	 vivo	 chicken	 chorioallantoic	membrane	model,	 myoferlin	 depletion	 reduced	 both	 tumor	
volumes	and	tumor	vascularization.	On	the	patients	level,	myoferlin	staining	in	PDAC	sections	
correlates	with	both	high	MVD	and	poor	survival.		
We	also	report	 in	here	for	the	first	time,	that	myoferlin	 is	expressed	in	different	breast	and	
pancreatic	cancer	cell-derived	exosomes.	We	prove	that	myoferlin	is	expressed	on	the	outer	
surface	of	exosomes	and	 is	 involved	 in	 the	 fusion	and	uptake	of	exosomes	by	HUVEC	cells.	
Myoferlin	 depletion	 of	 exosomes	 reduces	 uptake	 of	 exosomes	 by	 the	 target	 cells	 and	 so	
decreases	the	cargo	transfer	into	them.	Myoferlin	also	plays	a	role	in	exosome	biogenesis	as	
myoferlin-depleted	 exosomes	 are	 smaller	 and	 harbor	 altered	 protein	 content	 compared	 to	
normal	 counterparts.	 Overall,	 myoferlin	 plays	 a	 role	 in	 exosome	 functions,	 as	 myoferlin-
depleted	exosomes	are	able	to	mediate	less	phenotypic	changes	in	HUVEC	cells.			
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1.  INTRODUCTION  
	
Cell	 communication	broadly	 includes	all	 types	of	 inter-cellular	 communications.	 Since	 cells	
do	not	 live	 isolated,	 Cell	 survival	 is	 dependent	on	 sending	 and	 receiving	 information	 from	
their	environment	and	neighbors.	McCrea	described	cell	communication	as	“The	music	that	
the	 nucleus	 hears”	 as	 cell’s	 response	 to	 the	 surrounding	 environment	 affects	 gene	
transcription	programs	[2].	 It	means	that	cell	communication	intervenes	in	morphogenesis,	
cell	differentiation,	homeostasis,	cell	growth	and	cell	interactions	[1].		
In	 this	 review,	 we	 focus	 on	 the	 vesicle-mediated	 cellular	 communication,	 especially	
exocytosis	 vesicles	 and	 receptor-mediated	 endocytosis/endocytic	 recycling,	 and	 on	 the	
importance	of	Myoferlin	in	the	vesicle-mediated	communication.	
	
1.2. Vesicle mediated cel lular communication 
	
It	is	noteworthy	to	mention	at	first	that	endocytosis	and	exocytosis	are	related	fundamental	
biological	 processes.	 The	 endo-exocytosis	 relation	 could	 be	 described	 as	 an	 endless	 circle	
where	 endocytosis	 is	maintained	by	 endocytic-vesicle	 recycling	 and	 exocytosis,	 to	 prevent	
plasmic	membrane	exhaustion.	
Exocytosis	is	the	trafficking	of	secretory	vesicles	to	the	plasma	membrane.	It	is	the	basis	of	
cellular	 communication	 in	multicellular	 organisms	 through	 the	 release	 of	 a	wide	 range	 of	
extracellular	 acting	 molecules	 like	 growth	 factors,	 plasma	 proteins,	 antibodies	 and	
extracellular	 matrix	 components	 to	 exert	 various	 functions.	 Exocytosis	 vesicles	 formation	
starts	at	the	trans-Golgi	network	(TGN)	where	the	cargo	of	soluble	proteins	assembles	at	the	
inner	surface	of	the	TGN.	It	is	sought	that	this	aggregation	of	proteins	is	the	main	driver	of	
the	deformation	of	the	TGN	membrane	and	budding	of	vesicles.	Nascent	granules	bud	at	the	
surface	but	they	require	a	pinching	to	be	release	as	immature	secretory	granules	(ISG)	into	
the	cytoplasm.	At	that	point,	cholesterol	seems	to	play	an	important	role	 in	mediating	this	
fission	 process	 probably	 by	 directly	 facilitating	 negative	membrane	 curvature	 at	 the	 bud-
neck	or	 indirectly	 by	 recruiting	 raft	 associated	proteins	 that	 carry	 out	 the	 fission	 [179].	 In	
ISG,	 the	 lipid	bilayer	of	 the	 secretory	vesicle	 contains	phospholipids	and	proteins	 required	
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for	transport,	targeting	and	fusion.	While	the	dense	core	of	the	secretory	vesicles	contains	
the	soluble	protein	cargo	to	be	secreted	 [39,40].	However,	 there	are	still	unknowns	 in	 the	
exact	 composition	of	 the	 vesicle	membrane	 components	 that	might	be	 involved	 in	 vesicle	
transport,	targeting	and	fusion.	
Endocytosis-endosomal	recycling	is	a	more	complex	process	than	exocytosis.	Endocytosis	is	
the	 internalization	 of	 extracellular	 materials,	 membrane	 proteins	 and	 lipids	 while	 the	
endosomal	recycling	returns	much	of	these	components	back	to	the	plasma	membrane.	The	
balance	between	endocytosis,	exocytosis	and	endosomal	recycling	controls	the	composition	
of	the	plasma	membrane.	
Endocytosis	has	two	modes	of	action,	Clathrin	Dependent	Endocytosis	 (CDE)	that	 is	a	well-
studied	mode	and	Non-Clathrin	Dependent	Endocytosis	(NCE).	The	latter	mode	is	subdivided	
into	Dynamine-dependent	and	Dynamine-independent	NCE	but	yet,	it	remains	not	so	much	
studied	 as	 CDE.	 Primary	 endocytic	 vesicles	 are	 membrane	 bound	 intracellular	 vesicles	
formed	 by	 invagination	 of	 the	 plasma	membrane	 around	 an	 extracellular	 substrate,	 they	
could	 either	 be	 coated	 or	 stripped	 vesicles	 so	 they	 are	 by	 definition	 composed	 of	 plasma	
membrane	and	may	be	a	coat	[180].	The	cargo	of	the	endocytosis	arrives	in	primary	vesicles	
to	 the	 early	 endosomes	where	 cargos	 are	 being	 sorted	 to	 go	 back	 to	 the	 surface,	 to	 the	
endosomal	recycling	compartment,	to	 late	endosomes	for	degradation	or	to	Multivesicular	
Bodies	(MVB)	for	exosomes	biogenesis.	
	
1.3. Phospholipid binding proteins mediating fusion and f ission 
processes of vesicles 
	
As	previously	mentioned	for	exocytosis	vesicles,	the	exact	composition	of	lipids	and	proteins	
of	the	unilamellar	lipid	bilayer	membrane	of	vesicles	are	not	yet	totally	revealed.	However,	
studies	have	 identified	some	negatively	charged	phospholipids	 like	phosphatidylserine	 (PS)	
and	 phosphatidylinositol	 (PI),	 and	 some	 positively	 charged	 phospholipids	 like	
phosphatidylcholine	 (PC),	 phosphatidylethanolamine	 (PE),	 sphingomyelin	 (SM).	 An	
interesting	 observation	was	made	 for	 “Insulin	 Secretory	 Granules”	 of	 the	 pancreatic	 beta	
cells;	 they	 increase	 their	 membrane	 composition	 of	 negatively	 charged	 phospholipids	 in	
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response	 to	 glucose	 stimulation,	 increasing	 exocytosis	 of	 insulin.	 Moreover,	 they	 also	
increase	 their	 composition	of	unsaturated	 short	 fatty	acids	which	brings	more	 fluidity	and	
favors	membrane	 curvature	of	 vesicles	 that	would	enhance	docking	and	 fusion	of	 vesicles	
with	the	plasma	membrane	[40].	
There	 are	 evidences	 suggesting	 that	 negatively	 charged	 phospholipids	 on	 the	 outer	
(cytoplasmic)	leaflet	of	the	vesicles	membrane	and	inner	(cytoplasmic)	leaflet	of	the	plasma	
membrane	 act	 as	 coupling	 factors	 enhancing	 interaction	 between	 negatively	 charged	
phospholipids	 and	 positively	 charged	 motifs	 of	 SNAP	 (synaptosomal-associated	 protein)	
receptors	(SNARE)	which	are	a	large	protein	superfamily	with	a	primary	role	in	vesicle	fusion.	
It	 is	 believed	 that	 the	 anionic	 characteristic	 of	 the	 serine	 head	 group	 of	 PS	 promotes	
interaction	 between	 PS	 and	 positively	 charged	 SNARE	 proteins.	 SNARE	 proteins	 like	 the	
vesicular	 Synaptobrevin	 (VAMP2),	 the	membranous	 Syntaxin1a	 (Syxt1a)	 and	membranous	
synaptosome-associated	protein	of	25	kDa	(SNAP25),	mediate	fusion	events	with	the	plasma	
membrane.	 All	 these	 proteins	 share	 a	 highly	 conserved	 juxtamembrane	 poly-basic	 amino	
acid	sequence	called	SNARE	motif	that	binds	negatively	charged	phospholipids	such	as	PS	as	
mentioned	 [40].	 It	 was	 proven	 that	 a	 mutation	 of	 the	 Calcium-Calmodulin/phospholipids	
binding	motif	 of	 VAMP2,	 decreasing	 its	 net	 positive	 charge,	 decreases	 its	 interaction	with	
negatively	 charged	 phospholipids	 and	 interferes	with	 the	 normal	 catecholamine	 secretion	
from	 chromaffin	 cells	 [41].	 As	 well	 Synaptotagmin	 I	 (SYT1),	 a	 dual	 C2	 domains	 bearing	
protein	 implicated	 in	membrane	 fusion	events	and	exocytosis,	binds	 to	negatively	charged	
phospholipids	 in	a	Ca2+-dependent	manner,	 thanks	 to	 its	C2	domains.	 Increasing	PS	 levels	
leads	to	an	increase	in	Ca2+	triggered	vesicles	fusion	by	stabilizing	fusion	pores	in	PC12	cells	
and	increase	Ca2+	dependent	SYT1	binding	in	liposomes	[42].	
While	 for	 endocytosis,	 phospholipid	binding	C2	domains	bearing	proteins	 also	 seem	 to	be	
implicated,	it	has	been	proven	that	SYT1	binds	with	high	affinity	to	the	AP-2	adaptor	protein	
of	 clathrin-coated	vesicles	 via	a	dual	 interaction	with	 the	 second	C2	domain	of	 SYT1,	C2B.	
Mutants	SYT1	or	SYT7	lacking	the	C2B	domain	reduce	receptor	mediated	endocytosis	[181].	
Moreover	 SNARE	 protein,	 previously	 mentioned	 above;	 also	 seem	 to	 be	 implicated	 in	
endocytosis.	Tetanus	toxin	and	Botulinum	neurotoxin	E	treatment	results	in	the	cleavage	of	
VAMP	and	SNAP25	–	Syxt1	respectively,	and	that	these	cleavages	resulted	in	a	decrease	of	
both	 rapid	 and	 slow	 endocytosis	 at	 the	 calyx	 of	 Held,	 a	 particularly	 large	 synapse	 in	 the	
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mammalian	auditory	central	nervous	system.	These	results	were	a	surprising	insight	for	the	
dual	role	of	SNARE	proteins	in	both	exocytosis	and	endocytosis	[182].	
All	 these	 information	 emphasize	 on	 the	 importance	 of	 an	 interaction	 between	 negatively	
charged	phospholipids	of	 the	vesicles	membranes	with	positively	 charged	motifs/domains,	
like	SNARE	motif	and	C2	domains,	to	mediate	fusion	and	may	be	fission	events.	What	brings	
the	 attention	 to	 ferlin	 protein	 family	 which	 play	 important	 roles	 in	 fusion	 events	 as	 they	
harbors	multiple	tandem	phospholipid	binding	C2	domains;	and	especially	to	their	recently	
identified	new	member,	myoferlin.	
	
2.  THE FERLIN FAMILLY 
	
There	 are	 six	 mammalian	 ferlin	 proteins	 (Fer1L1-6).	 Mutation	 in	 Fer1L1	 (Dysferlin)	 and	
Fer1L2	(Otoferlin)	are	known	to	be	responsible	for	inherited	autosomal	recessive	diseases	in	
human	[5,13,14].	
	
2.1. Myoferl in’s structure reveals multiple domains 
	
Fer1L3,	 also	 known	 as	myoferlin,	 a	member	 of	mammalian	 ferlin	 protein	 family	 was	 first	
identified	and	characterized	in	2000	to	harbor	multiple	C2	domains,	a	unique	characteristic	
of	 the	 ferlin	 family	 [18,19].	 Myoferlin	 shares	 some	 common	 characteristics	 with	 all	 the	
members	of	the	mammalian	ferlin	family;	it	is	a	type	II	transmembrane	proteins	with	a	single	
pass	transmembrane	region	located	at	the	carboxy	terminus.	The	rest	of	the	protein	resides	
in	the	cytosol	bearing	multiple	tandem	C2	domains.	Myoferlin	harbors	several	other	specific	
domains	as	SH3,	Ferlin	(Fer)	and	Dysferlin	(DysF)	domains.	
An	unique	characteristic	of	 ferlin	 family	 is	 to	possess	multiple	C2	domains,	while	there	are	
about	one	hundred	proteins	harboring	only	a	couple	of	C2	domains.	These	proteins	are	all	
membrane-associated	 proteins	 implicated	 in	 protein-protein,	 protein-Ca2+	 or	 protein-lipid	
interactions	[5].	Myoferlin	harbors	six	C2	domains:	C2A	at	amino	acids	1-85,	C2B	at	200-281,	
C2C	at	359-458,	C2D	at	1126-1231,	C2E	at	1538-1638	and	C2F	at	1790-1903;	SH3	domain	at	
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676-689	 between	 the	 C2C	 and	 C2D	 domains;	 a	 transmembrane	 region	 at	 2027-2042	 and	
finally	an	extracellular	domain	at	2043-2061	[6,18]	(Fig.	1A).	
C2	 domain	 is	 a	 Ca2+-dependent	 phospholipid-binding	 domain	 found	 in	 a	 variety	 of	
membrane-associated	proteins.	C2	domain	is	an	independently	folding	domain	composed	of	
eight	beta-strands	 forming	a	 sandwich-like	 structure	and	coordinating	2	or	3	Ca2+	 ions	by	
conserved	aspartic	acid	residues	(Fig.	1B).	In	vitro,	the	C2A	domain,	the	first	C2	domain	from	
the	 animo-terminal	 extremity	 of	 myoferlin,	 bounds	 to	 negatively	 charged	 phospholipids	
mixture	 similar	 to	 the	 phospholipid	 composition	 of	 the	 inner	 leaflet	 of	 the	 plasma	
membrane.	It	has	been	shown	that	the	C2A	domain	is	able	to	bind	a	mixture	of	50%	PS	and	
50%	PC	in	the	presence	of	1mM	of	Ca2+.	However,	it	failed	to	bind	a	mixture	of	25%	PS	in	PC	
meaning	that	this	domain	requires	a	certain	amount	of	negatively	charged	phospholipids	to	
bind.	 The	 requirement	 of	 negatively	 charged	 phospholipids	 may	 be	 influenced	 by	 the	
number	 of	 positively	 charged	 residues	 in	 the	 Ca2+	 binding	 loop	 of	 the	 C2A	 domain.	 This	
could	hypothesize	that	myoferlin	interacts	with	specific	regions	of	the	plasma	membrane	or	
vesicles	that	are	enriched	with	high	concentration	of	negatively	charged	phospholipids	[85].	
																										 	
Figure	1.	Schematic	 representation	of	myoferlin.	 	A.	Schematic	 representation	of	myoferlin	 structure	according	 to	Davis	
and	colleagues[14]	and	GenPept	at	NCBI	(Accession	number:	AAF27176).	Myoferlin	possesses	6	C2	domains	(C2A-F),	SH3,	
FerI,	FerA,	FerB	and	2	DysFN	domains	within	the	cytoplasmic	region.	B.	Solution	structure	of	the	first	C2	domains	(C2A)	of	
human	myoferlin	(2DMH,	10.2210/pdb2dmh/pdb).	
	
However,	it	has	been	shown	that	myoferlin	C2A	domain	cannot	bind	phospholipids	in	basal	
physiological	 Ca2+	 concentration,	which	 is	 about	 0,1µM.	 Indeed,	 it	 requires	 1µM	 of	 Ca2+	
concentration	 [4].	 Suggesting	 that	 it	 is	 implicated	 in	 specific	 processes	 inside	 the	 cell	
requiring	Ca2+	release	from	intracellular	stock	like	in	Ca2+-regulated	exocytosis.	When	cells	
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are	 stimulated	by	 various	mean,	 including	 depolarization	 and	 ligand	binding,	 the	 cytosolic	
Ca2+	concentration	increases	to	levels	of	1	µM	or	more	[183].	
More	 interestingly,	 a	 point	 mutation	 in	 myoferlin	 (I67D)	 provokes	 an	 abolishment	 of	 the	
Ca2+-	 dependent	 phospholipids	 binding.	 The	 same	 study	 has	 also	 showed	 that	 unlike	 the	
C2A	domain,	the	remaining	C2	domains	(C2B	to	C2F)	were	unable	to	bind	the	mixture	of	50%	
PS	and	50%	PC.	But	this	doesn’t	mean	that	they	do	not	bind	to	other	mixtures.	In	fact,	their	
role	 is	 still	 poorly	 known	 but	 like	 all	 the	 other	 C2	 bearing	 proteins,	 they	 are	 probably	
implicated	 in	 protein-protein	 interactions	 [4].	 Further	 on,	 a	 pilot	 study	 has	 shown	 that	
recombinant	 fragments	of	 the	 first	 three	C2	domains	 (C2A,	C2B	and	C2B)	of	myoferlin	are	
able	to	bind	small	unilamellar	vesicles	composed	of	25%	PS	in	PC	[11].	
Myoferlin	bears	also	Fer	and	DysF	domains	which	functions	are	yet	unknown,	but	it	has	been	
observed	 in	 myoferlin	 and	 other	 members	 of	 mammalian	 ferlin	 family,	 that	 Fer	 domain	
appears	concomitantly	with	DysF	domain,	implying	probably	a	functional	relation.	Myoferlin	
also	bears	a	SH3	domain	that	is	known	to	interact	with	proline	rich	domains	of	proteins	[6].	
	
2.2. Structure activity relationship of myoferl in  
	
Unlike	most	of	the	C2	domain	bearing	proteins,	myoferlin	possesses	six	C2	domains.	Where	
not	only	the	number	of	the	C2	domains	but	also	special	characteristics	make	the	difference	
between	myoferlin	and	 the	other	C2	domain	bearing	proteins,	 implying	probably	a	 special	
function	of	this	protein	that	is	dictated	by	its	unique	structure.	
Like	most	of	the	membrane-associated	proteins,	myoferlin	has	a	typical	plasma	membrane-
targeting	 C2	 domain	 as	 its	 C2	 domains	 target	 negatively	 charged	 lipids;	 unlike	 the	 C2	
domains	 of	 “Golgi	 localized	proteins”	which	bind	 to	 zwitterionic	 lipids.	 Also	 and	unlike	C2	
domains	of	Synaptotagmin	 I,	myoferlin’s	C2	domains	have	been	proven	 to	bind	negatively	
charged	phospholipid	vesicles	 in	a	 salt	 insensitive	manner,	 suggesting	an	hydrophobic	and	
non-electrostatic	interaction	contributing	to	the	interaction	of	C2	domains	and	lipid	bilayer	
[11].	 These	 information	 provide	 insights	 that	 myoferlin	 could	 be	 a	 key	 player	 in	 vesicles	
trafficking	thanks	to	its	ability	to	stably	bind	negatively	charged	phospholipids	at	the	vesicles	
or	plasma	membrane	sites.	
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Further	on,	it	has	been	shown	that	myoferlin	C2	domains	do	not	solely	passively	stick	to	the	
membranes	thanks	to	electrostatic	attraction	but	they	sculpt	 lipid	bilayers	which	results	 in	
high	curvature	or	disorder	of	membrane	regions	that	could	facilitate	membrane	fusion	and	
fission	or	recruitment	of	other	membrane	trafficking	proteins	by	an	increase	in	fluidity	and	
alteration	of	the	lipid	order	of	the	lipid	bilayer.	Of	interest,	a	study	has	shown	that	the	more	
the	C2	domains	number	increases	the	more	they	perturb	the	structural	state	of	lipid	bilayer	
in	 an	 additive	 manner.	 It	 means	 that	 myoferlin	 possession	 of	 six	 C2	 domains	 probably	
implies	 a	more	 special	 role	 than	most	of	 the	proteins	bearing	maximum	 two	C2	domains.	
Moreover,	 this	 structural	 disruption	 property	 of	 lipid	 vesicles	 was	 shown	 to	 be	 Ca2+-
enhanced	specially	for	domains	bearing	calcium	binding	motifs	[11].	Overall,	this	means	that,	
the	 “Insulin	 Secretory	Granules”	 fluidity	 brought	 by	 increasing	 their	 composition	 of	 short,	
unsaturated	 and	 negatively	 charged	 phospholipids	 could	 also	 be	 brought	 instead	 by	
recruiting	myoferlin	at	the	vesicles	surface.	
The	 C2	 domain	 structure	 folds	 independently	 and	 reveals	 eight	 antiparallel	 beta-strands	
connected	by	highly	variable	surface	loop	forming	a	beta-sandwich	with	a	highly	conserved	
Ca2+-binding	 loop	at	one	end	of	 the	sandwich.	The	C2	domains	are	classically	observed	to	
function	as	Ca2+-dependent	lipid	binding	modules.	However,	some	C2	domains,	like	the	C2B	
domain	 of	 myoferlin,	 lost	 their	 Ca2+-sensing	 ability	 and	 instead	 specialized	 in	 protein-
protein	interaction	[8].	
While	most	of	the	research	focus	on	the	first	C2	domain,	C2A,	phylogenetic	analysis	reveals	
that	 it	 is	 the	 least	conserved	domain	among	mammalian	 ferlin	 family.	Homology	modeling	
among	mammalian	ferlin	proteins	suggests	a	higher	conservation	of	the	two	most	carboxy	
terminus	C2	domains	(C2E	and	C2F)	relative	to	C2A	and	C2C	that	showed	great	variability	in	
predicted	structure	and	electrostatic	properties	[3].	It	has	been	also	demonstrated	that	the	
three	most	 carboxy-terminus	 C2	 domains	 (C2DEF)	 of	 otoferlin	 and	 dysferlin	 perturb	more	
the	 structural	 state	 of	 small	 unilamellar	 lipid	 bilayer	 vesicles	 than	 the	 three	most	 amino-
terminus	C2	domains	(C2ABC)	[11].	
Of	 interest	 to	 these	 two	 particular	 C2	 domains	 (C2E	 and	 C2F),	 it	 has	 been	 shown	 that	
myoferlin	 possesses	 an	 alternative	 splicing	 variant	 that	 gives	 rise	 to	 an	 isoform	 bearing	 a	
putative	 motif	 for	 calpain	 cleavage.	 This	 cleavage	 produce	 a	 fragment	 (mini-protein)	
composed	 of	 the	 last	 two	 C2	 domains	 at	 the	 carboxy	 terminus	 (C2E	 and	 C2F)	 and	 the	
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transmembrane	region,	and	being	structurally	similar	to	synaptotagmin.	Unlike	dysferlin	and	
otoferlin,	 myoferlin	 cleavage	 by	 the	 calpain	 was	 Ca2+-independent	 but	 the	 Ca2+	 would	
solely	increase	the	yield	of	the	reaction;	in	fact,	this	fragment	was	observed	constitutively	in	
ectopic	expression	model	[84].	Moreover,	sequence	analysis	of	myoferlin	revealed	that	C2D,	
C2E	and	C2F	domains	have	putative	Ca2+-binding	motives	at	positions	similar	to	the	first	C2	
domain	of	synaptotagmin-1	[19].	Allover,	these	information	and	the	constitutive	expression	
of	myoferlin	mini-protein	may	imply	its	implication	in	a	constitutive	cellular	processes,	liked	
vesicle	trafficking.	
	
2.3. Myoferl in’s implication in exocytosis  
	
Apart	 from	 the	 structure-based	 activity	 of	 ferlins,	 the	 observation	 of	 ferlin	 proteins	
implication	in	exocytosis	events	was	first	revealed	for	otoferlin.	Otoferlin	is	expressed	in	the	
auditory	Inner	Hair	Cells	(IHC)	ribbon	synapse;	precisely	at	the	surface	of	synaptic	exocytosis	
vesicles,	mediating	their	exocytosis	via	 its	binding	to	exocytosis	component	syntaxin-1	and	
SNAP25	 in	 a	 Ca2+-dependent	manner.	 Otoferlin	mutation	 in	 human	 causes	 an	 autosomal	
recessive	 form	 of	 non-syndromic	 deafness	 (DFNB9);	 as	 well,	 otoferlin	 null	 mice	 are	
profoundly	deaf	[13,14].	
A	recent	study	published	by	our	group	highlighted	a	new	function	of	myoferlin	in	exocytosis.	
We	showed	that	myoferlin	silencing	provoked	a	decrease	 in	VEGF-A	secretion	by	pancreas	
cancer	cell	line	BxPC-3.	This	decrease	in	secretion	was	not	due	to	a	transcriptional	effect	of	
myoferlin	 but	 due	 to	 an	 accumulation	 of	 VEGF-A	 at	 the	 vicinity	 of	 the	 plasma	membrane	
coincidently	 with	 the	 ultrastructure	 observation	 of	 vesicles	 accumulated	 near	 the	 plasma	
membrane.	We	hypothesized	that	myoferlin	depletion	disabled	VEGF-A	exocytic	vesicles	to	
fuse	 with	 the	 plasma	membrane	 and	 release	 their	 cargo.	 In	 order	 to	 confirm	myoferlin’s	
implication	 in	 the	 exocytosis	 machinery,	 we	 further	 demonstrated	 a	 colocalization	 of	
myoferlin	 with	 Sec5/Exoc2,	 a	 component	 of	 a	 complex	 essential	 for	 targeting	 exocytosis	
vesicles,	 mainly	 at	 the	 periphery	 of	 the	 cells	 where	 exocytosis	 vesicles	 fusion	 with	 the	
plasma	 membrane	 occurs.	 This	 myoferlin	 control	 over	 the	 fusion	 of	 exocytic	 vesicles	
containing	VEGF-A	was	 confirmed	by	 a	 decrease	 in	micro-vessels	 density	 (MVD)	 in	 animal	
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model	and	a	statistical	significance	was	observed	between	myoferlin	expression	and	MVD	in	
pancreas	cancer	patient	sections	[9].	
Noteworthy	to	mention	that	a	mathematical	model	was	established	to	examine	the	role	of	
myoferlin	 in	 cancer	 cell	 invasion;	 as	 a	 tool	 to	 generate	 hypotheses	 which	 then	 can	 be	
experimentally	tested.	This	model	proposed	a	diversified	role	of	myoferlin	 in	breast	cancer	
invasion	including	a	mathematical	hypothesis	that	myoferlin	impacts	matrix	metalloprotease	
production	and/or	secretion;	hypothesizing	a	probable	role	of	myoferlin	in	exocytosis	[31].	
As	 previously	 mentioned	 above,	 myoferlin	 was	 proven	 to	 be	 processed	 by	 the	 calpain	
enzyme	releasing	a	 fragment;	while	this	observation	was	 initially	conducted	for	dysferlin	 it	
has	been	then	extended	for	myoferlin	and	otoferlin.	Where	all	three	proteins	gave	rise	to	a	
70	kDa	 fragment	 called	mini-protein.	Mini-dysferlin	was	 further	 shown	 to	be	generated	 in	
myoblast	cells	after	injury	and	to	be	present	and	active	in	cell	membrane	repair	at	the	injury	
site	 confirming	 that	 these	 mini-proteins	 could	 be	 functionally	 active.	 Of	 interest,	 these	
fragments	released	are	structurally	similar	to	synaptotagmin.	Mini-myoferlin,	unlike	dysferlin	
and	 otoferlin,	 was	 constitutively	 generated	 in	 ectopic	 expression	 model	 in	 a	 Ca2+-
independent	but	favored	circumstances	implying	that	it	could	be	implicated	in	a	constitutive	
process	like	exocytosis.	
Based	 on	 structural	 data,	 on	 the	 constitutive	 expression	 of	 mini-myoferlin	 and	 on	 the	
regulation	 of	 VEGF-A	 secretion	 by	 myoferlin,	 we	 hypothesize	 that	 this	 protein	 could	 be	
present	either	or	both	on	 the	outer	 leaflet	of	exocytosis	vesicle	or	 the	 inner	 leaflet	of	 the	
plasma	membrane	mediating	the	fusion	process	of	secretory	vesicles	(Fig.	2).	
																	 	
Figure	2.	 Schematic	 representation	of	possible	myoferlin	 role	 in	 exocytosis	 vesicles	 fusion.	Synaptotagmin	or	mini-myoferlin	 could	be	
present	 on	 the	 external	 (cytoplasmic)	 leaflet	 of	 exocytosis	 vesicles	 and	 interact	with	 SNARE	protein	 present	 on	 the	 inner	 (cytoplasmic)	
leaflet	of	cytoplasmic	membrane	mediating	exocytosis	vesicles	fusion	and	exocytosis	of	the	content.	
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2.4. Myoferl in’s implication in endocytosis/endocytic recycl ing 
	
While	myoferlin	harbors	multiple	tandem	C2	domains,	 it	also	harbors	several	domains	and	
motifs	that	promote	other	functions.	Where	it	has	been	shown	that	myoferlin	intervenes	in	
different	surface	receptor	fate	determination	via	different	mechanisms.	
Myoferlin	 plays	 an	 important	 role	 in	 Insulin	 Growth	 Factor	 Receptor	 (IGFR)	 stability	 after	
activation	 and	 internalization.	 In	 normal	 conditions,	 once	 IGFR	 is	 internalized	 it	 should	 be	
processed	again	to	the	surface	of	 the	cell,	where	normally	80%	of	 the	receptor	 is	 recycled	
and	20%	is	degraded.	However,	 in	myoferlin	depletion	this	ratio	 is	not	respected	and	IGFR	
accumulates	 in	 aggregates	 in	 the	 cytoplasm	and	 colocalizes	with	 LAMP-2	positive	 vesicles,	
implying	 that	 it	 is	 shuttled	 in	 to	 the	 lysosomal	 degradation	 pathway	 (Fig.	 3A).	 It	was	 also	
observed	 an	 increase	 in	 LAMP-2	 positive	 vesicles	 number	 and	 size	 in	myoferlin	 null	 mice	
myoblast.	 In	 absence	 of	 myoferlin,	 this	 degradation	 also	 leads	 to	 a	 decrease	 in	 IGFR	
activation	of	downstream	signaling	pathways	like	AKT	and	MAPK.	Mechanistically,	myoferlin	
physically	interacts	with	IGFR	and	EHD-2	preventing	IGFR	degradation	but	mediating	surface	
export	 [12].	 The	 provoked	 defect	 on	 internalized	 vesicles	 recycling	 after	 a	 myoferlin	 loss	
resembles	the	phenotype	due	to	mutations	in	the	EHD	protein	family.	EHD	family	contains	4	
proteins	 (EHD1-4)	 that	 are	 linked	 to	 endosomal	 trafficking	 including	 recycling	 of	 surface	
receptor	 to	 the	 plasma	 membrane.	 It	 has	 been	 shown	 in	 myoblasts	 that	 at	 least	 EHD-2	
physically	interacts	with	the	amino	acid	sequence	“Asparagine-Proline-Phenylalanine”-(NPF)	
present	in	the	C2B	domain	of	myoferlin.	This	binding	of	both	protein	was	calcium	insensitive	
as	the	C2B	domain	of	myoferlin	lacks	a	Ca2+	sensing	motif	and	solely	implicated	in	protein-
protein	 interactions,	 as	 mentioned	 before	 [21].	 It	 was	 also	 observed	 a	 decrease	 in	
transferring	receptor	recycling	after	myoferlin	silencing	in	myoblast	cells.	
Another	 role	 of	 myoferlin	 is	 the	 control	 of	 the	 signaling	 and	 the	 stability	 of	 Vascular	
Endothelial	Growth	Factor	Receptor-2	(VEGFR2)	after	VEGF	stimulation.	Myoferlin	depletion	
in	 endothelial	 cells	 leads	 to	 the	 polyubiquitination	 of	 VEGFR2	 and	 its	 subsequent	
degradation	 by	 the	 proteasome,	 leading	 to	 less	 surface	 receptor	 recycling	 (Fig.	 3A).	 This	
leads	to	the	decrease	of	VEGFR	phosphorylation	itself	and	downstream	phosphorylation	of	
ERK1/2,	JNK	and	PLC-γ	and	subsequently	endothelial	cells	migration	and	proliferation.	While	
myoferlin	has	a	SH3	domain	that	is	known	to	interact	with	proline	rich	proteins,	it	has	been	
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shown	 that	 it	 directly	 interacts	with	 the	proline	 rich	 protein:	 dynamine-2	 via	 this	 domain,	
and	 complexes	 VEGFR-2	 preventing	 casitas	 B-lineage	 lymphoma	 (CBL)	 dependent	
polyubiquitination	and	degradation	[6].	
In	 breast	 cancer	 cells,	myoferlin	 depletion	provoked	 a	 sustained	 Epidermal	Growth	 Factor	
Receptor	 (EGFR)	 phosphorylation,	 after	 stimulation	 with	 EGF,	 with	 downstream	
phosphorylation	 of	 Akt.	 Mechanistically,	 caveolin	 was	 shown	 to	 colocalize	 with	
phosphorylated-EGFR	 and	 myoferlin,	 and	 that	 the	 interaction	 between	 myoferlin	 and	
caveolin	 was	 essential	 for	 the	 proper	 assembly	 of	 caveolae.	 In	 the	 absence	 of	myoferlin,	
caveolin	 showed	 less	 colocalization	 with	 phosphorylated-EGFR	 and	 aberrant	 homo-
oligomerization	and	no	alteration	of	 the	EGFR	 internalization	kinetics	after	EGF	 treatment.	
This	hypothesizes	that	myoferlin	depletion	does	not	alter	non-clathrin-mediated	endocytosis	
but	hinders	the	degradation	of	the	activated	receptor	in	that	model	[34].	
														 	
Figure	3.	Schematic	representation	of	possible	myoferlin	implication	in	endocytic	recycling.	Myoferlin	interferes	via	different	mechanism	
in	 surface	 receptor	 internalization	 and	 could	 be	 present	 on	 early	 endosomes	 until	 its	 trafficking	 to	 the	 recycling	 compartment.	 In	 the	
presence	of	myoferlin,	 surface	 receptor	are	protected	 from	degradation	and	recycled	 to	 the	surface.	However,	 in	absence	of	myoferlin,	
surface	receptors	can	undergo	degradation	via	different	pathways.	
	
However,	 another	 study	 highlighted	 a	 new	 role	 of	 myoferlin	 in	 receptor-mediated	
endocytosis	for	both	clathrin-mediated	endocytosis	and	non-clathrin	mediated	endocytosis.	
It	has	been	shown	that	myoferlin	depletion	in	endothelial	cells	provoked	a	50	%	decrease	in	
the	 internalization	 of	 both	 transferrin	 and	 cholera	 toxin-b	 chain.	 The	 first	 one	 is	 a	 CD71	
ligand	 requiring	 clathrin	 pits	 for	 endocytosis.	 The	 second	 is	 a	 GM-1	 ligand	 requiring	
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caveolin/lipid	 raft	 for	 endocytosis.	 The	 myoferlin	 ectopic	 expression	 increased	 both	 the	
uptake	 of	 transferrin	 and	 cholera	 toxin.	 Mechanistically,	 it	 has	 been	 proven	 that	 both	
myoferlin	 and	 caveolin-1	 act	 on	 receptor	 endocytosis	 in	 a	 similar	 rather	 than	 a	 parallel	
manner	to	mediate	caveolin-mediated	endocytosis	and	that	they	physically	interact	together	
in	a	cell	free	system.	Furthermore,	that	myoferlin	colocalizes	with	Dynamine-2	in	endothelial	
cells.	 These	 data	 show	 that	 myoferlin	 regulates	 caveolin-mediated	 endocytosis	 and	 also	
clathrin	mediated	endocytosis	[24].	
Again	 in	 endothelial	 cells,	myoferlin	 depletion	 provokes	 a	 decrease	 of	 Tie-2	 receptor	 in	 a	
non-angiopoietin	challenged	system	without	neither	altering	 its	 transcription	 level	nor	 in	a	
CBL-dependent	 polyubiquitination	 and	 degradation	 [23].	 This	 implies	 yet	 unknown	
mechanisms	 of	 myoferlin	 implication	 in	 endocytic	 recycling	 other	 than	 the	 previously	
mentioned	 ones.	 Noteworthy,	 is	 was	 observed	 that	 myoferlin	 depletion	 leads	 to	 a	 down	
regulation	 of	 the	 phosphorylation	 of	 several	 Tyrosine	 Kinase	 receptors	 including	 EphB4,	
FGFR-2,	HcK,	Jak-2,	and	TXK	but	yet	the	mechanism	has	not	been	investigated	[31,32].	
2.5. What is  the importance of myoferl in in translational oncology? 
	
Myoferlin	has	been	reported	to	be	overexpressed	at	protein	 level	 in	different	cancer	types	
including	 pancreas	 [28–30],	 breast	 [34],	 lung	 	 [35]and	 oropharyngeal	 squamous	 cell	
carcinoma	 [37].	 In	 these	 cases,	myoferlin	expression	 is	 correlated	with	a	bad	outcome	 for	
the	patients.	
Self-sufficiency	 in	 growth	 factor	 signaling	 is	 a	 hallmark	 of	 cancer	 cells.	 Cancer	 cells	
overproduce	 growth	 factor	 to	 stimulate	 unregulated	 proliferation	 of	 themselves	 in	 an	
autocrine,	juxtacrine	or	paracrine	fashions.	In	this	context,	myoferlin	can	be	considered	as	a	
growth	support	for	the	cancer	cells	as	it	helps	the	exocytosis	of	growth	factors.	
Myoferlin	 was	 described	 in	 breast	 cancer	 [34]	 and	 in	 endothelial	 cell	 [6]	 as	 involved	 in	
receptor	 tyrosine	 kinase	 (EGFR,	 VEGFR)	 recycling	 or	 expression,	 allowing	 as	 such	 the	 cell	
response	 to	 growth	 factors.	 Knowing	 that	 some	 cancer	 cells	 exhibit	mutations	 in	 tyrosine	
kinase	receptors,	which	lead	to	a	constitutive	receptor	activation	triggering	the	downstream	
pathways,	we	can	speculate	that	myoferlin	depletion	could	impede	cell	proliferation	in	these	
cases.	
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Exosomes	 are	 small	 extracellular	 vesicles	 released	 on	 exocytosis	 of	 multivesicular	 bodies	
filled	 with	 intraluminal	 vesicles.	 They	 represent	 an	 important	 role	 in	 intercellular	
communication,	 serving	 as	 carrier	 for	 transfer	 of	 miRNA,	 proteins,	 …	 between	 cells.	 The	
exosomes	 are	 more	 and	 more	 described	 as	 cancer	 biomarker	 [184]	 and	 involved	 in	 the	
preparation	of	the	tumor	microenvironment	[185].	The	exosome	biogenesis,	particularly	the	
docking	of	the	multivesicular	bodies	to	the	plasmic	membrane,	required	SNARE	complexes	
[186].	 Interestingly,	myoferlin	was	demonstrated	 to	be	present	 in	exosomes	 isolated	 from	
several	 cancer	 cell	 types,	 including	 bladder,	 colon	 and	 ovary	 [89,94–96,187,188].	 In	 this	
context,	we	 suggest	 that	myoferlin	 can	 be	 used	 as	 therapeutic	 target	 in	 order	 to	 prevent	
exosome	release	from	cancer	cells.	
Myoferlin,	 being	 overexpressed	 in	 several	 cancer	 types	 and	 a	 potential	 modulator	 of	
exocytosis	 and	 surface	 receptor	 fate	 determination,	 offers	 a	 very	 promising	 therapeutic	
advantage	in	cancer	management.	Myoferlin’s	promising	properties	make	one	think	that	its	
targeting	 may	 confer	 to	 the	 therapy	 a	 multi-functional	 aspect,	 starting	 from	 tumor-
detection,	 to	 tumor-targeting,	 to	 the	 growth	 factor	 signaling.	 Targeting	 myoferlin	 at	 the	
expression	or	functional	levels	remains	however	the	next	challenge.	
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Table	S1/	publication	2:	List	of	proteins	identified	by	MS	in	MDA-MB-231	and	BxPC-3	derived	exosomes.	Protein	
commonly	expressed	in	at	least	50%	of	the	replicated.	
Accession Protein Description Gene Name CTRL/MYO
F Ratio
P62258 14-3-3	protein	epsilon YWHAE 0.72
P61981 14-3-3	protein	gamma YWHAG CTRL
P31947 14-3-3	protein	sigma SFN 0.62
P63104 14-3-3	protein	zeta/delta YWHAZ 0.85
P09543 2,3-cyclic-nucleotide	3-phosphodiesterase CNP 1.10
P62333 26S	protease	regulatory	subunit	10B PSMC6 3.01
P62191 26S	protease	regulatory	subunit	4 PSMC1 CTRL
P17980 26S	protease	regulatory	subunit	6A PSMC3 CTRL
P43686 26S	protease	regulatory	subunit	6B PSMC4 4.51
P35998 26S	protease	regulatory	subunit	7 PSMC2 2.49
P62195 26S	protease	regulatory	subunit	8 PSMC5 CTRL
Q99460 26S	proteasome	non-ATPase	regulatory	subunit	1 PSMD1 CTRL
O00231 26S	proteasome	non-ATPase	regulatory	subunit	11 PSMD11 1.30
Q13200 26S	proteasome	non-ATPase	regulatory	subunit	2 PSMD2 1.78
P48556 26S	proteasome	non-ATPase	regulatory	subunit	8 PSMD8 3.68
P62277 40S	ribosomal	protein	S13 RPS13 CTRL
P62249 40S	ribosomal	protein	S16 RPS16 CTRL
P15880 40S	ribosomal	protein	S2 RPS2 CTRL
P61247 40S	ribosomal	protein	S3a RPS3A CTRL
P62701 40S	ribosomal	protein	S4,	X	isoform RPS4X CTRL
P62241 40S	ribosomal	protein	S8 RPS8 CTRL
P46781 40S	ribosomal	protein	S9 RPS9 3.31
P08865 40S	ribosomal	protein	SA RPSA CTRL
P21589 5-nucleotidase NT5E 1.08
P50914 60S	ribosomal	protein	L14 RPL14 CTRL
P61313 60S	ribosomal	protein	L15 RPL15 2.65
P18621 60S	ribosomal	protein	L17 RPL17 CTRL
P83731 60S	ribosomal	protein	L24 RPL24 CTRL
P36578 60S	ribosomal	protein	L4 RPL4 2.62
P46777 60S	ribosomal	protein	L5 RPL5 CTRL
Q02878 60S	ribosomal	protein	L6 RPL6 5.92
P18124 60S	ribosomal	protein	L7 RPL7 CTRL
P62424 60S	ribosomal	protein	L7a RPL7A 5.21
P11021 78	kDa	glucose-regulated	protein HSPA5 2.56
P61158 Actin-related	protein	3 ACTR3 CTRL
P07741 Adenine	phosphoribosyltransferase APRT 0.79
P23526 Adenosylhomocysteinase AHCY 0.87
P84077 ADP-ribosylation	factor	1 ARF1 1.78
P18085 ADP-ribosylation	factor	4 ARF4 1.71
P62330 ADP-ribosylation	factor	6 ARF6 1.91
Q9NVJ2 ADP-ribosylation	factor-like	protein	8B ARL8B 8.22
O00468 Agrin AGRN 2.83
P14550 Alcohol	dehydrogenase	[NADP(+)] AKR1A1 0.65
P00330 Alcohol	dehydrogenase	1 ADH1 0.98
O43707 Alpha-actinin-4 ACTN4 1.51
P06733 Alpha-enolase ENO1 1.07
P50995 Annexin	A11 ANXA11 1.29
P07355 Annexin	A2 ANXA2 0.80
P12429 Annexin	A3 ANXA3 CTRL
P08758 Annexin	A5 ANXA5 1.24
P08133 Annexin	A6 ANXA6 1.17
P20073 Annexin	A7 ANXA7 CTRL
P63010 AP-2	complex	subunit	beta AP2B1 2.64
P04114 Apolipoprotein	B-100 APOB 0.59
P00966 Argininosuccinate	synthase ASS1 0.41
Q8N5I2 Arrestin	domain-containing	protein	1 ARRDC1 CTRL
P14868 Aspartate--tRNA	ligase,	cytoplasmic DARS 1.33
P53396 ATP-citrate	synthase ACLY 1.98
Q01813 ATP-dependent	6-phosphofructokinase,	platelet	type PFKP 2.60
O00148 ATP-dependent	RNA	helicase	DDX39A DDX39A CTRL
O00571 ATP-dependent	RNA	helicase	DDX3X DDX3X CTRL
P98160 Basement	membrane-specific	heparan	sulfate	proteoglycan	core	protein HSPG2 1.50
P35613 Basigin BSG 0.72
P61769 Beta-2-microglobulin B2M 0.55
P07814 Bifunctional	glutamate/proline--tRNA	ligase EPRS 4.63
Q9UQB8 Brain-specific	angiogenesis	inhibitor	1-associated	protein	2 BAIAP2 CTRL
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Q5VW32 BRO1	domain-containing	protein	BROX BROX CTRL
P11586 C-1-tetrahydrofolate	synthase,	cytoplasmic MTHFD1 1.29
Q9Y376 Calcium-binding	protein	39 CAB39 0.68
P17655 Calpain-2	catalytic	subunit CAPN2 0.70
O15484 Calpain-5 CAPN5 CTRL
Q8NEV1 Casein	kinase	II	subunit	alpha	3 CSNK2A3 CTRL
P35222 Catenin	beta-1 CTNNB1 3.62
P07339 Cathepsin	D CTSD 0.83
Q03135 Caveolin-1 CAV1 2.17
P48509 CD151	antigen CD151 0.81
Q9Y5K6 CD2-associated	protein CD2AP CTRL
P08962 CD63	antigen CD63 CTRL
P21926 CD9	antigen CD9 1.22
P60953 Cell	division	control	protein	42	homolog CDC42 0.82
Q16739 Ceramide	glucosyltransferase UGCG CTRL
O43633 Charged	multivesicular	body	protein	2a CHMP2A CTRL
Q8IWA5 Choline	transporter-like	protein	2 SLC44A2 3.68
Q00610 Clathrin	heavy	chain	1 CLTC 2.59
P09497 Clathrin	light	chain	B CLTB CTRL
P00742 Coagulation	factor	X F10 1.02
P20908 Collagen	alpha-1(V)	chain COL5A1 1.79
P12109 Collagen	alpha-1(VI)	chain COL6A1 0.75
P39060 Collagen	alpha-1(XVIII)	chain COL18A1 1.72
Q99829 Copine-1 CPNE1 CTRL
O75131 Copine-3 CPNE3 2.15
Q86YQ8 Copine-8 CPNE8 3.29
P31146 Coronin-1A CORO1A 0.78
Q9H5V8 CUB	domain-containing	protein	1 CDCP1 1.27
P06493 Cyclin-dependent	kinase	1 CDK1 3.00
Q14204 Cytoplasmic	dynein	1	heavy	chain	1 DYNC1H1 3.08
O00154 Cytosolic	acyl	coenzyme	A	thioester	hydrolase ACOT7 CTRL
Q14126 Desmoglein-2 DSG2 3.16
P15924 Desmoplakin DSP 0.54
Q16555 Dihydropyrimidinase-related	protein	2 DPYSL2 0.91
Q9P265 Disco-interacting	protein	2	homolog	B DIP2B 2.26
O14672 Disintegrin	and	metalloproteinase	domain-containing	protein	10 ADAM10 1.27
P11387 DNA	topoisomerase	1 TOP1 CTRL
P78527 DNA-dependent	protein	kinase	catalytic	subunit PRKDC CTRL
O60884 DnaJ	homolog	subfamily	A	member	2 DNAJA2 2.82
P25685 DnaJ	homolog	subfamily	B	member	1 DNAJB1 2.19
P50570 Dynamin-2 DNM2 3.98
Q14258 E3	ubiquitin/ISG15	ligase	TRIM25 TRIM25 CTRL
P22413 Ectonucleotide	pyrophosphatase/phosphodiesterase	family	member	1 ENPP1 0.63
O43854 EGF-like	repeat	and	discoidin	I-like	domain-containing	protein	3 EDIL3 1.54
Q9NZN4 EH	domain-containing	protein	2 EHD2 2.20
P26641 Elongation	factor	1-gamma EEF1G 2.55
P13639 Elongation	factor	2 EEF2 1.10
P14625 Endoplasmin HSP90B1 CTRL
P29317 Ephrin	type-A	receptor	2 EPHA2 1.28
Q99808 Equilibrative	nucleoside	transporter	1 SLC29A1 1.20
P60842 Eukaryotic	initiation	factor	4A-I EIF4A1 1.28
P38919 Eukaryotic	initiation	factor	4A-III EIF4A3 CTRL
P63241 Eukaryotic	translation	initiation	factor	5A-1 EIF5A 2.93
P56537 Eukaryotic	translation	initiation	factor	6 EIF6 CTRL
P49327 Fatty	acid	synthase FASN 1.78
P02794 Ferritin	heavy	chain FTH1 2.63
P02792 Ferritin	light	chain FTL 1.97
P02751 Fibronectin FN1 1.41
P21333 Filamin-A FLNA 1.31
O75369 Filamin-B FLNB 8.50
O75955 Flotillin-1 FLOT1 4.22
Q14254 Flotillin-2 FLOT2 4.25
P04075 Fructose-bisphosphate	aldolase	A ALDOA 0.76
P09382 Galectin-1 LGALS1 0.74
P11413 Glucose-6-phosphate	1-dehydrogenase G6PD 5.14
P06744 Glucose-6-phosphate	isomerase GPI 1.31
Q06210 Glutamine--fructose-6-phosphate	aminotransferase	[isomerizing]	1 GFPT1 2.94
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Q7RTV2 Glutathione	S-transferase	A5 GSTA5 0.54
P04406 Glyceraldehyde-3-phosphate	dehydrogenase GAPDH 1.32
P62993 Growth	factor	receptor-bound	protein	2 GRB2 CTRL
P01111 GTPase	NRas NRAS 1.29
P62826 GTP-binding	nuclear	protein	Ran RAN 0.76
Q15382 GTP-binding	protein	Rheb RHEB 2.32
P04899 Guanine	nucleotide-binding	protein	G(i)	subunit	alpha-2 GNAI2 0.88
P62879 Guanine	nucleotide-binding	protein	G(I)/G(S)/G(T)	subunit	beta-2 GNB2 1.32
P63092 Guanine	nucleotide-binding	protein	G(s)	subunit	alpha	isoforms	short GNAS 1.38
Q14344 Guanine	nucleotide-binding	protein	subunit	alpha-13 GNA13 1.16
P63244 Guanine	nucleotide-binding	protein	subunit	beta-2-like	1 GNB2L1 CTRL
P48723 Heat	shock	70	kDa	protein	13 HSPA13 0.74
P08107 Heat	shock	70	kDa	protein	1A/1B HSPA1A 1.59
P11142 Heat	shock	cognate	71	kDa	protein HSPA8 1.50
Q92598 Heat	shock	protein	105	kDa HSPH1 2.69
P04792 Heat	shock	protein	beta-1 HSPB1 1.18
P08238 Heat	shock	protein	HSP	90-beta HSP90AB1 1.18
P26927 Hepatocyte	growth	factor-like	protein MST1 MYOF
P61978 Heterogeneous	nuclear	ribonucleoprotein	K HNRNPK CTRL
P52272 Heterogeneous	nuclear	ribonucleoprotein	M HNRNPM CTRL
P30825 High	affinity	cationic	amino	acid	transporter	1 SLC7A1 2.37
P16403 Histone	H1.2 HIST1H1C 1.33
Q16778 Histone	H2B	type	2-E HIST2H2BE 1.43
Q71DI3 Histone	H3.2 HIST2H3A 1.36
P62805 Histone	H4 HIST1H4A 1.88
P01892 HLA	class	I	histocompatibility	antigen,	A-2	alpha	chain HLA-A 1.74
Q04826 HLA	class	I	histocompatibility	antigen,	B-40	alpha	chain HLA-B 0.71
Q969P0 Immunoglobulin	superfamily	member	8 IGSF8 CTRL
P12268 Inosine-5-monophosphate	dehydrogenase	2 IMPDH2 3.36
P17301 Integrin	alpha-2 ITGA2 0.89
P08648 Integrin	alpha-5 ITGA5 0.98
P23229 Integrin	alpha-6 ITGA6 0.84
P06756 Integrin	alpha-V ITGAV 1.52
P05106 Integrin	beta-3 ITGB3 1.68
P16144 Integrin	beta-4 ITGB4 0.86
Q13418 Integrin-linked	protein	kinase ILK 1.09
O75874 Isocitrate	dehydrogenase	[NADP]	cytoplasmic IDH1 CTRL
P41252 Isoleucine--tRNA	ligase,	cytoplasmic IARS CTRL
P53990 IST1	homolog IST1 1.52
P14923 Junction	plakoglobin JUP 0.67
Q08431 Lactadherin MFGE8 2.12
Q9P2J5 Leucine--tRNA	ligase,	cytoplasmic LARS CTRL
Q86X29 Lipolysis-stimulated	lipoprotein	receptor LSR 3.77
P00338 L-lactate	dehydrogenase	A	chain LDHA 0.85
P07195 L-lactate	dehydrogenase	B	chain LDHB 0.81
O60488 Long-chain-fatty-acid--CoA	ligase	4 ACSL4 2.14
Q7Z4F1 Low-density	lipoprotein	receptor-related	protein	10 LRP10 CTRL
Q9H3U5 Major	facilitator	superfamily	domain-containing	protein	1 MFSD1 CTRL
Q14764 Major	vault	protein MVP 2.18
P20774 Mimecan OGN 0.58
O15427 Monocarboxylate	transporter	4 SLC16A3 1.14
O95297 Myelin	protein	zero-like	protein	1 MPZL1 0.27
Q96S97 Myeloid-associated	differentiation	marker MYADM CTRL
Q9NZM1 Myoferlin MYOF CTRL
Q9Y2A7 Nck-associated	protein	1 NCKAP1 CTRL
Q09666 Neuroblast	differentiation-associated	protein	AHNAK AHNAK 1.20
O14786 Neuropilin-1 NRP1 1.37
Q15758 Neutral	amino	acid	transporter	B(0) SLC1A5 1.84
Q96TA1 Niban-like	protein	1 FAM129B MYOF
P43490 Nicotinamide	phosphoribosyltransferase NAMPT 2.53
O15118 Niemann-Pick	C1	protein NPC1 3.85
P22392 Nucleoside	diphosphate	kinase	B NME2 0.91
Q99650 Oncostatin-M-specific	receptor	subunit	beta OSMR CTRL
Q9C0B5 Palmitoyltransferase	ZDHHC5 ZDHHC5 CTRL
P62937 Peptidyl-prolyl	cis-trans	isomerase	A PPIA 1.17
Q06830 Peroxiredoxin-1 PRDX1 1.16
Q9BTU6 Phosphatidylinositol	4-kinase	type	2-alpha PI4K2A CTRL
P20020 Plasma	membrane	calcium-transporting	ATPase	1 ATP2B1 1.36
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P05121 Plasminogen	activator	inhibitor	1 SERPINE1 CTRL
Q15149 Plectin PLEC CTRL
O15031 Plexin-B2 PLXNB2 1.48
Q9UKK3 Poly	[ADP-ribose]	polymerase	4 PARP4 4.87
P11940 Polyadenylate-binding	protein	1 PABPC1 CTRL
P0CG47 Polyubiquitin-B UBB 1.62
Q8WUM4 Programmed	cell	death	6-interacting	protein PDCD6IP 1.33
O75340 Programmed	cell	death	protein	6 PDCD6 2.18
O00622 Protein	CYR61 CYR61 3.88
P07237 Protein	disulfide-isomerase P4HB CTRL
Q92734 Protein	TFG TFG CTRL
Q9C0H2 Protein	tweety	homolog	3 TTYH3 2.15
P12931 Proto-oncogene	tyrosine-protein	kinase	Src SRC 2.35
Q9Y315 Putative	deoxyribose-phosphate	aldolase DERA CTRL
Q5VTE0 Putative	elongation	factor	1-alpha-like	3 EEF1A1P5 1.30
O43143 Putative	pre-mRNA-splicing	factor	ATP-dependent	RNA	helicase	DHX15 DHX15 CTRL
P14618 Pyruvate	kinase	PKM PKM 0.87
P50395 Rab	GDP	dissociation	inhibitor	beta GDI2 1.83
Q14699 Raftlin RFTN1 2.35
P46940 Ras	GTPase-activating-like	protein	IQGAP1 IQGAP1 3.04
Q15404 Ras	suppressor	protein	1 RSU1 0.50
P63000 Ras-related	C3	botulinum	toxin	substrate	1 RAC1 0.78
P15153 Ras-related	C3	botulinum	toxin	substrate	2 RAC2 3.12
P61026 Ras-related	protein	Rab-10 RAB10 1.23
Q15907 Ras-related	protein	Rab-11B RAB11B 1.13
P61106 Ras-related	protein	Rab-14 RAB14 1.29
Q9H0U4 Ras-related	protein	Rab-1B RAB1B 0.87
Q9UL26 Ras-related	protein	Rab-22A RAB22A 4.12
P61019 Ras-related	protein	Rab-2A RAB2A CTRL
P61020 Ras-related	protein	Rab-5B RAB5B 2.33
P51148 Ras-related	protein	Rab-5C RAB5C 1.74
P51149 Ras-related	protein	Rab-7a RAB7A 1.55
P61006 Ras-related	protein	Rab-8A RAB8A 0.78
P61224 Ras-related	protein	Rap-1b RAP1B 0.83
P10301 Ras-related	protein	R-Ras RRAS 1.92
P62070 Ras-related	protein	R-Ras2 RRAS2 2.29
P18433 Receptor-type	tyrosine-protein	phosphatase	alpha PTPRA CTRL
P10586 Receptor-type	tyrosine-protein	phosphatase	F PTPRF 3.97
P23470 Receptor-type	tyrosine-protein	phosphatase	gamma PTPRG CTRL
Q15262 Receptor-type	tyrosine-protein	phosphatase	kappa PTPRK 4.22
Q8NFJ5 Retinoic	acid-induced	protein	3 GPRC5A 4.24
Q9Y265 RuvB-like	1 RUVBL1 4.07
Q9Y230 RuvB-like	2 RUVBL2 CTRL
O14828 Secretory	carrier-associated	membrane	protein	3 SCAMP3 3.23
Q13501 Sequestosome-1 SQSTM1 CTRL
O95747 Serine/threonine-protein	kinase	OSR1 OXSR1 4.35
P30153 Serine/threonine-protein	phosphatase	2A	65	kDa	regulatory	subunit	A	alpha	isoform PPP2R1A 0.74
Q92783 Signal	transducing	adapter	molecule	1 STAM 3.98
P62318 Small	nuclear	ribonucleoprotein	Sm	D3 SNRPD3 CTRL
Q8NCG7 Sn1-specific	diacylglycerol	lipase	beta DAGLB CTRL
P05023 Sodium/potassium-transporting	ATPase	subunit	alpha-1 ATP1A1 1.27
P05026 Sodium/potassium-transporting	ATPase	subunit	beta-1 ATP1B1 1.30
P54709 Sodium/potassium-transporting	ATPase	subunit	beta-3 ATP1B3 CTRL
Q9H2H9 Sodium-coupled	neutral	amino	acid	transporter	1 SLC38A1 1.50
P55011 Solute	carrier	family	12	member	2 SLC12A2 2.76
P11166 Solute	carrier	family	2,	facilitated	glucose	transporter	member	1 SLC2A1 1.71
Q8NBI5 Solute	carrier	family	43	member	3 SLC43A3 1.24
Q15036 Sorting	nexin-17 SNX17 CTRL
O60493 Sorting	nexin-3 SNX3 3.65
P31948 Stress-induced-phosphoprotein	1 STIP1 1.09
Q6UWP8 Suprabasin SBSN 0.65
O43752 Syntaxin-6 STX6 CTRL
O00560 Syntenin-1 SDCBP 1.80
Q9Y490 Talin-1 TLN1 1.12
Q86VP1 Tax1-binding	protein	1 TAX1BP1 CTRL
P78371 T-complex	protein	1	subunit	beta CCT2 1.26
P50991 T-complex	protein	1	subunit	delta CCT4 1.46
P48643 T-complex	protein	1	subunit	epsilon CCT5 2.08
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Q99832 T-complex	protein	1	subunit	eta CCT7 CTRL
P49368 T-complex	protein	1	subunit	gamma CCT3 1.17
Q9P273 Teneurin-3 TENM3 CTRL
Q8NG11 Tetraspanin-14 TSPAN14 4.47
P37173 TGF-beta	receptor	type-2 TGFBR2 CTRL
P10599 Thioredoxin TXN CTRL
Q9H3M7 Thioredoxin-interacting	protein TXNIP CTRL
P13726 Tissue	factor F3 CTRL
P02786 Transferrin	receptor	protein	1 TFRC 3.02
Q15582 Transforming	growth	factor-beta-induced	protein	ig-h3 TGFBI 0.36
P37802 Transgelin-2 TAGLN2 0.92
P55072 Transitional	endoplasmic	reticulum	ATPase VCP 1.43
Q92616 Translational	activator	GCN1 GCN1L1 CTRL
P13693 Translationally-controlled	tumor	protein TPT1 0.87
P60174 Triosephosphate	isomerase TPI1 1.03
P29144 Tripeptidyl-peptidase	2 TPP2 2.77
Q9BQE3 Tubulin	alpha-1C	chain TUBA1C 1.99
P68366 Tubulin	alpha-4A	chain TUBA4A 1.31
P07437 Tubulin	beta	chain TUBB 1.82
P68371 Tubulin	beta-4B	chain TUBB4B 1.59
Q99816 Tumor	susceptibility	gene	101	protein TSG101 5.07
P23458 Tyrosine-protein	kinase	JAK1 JAK1 CTRL
P30530 Tyrosine-protein	kinase	receptor	UFO AXL 2.61
P07947 Tyrosine-protein	kinase	Yes YES1 CTRL
P09012 U1	small	nuclear	ribonucleoprotein	A SNRPA MYOF
A0AVT1 Ubiquitin-like	modifier-activating	enzyme	6 UBA6 CTRL
O60701 UDP-glucose	6-dehydrogenase UGDH CTRL
O00159 Unconventional	myosin-Ic MYO1C 2.69
P00749 Urokinase-type	plasminogen	activator PLAU 0.66
Q16851 UTP--glucose-1-phosphate	uridylyltransferase UGP2 0.68
Q9UK41 Vacuolar	protein	sorting-associated	protein	28	homolog VPS28 6.45
Q9H9H4 Vacuolar	protein	sorting-associated	protein	37B VPS37B CTRL
O75351 Vacuolar	protein	sorting-associated	protein	4B VPS4B 6.04
P51809 Vesicle-associated	membrane	protein	7 VAMP7 CTRL
P08670 Vimentin VIM 0.91
P18206 Vinculin VCL 0.74
P13010 X-ray	repair	cross-complementing	protein	5 XRCC5 CTRL
P12956 X-ray	repair	cross-complementing	protein	6 XRCC6 2.50
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Accession Protein Description CTRL/MYOF Ratio
P62191 26S protease regulatory subunit 4 CTRL
P43686 26S protease regulatory subunit 6B 0.43
O00232 26S proteasome non-ATPase regulatory subunit 12 0.37
Q9UNM6 26S proteasome non-ATPase regulatory subunit 13 0.49
P48556 26S proteasome non-ATPase regulatory subunit 8 0.54
P25398 40S ribosomal protein S12 MYOF
P62277 40S ribosomal protein S13 MYOF
P62249 40S ribosomal protein S16 0.51
P60866 40S ribosomal protein S20 0.23
P23396 40S ribosomal protein S3 0.23
P61247 40S ribosomal protein S3a 0.38
P62701 40S ribosomal protein S4, X isoform 0.40
P08865 40S ribosomal protein SA 0.32
P52209 6-phosphogluconate dehydrogenase, decarboxylating 0.57
P05388 60S acidic ribosomal protein P0 MYOF
P27635 60S ribosomal protein L10 0.41
P62906 60S ribosomal protein L10a MYOF
P18621 60S ribosomal protein L17 0.52
Q02878 60S ribosomal protein L6 0.35
P11021 78 kDa glucose-regulated protein 3.66
P61160 Actin-related protein 2 0.52
O15144 Actin-related protein 2/3 complex subunit 2 0.42
O15145 Actin-related protein 2/3 complex subunit 3 0.49
P61158 Actin-related protein 3 0.37
P55263 Adenosine kinase 0.42
Q9NVJ2 ADP-ribosylation factor-like protein 8B 1.85
P11766 Alcohol dehydrogenase class-3 MYOF
P47895 Aldehyde dehydrogenase family 1 member A3 0.61
Q04828 Aldo-keto reductase family 1 member C1 0.38
O43707 Alpha-actinin-4 1.98
P50995 Annexin A11 0.63
P20073 Annexin A7 0.64
P04424 Argininosuccinate lyase MYOF
P08243 Asparagine synthetase [glutamine-hydrolyzing] CTRL
P14868 Aspartate--tRNA ligase, cytoplasmic 0.36
P06576 ATP synthase subunit beta, mitochondrial MYOF
P61221 ATP-binding cassette sub-family E member 1 MYOF
Q01813 ATP-dependent 6-phosphofructokinase, platelet type 0.30
Q08211 ATP-dependent RNA helicase A 0.22
O00148 ATP-dependent RNA helicase DDX39A 0.33
O00571 ATP-dependent RNA helicase DDX3X 0.40
Q9H4G0 Band 4.1-like protein 1 1.54
P61769 Beta-2-microglobulin 0.20
P07686 Beta-hexosaminidase subunit beta 1.80
P07814 Bifunctional glutamate/proline--tRNA ligase MYOF
P31939 Bifunctional purine biosynthesis protein PURH 0.47
P11586 C-1-tetrahydrofolate synthase, cytoplasmic 0.45
P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit CTRL
Q9HCP0 Casein kinase I isoform gamma-1 0.43
Q9Y6M4 Casein kinase I isoform gamma-3 MYOF
Q03135 Caveolin-1 1.77
P08962 CD63 antigen 2.29
Q9HD42 Charged multivesicular body protein 1a 0.51
O43633 Charged multivesicular body protein 2a 0.41
Q9BY43 Charged multivesicular body protein 4a 0.52
Q9H444 Charged multivesicular body protein 4b 0.48
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Q9Y696 Chloride intracellular channel protein 4 2.11
O75390 Citrate synthase, mitochondrial MYOF
O95832 Claudin-1 0.50
P53618 Coatomer subunit beta 0.36
P23528 Cofilin-1 0.65
Q99715 Collagen alpha-1(XII) chain 3.49
Q9UMD9 Collagen alpha-1(XVII) chain 0.53
P08174 Complement decay-accelerating factor MYOF
Q12860 Contactin-1 2.16
Q86YQ8 Copine-8 0.58
P06493 Cyclin-dependent kinase 1 0.64
Q9H1C7 Cysteine-rich and transmembrane domain-containing protein 1 CTRL
Q14204 Cytoplasmic dynein 1 heavy chain 1 0.45
O00154 Cytosolic acyl coenzyme A thioester hydrolase MYOF
Q13443 Disintegrin and metalloproteinase domain-containing protein 9 0.45
P31689 DnaJ homolog subfamily A member 1 0.33
Q02750 Dual specificity mitogen-activated protein kinase kinase 1 0.29
O95834 Echinoderm microtubule-associated protein-like 2 CTRL
Q9H223 EH domain-containing protein 4 0.60
P13639 Elongation factor 2 0.48
P27105 Erythrocyte band 7 integral membrane protein 0.31
P60842 Eukaryotic initiation factor 4A-I 0.57
P38919 Eukaryotic initiation factor 4A-III MYOF
Q14152 Eukaryotic translation initiation factor 3 subunit A MYOF
P56537 Eukaryotic translation initiation factor 6 MYOF
P52907 F-actin-capping protein subunit alpha-1 MYOF
Q16658 Fascin 0.55
P49327 Fatty acid synthase 0.55
Q96NE9 FERM domain-containing protein 6 0.43
Q86UX7 Fermitin family homolog 3 0.49
P02794 Ferritin heavy chain 1.75
Q14512 Fibroblast growth factor-binding protein 1 1.53
P02751 Fibronectin 2.25
O75369 Filamin-B 0.19
O75955 Flotillin-1 1.89
Q14254 Flotillin-2 2.09
Q9NQ84 G-protein coupled receptor family C group 5 member C 0.40
P09382 Galectin-1 0.17
P06744 Glucose-6-phosphate isomerase 2.12
Q7RTV2 Glutathione S-transferase A5 0.44
P41250 Glycine--tRNA ligase MYOF
P11216 Glycogen phosphorylase, brain form MYOF
P35052 Glypican-1 1.64
P49915 GMP synthase [glutamine-hydrolyzing] MYOF
Q7Z5G4 Golgin subfamily A member 7 0.49
P62826 GTP-binding nuclear protein Ran 0.64
P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 0.30
P09651 Heterogeneous nuclear ribonucleoprotein A1 0.47
Q14103 Heterogeneous nuclear ribonucleoprotein D0 2.20
P61978 Heterogeneous nuclear ribonucleoprotein K 0.32
Q16778 Histone H2B type 2-E 2.48
P62805 Histone H4 2.02
P52292 Importin subunit alpha-1 MYOF
Q14974 Importin subunit beta-1 0.42
Q13308 Inactive tyrosine-protein kinase 7 2.17
P08648 Integrin alpha-5 0.34
Q9NPH3 Interleukin-1 receptor accessory protein MYOF
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O15554 Intermediate conductance calcium-activated potassium channel protein 4 CTRL
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic 2.76
P41252 Isoleucine--tRNA ligase, cytoplasmic 0.29
Q96J84 Kin of IRRE-like protein 1 3.15
O43278 Kunitz-type protease inhibitor 1 0.34
Q13751 Laminin subunit beta-3 0.21
Q13753 Laminin subunit gamma-2 0.53
O43813 LanC-like protein 1 MYOF
Q08722 Leukocyte surface antigen CD47 0.43
Q7Z4F1 Low-density lipoprotein receptor-related protein 10 1.73
P11279 Lysosome-associated membrane glycoprotein 1 4.56
P40926 Malate dehydrogenase, mitochondrial MYOF
Q99102 Mucin-4 3.01
P33527 Multidrug resistance-associated protein 1 MYOF
Q9NZM1 Myoferlin 11.68
Q15223 Nectin-1 1.54
Q9BT67 NEDD4 family-interacting protein 1 3.46
Q9NV92 NEDD4 family-interacting protein 2 CTRL
Q09666 Neuroblast differentiation-associated protein AHNAK 0.61
Q14697 Neutral alpha-glucosidase AB 0.66
Q96TA1 Niban-like protein 1 MYOF
P43490 Nicotinamide phosphoribosyltransferase MYOF
O15118 Niemann-Pick C1 protein 5.71
P06748 Nucleophosmin 0.30
Q9NTK5 Obg-like ATPase 1 CTRL
Q99650 Oncostatin-M-specific receptor subunit beta 1.68
Q9BTU6 Phosphatidylinositol 4-kinase type 2-alpha CTRL
P36969 Phospholipid hydroperoxide glutathione peroxidase, mitochondrial MYOF
Q99569 Plakophilin-4 0.41
P05120 Plasminogen activator inhibitor 2 0.16
P13797 Plastin-3 0.32
Q15149 Plectin 0.59
Q9UKK3 Poly [ADP-ribose] polymerase 4 2.05
Q15365 Poly(rC)-binding protein 1 0.63
Q15366 Poly(rC)-binding protein 2 MYOF
P11940 Polyadenylate-binding protein 1 0.63
P09668 Pro-cathepsin H 0.44
Q9H3G5 Probable serine carboxypeptidase CPVL CTRL
Q02809 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 MYOF
P12004 Proliferating cell nuclear antigen MYOF
Q9UQ80 Proliferation-associated protein 2G4 0.14
P28072 Proteasome subunit beta type-6 2.55
Q99873 Protein arginine N-methyltransferase 1 0.43
P07237 Protein disulfide-isomerase 1.60
Q92520 Protein FAM3C 1.60
Q92597 Protein NDRG1 0.39
Q9UGV2 Protein NDRG3 MYOF
P60903 Protein S100-A10 4.45
Q9C0H2 Protein tweety homolog 3 1.59
Q9GZT5 Protein Wnt-10a CTRL
O75695 Protein XRP2 1.58
Q14517 Protocadherin Fat 1 0.49
Q9UN70 Protocadherin gamma-C3 1.52
O43865 Putative adenosylhomocysteinase 2 MYOF
O43143 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 MYOF
P14618 Pyruvate kinase PKM 0.50
P35241 Radixin 2.10
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Table	S2/	publication	2:	List	of	proteins	identified	by	MS	in	MDA-MB-231	and	BxPC-3	derived	exosomes.	Protein	
commonly	expressed	in	exosomes	derived	from	both	cell	lines	MDA-MB-231	and	BxPC-3.	
P46940 Ras GTPase-activating-like protein IQGAP1 0.55
P51149 Ras-related protein Rab-7a 1.59
Q9Y3L5 Ras-related protein Rap-2c 0.46
P10586 Receptor-type tyrosine-protein phosphatase F 1.54
O14828 Secretory carrier-associated membrane protein 3 2.25
Q12884 Seprase CTRL
Q13501 Sequestosome-1 2.51
O15269 Serine palmitoyltransferase 1 1.52
Q92743 Serine protease HTRA1 3.01
Q7KZI7 Serine/threonine-protein kinase MARK2 MYOF
P30153 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 0.54
P62318 Small nuclear ribonucleoprotein Sm D3 MYOF
Q8NCG7 Sn1-specific diacylglycerol lipase beta CTRL
Q96QD8 Sodium-coupled neutral amino acid transporter 2 0.52
Q08357 Sodium-dependent phosphate transporter 2 2.11
P19634 Sodium/hydrogen exchanger 1 MYOF
P05026 Sodium/potassium-transporting ATPase subunit beta-1 0.45
P54709 Sodium/potassium-transporting ATPase subunit beta-3 2.25
Q9UMY4 Sorting nexin-12 2.37
Q15036 Sorting nexin-17 CTRL
P38646 Stress-70 protein, mitochondrial MYOF
Q8TED4 Sugar phosphate exchanger 2 CTRL
O43760 Synaptogyrin-2 1.65
O43752 Syntaxin-6 1.79
P17987 T-complex protein 1 subunit alpha 0.60
P78371 T-complex protein 1 subunit beta 0.60
P50991 T-complex protein 1 subunit delta 0.55
P48643 T-complex protein 1 subunit epsilon 0.44
Q99832 T-complex protein 1 subunit eta 0.60
P50990 T-complex protein 1 subunit theta 0.67
P40227 T-complex protein 1 subunit zeta 0.65
Q86VP1 Tax1-binding protein 1 2.09
O95858 Tetraspanin-15 CTRL
P26639 Threonine--tRNA ligase, cytoplasmic 0.46
P07204 Thrombomodulin 0.36
P00750 Tissue-type plasminogen activator 3.70
P02786 Transferrin receptor protein 1 1.69
Q15582 Transforming growth factor-beta-induced protein ig-h3 0.10
P29401 Transketolase 1.87
Q7Z403 Transmembrane channel-like protein 6 0.42
Q9BXS4 Transmembrane protein 59 1.51
P29144 Tripeptidyl-peptidase 2 2.95
P07437 Tubulin beta chain 0.66
Q14166 Tubulin--tyrosine ligase-like protein 12 MYOF
P21580 Tumor necrosis factor alpha-induced protein 3 0.59
O75509 Tumor necrosis factor receptor superfamily member 21 2.13
P23458 Tyrosine-protein kinase JAK1 2.10
O75643 U5 small nuclear ribonucleoprotein 200 kDa helicase MYOF
P61088 Ubiquitin-conjugating enzyme E2 N 0.37
Q8IX04 Ubiquitin-conjugating enzyme E2 variant 3 0.64
P22314 Ubiquitin-like modifier-activating enzyme 1 0.53
Q9P206 Uncharacterized protein KIAA1522 MYOF
Q16851 UTP--glucose-1-phosphate uridylyltransferase 0.53
O75436 Vacuolar protein sorting-associated protein 26A MYOF
A5D8V6 Vacuolar protein sorting-associated protein 37C 2.25
P50552 Vasodilator-stimulated phosphoprotein 2.03
Q9UEU0 Vesicle transport through interaction with t-SNAREs homolog 1B 2.59
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Table	S2/	publication	2:	List	of	proteins	identified	by	MS	in	MDA-MB-231	and	BxPC-3	derived	exosomes.	Protein	
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P51809 Vesicle-associated membrane protein 7 1.88
O75083 WD repeat-containing protein 1 0.52
Q9Y6W5 Wiskott-Aldrich syndrome protein family member 2 MYOF
P13010 X-ray repair cross-complementing protein 5 MYOF
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Table	S3/	publication	2:	List	of	proteins	identified	by	MS	in	MDA-MB-231	and	BxPC-3	derived	exosomes.	Protein	
commonly	down	regulated	in	myoferlin-deplete	exosomes	of	both	cell	lines	MDA-MB-231	and	BxPC-3.	
 
 
 
 
 
 
 
Accession Protein Description CTRL/MYOF Ratio MDA-
MB-231
CTRL/MYOF Ratio BXPC-3
P62191 26S protease regulatory subunit 4 CTRL CTRL
P11021 78 kDa glucose-regulated protein 2.56 3.66
Q9NVJ2 ADP-ribosylation factor-like protein 8B 8.22 1.85
O43707 Alpha-actinin-4 1.51 1.98
Q03135 Caveolin-1 2.17 1.77
P08962 CD63 antigen CTRL 2.29
P02794 Ferritin heavy chain 2.63 1.75
O75955 Flotillin-1 4.22 1.89
Q14254 Flotillin-2 4.25 2.09
P62805 Histone H4 1.88 2.02
O75874
Isocitrate dehydrogenase [NADP] 
cytoplasmic
CTRL 2.76
Q7Z4F1
Low-density lipoprotein receptor-related 
protein 10
CTRL 1.73
Q9NZM1 Myoferlin CTRL 11.68
O15118 Niemann-Pick C1 protein 3.85 5.71
Q99650 Oncostatin-M-specific receptor subunit beta CTRL 1.68
Q9BTU6 Phosphatidylinositol 4-kinase type 2-alpha CTRL CTRL
Q9UKK3 Poly [ADP-ribose] polymerase 4 4.87 2.05
P07237 Protein disulfide-isomerase CTRL 1.60
Q9C0H2 Protein tweety homolog 3 2.15 1.59
P51149 Ras-related protein Rab-7a 1.55 1.59
P10586
Receptor-type tyrosine-protein phosphatase 
F
3.97 1.54
O14828
Secretory carrier-associated membrane 
protein 3
3.23 2.25
Q13501 Sequestosome-1 CTRL 2.51
Q8NCG7 Sn1-specific diacylglycerol lipase beta CTRL CTRL
P54709
Sodium/potassium-transporting ATPase 
subunit beta-3
CTRL 2.25
Q15036 Sorting nexin-17 CTRL CTRL
O43752 Syntaxin-6 CTRL 1.79
Q86VP1 Tax1-binding protein 1 CTRL 2.09
P02786 Transferrin receptor protein 1 3.02 1.69
P29144 Tripeptidyl-peptidase 2 2.77 2.95
P23458 Tyrosine-protein kinase JAK1 CTRL 2.10
P51809 Vesicle-associated membrane protein 7 CTRL 1.88
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